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Abstract 
 
Understanding how the brain controls appetite offers promising inroads towards developing 
new therapies for obesity. Peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) are 
anorectic hormones that are co-released post-prandially by the gut. Both have been shown 
to physiologically inhibit appetite and food intake when administered to humans. However, 
the mechanisms by which they regulate appetite through the central nervous system (CNS) 
remain poorly understood. Functional magnetic resonance imaging (fMRI) is a tool that has 
recently been used to determine the CNS pathways that mediate the action of appetite-
modulating hormones. 
 
This dissertation investigates the action of the anorectic gut hormones PYY3-36 and GLP-17-36 
amide, infused intravenously over 90 minutes in 15 lean, healthy human subjects following an 
overnight fast. Using blood oxygen level dependent (BOLD) fMRI, I have determined the 
effects of PYY3-36 and GLP-17-36 amide on CNS appetite centres and subsequent food intake, 
comparing the effects with those seen physiologically following a standard meal.  
 
The combined administration of PYY3-36 and GLP-17-36 amide to fasted human subjects led to 
similar reductions in BOLD fMRI brain activity in a priori regions of interest as observed 
physiologically following feeding, especially in the insular cortex. Additionally, compared with 
infusion of saline, co-administration of PYY3-36 at 0.3 pmol/kg/min with GLP-17-36 amide at 0.8 
pmol/kg/min led to a 27.0% reduction in ad libitum energy intake at a buffet lunch served 
immediately after the infusion. The reduction in ad libitum energy intake following the 
combination infusion of PYY3-36 and GLP-17-36 amide was similar to that observed when saline 
was infused in subjects following consumption of a set breakfast (23.5% reduction in ad 
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libitum energy intake at a buffet lunch served immediately after the infusion). My findings 
provide direct evidence that the combined action of PYY3-36 and GLP-17-36 amide in the brain 
could explain post-prandial satiety. 
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General Introduction 
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1.1. Obesity 
 
In 2008, The Health Survey of England classified 24% of adults and 16% of children as 
obese (defined by a body mass index (BMI) ≥ 30 kg/m2). In Europe as a whole, it is currently 
estimated that 17% of the population is obese (von Ruesten et al., 2011). This figure is rising 
sharply due to the combination of readily available high-calorie food and sedentary lifestyle; 
extrapolation of recent trends predicts that by 2015, as many as 30% of European adults will 
be obese (von Ruesten et al., 2011). It is well known that being overweight or obese carries 
an increased risk of type 2 diabetes, hypertension, ischaemic heart disease, stroke, 
osteoarthritis, sleep apnoea and cancer. It has even been predicted that the coming decades 
could see a reversal of twentieth century gains in life expectancy, due to detrimental health 
consequences arising from the obesity epidemic (Olshansky et al., 2005).  
 
Effective treatment of obesity has been shown to prove worthwhile; a 92% reduction in 
diabetes deaths, 60% reduction in cancer deaths, 56% reduction in coronary artery disease 
deaths and 40% reduction in all cause mortality was demonstrated in a retrospective 
matched cohort study of obese individuals undergoing bariatric surgery (Adams et al., 2007). 
Bariatric surgery, in particular Roux-en-Y gastric bypass (which involves the formation of a 
small stomach pouch and bypass of the proximal small bowel), is the most effective current 
treatment for obesity, leading to sustained weight loss of approximately 30% (Maggard et al., 
2005). However, the procedure is not without risk and carries a mortality rate of 0.5% (Marsk 
et al., 2008).  
 
Lifestyle modification strategies (diet and exercise) currently form the main treatments for 
obesity. However, results are generally disappointing and the majority of people who attempt 
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lifestyle modification regain any lost weight within 5 years (Weiss et al., 2007). Drug 
treatments sibutramine and rimonabant were recently withdrawn due to cardiovascular and 
neuropsychiatric side effects respectively. The only licensed pharmacological treatment for 
obesity in the UK is orlistat, an intestinal lipase inhibitor. This produces modest weight loss 
(in a systematic review of randomized clinical trials, 60% of patients on orlistat achieved 
>5% weight loss after 1 year of treatment (Hutton and Fergusson, 2004)). Furthermore, as a 
consequence of its mechanism of action, orlistat often leads to unacceptable gastrointestinal 
side effects when fat is consumed. Therefore, effective pharmacotherapy to tackle obesity 
remains an elusive goal, despite an ever-growing need.  
 
1.2. The importance of understanding appetite regulation 
 
Accumulation of excess body fat (and hence development of obesity) occurs when energy 
intake exceeds energy expenditure in the long term. The relative balance between energy 
intake and expenditure is an important regulator of appetite; following a meal, appetite is 
suppressed, whereas following significant energy expenditure, we feel hungry. The 
intricacies underpinning this fine-tuned regulation of energy balance form part of a complex 
field that has been the focus of intense research over the past decade, bridging the 
disciplines of endocrinology, gastroenterology and neurobiology. An enhanced 
understanding of the physiological mechanisms that regulate appetite is essential for the 
development of pharmacological strategies to combat obesity. In particular, within the field of 
neuroendocrinology, identification of hormone-brain interactions that modulate appetite (and 
subsequent food intake) will aid the manipulation of naturally occurring hormones to develop 
safe and effective anti-obesity therapies. This strategy, exploiting physiological pathways of 
appetite control, holds promise for the future treatment of obesity, especially given the 
shortage of effective pharmacotherapies for obesity in the existing market. In particular, 
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identification of how hormones that are secreted post-prandially by the gut interact with brain 
regions that modulate appetite may eventually allow for their manipulation as therapeutic 
strategies in obese patients. These anorectic gut hormones, amongst others, include peptide 
YY (PYY) and glucagon-like peptide 1 (GLP-1). These peptide hormones will form the focus 
of this thesis and will be considered in detail. Alongside this, a general overview of the 
control of appetite and food intake will be covered in order to better understand the specific 
roles of PYY and GLP-1 within this field.  
 
1.3. Homeostatic and non-homeostatic controls of appetite and food intake 
 
Traditionally, there has been distinction between ‘homeostatic’ and ‘non-homeostatic’ control 
of appetite and food intake. Homeostatic control refers to the alteration in consumption of 
food that follows sensing of energy balance. Post-prandially, activation of gut 
mechanoreceptors, changes in circulating nutrient concentration, and release of anorectic 
gut hormones all lead to a reduction in subsequent feeding (Delzenne et al., 2010). Longer 
term adiposity signals of energy balance such as leptin also interact with central nervous 
system (CNS) circuits to regulate food intake (Farooqi et al., 2007, Morris and Rui, 2009). 
Appropriately matching food intake with metabolic need is achieved by the interaction of the 
above inputs with key central neural appetite circuits.  
 
Across species, food intake is also driven by factors other than basic physiological or 
homeostatic need. Food appearance, flavour, timing and location of meals, social, cultural, 
emotional, and economic influences affect food intake by non-homeostatic mechanisms. 
Importantly, there is also modulation of food intake by hedonic and mnemonic neuronal 
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circuits (Zheng and Berthoud, 2007). Figure 1.1 summarises the major determinants of 
appetite control.  
FOOD INTAKE
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1.4. Role of the hypothalamus 
 
The hypothalamus is widely recognised as the ‘gate-keeper’ in the control of appetite and 
food intake. Peripheral signals of energy balance may act directly on the hypothalamus to 
control food intake and this forms one important focus of current appetite research. 
Historically, the lateral hypothalamus was thought of as the ‘hunger centre’ and the medial 
hypothalamus the ‘satiety centre’. This was based on lesioning experiments in animals; 
damage to the lateral hypothalamus produced anorexia, whereas damage to the medial 
hypothalamus led to hyperphagia (Mayer and Thomas, 1967). Whilst this view still largely 
holds true, it has been recently refined by our enhanced understanding of the role of 
Figure 1.1: The major determinants of appetite control. A variety of homeostatic, hedonic and 
environmental inputs contribute to the overall control of food intake. ‘+’ indicates factors that 
increase food intake, whereas ‘−‘ indicates factors that reduce food intake. 
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individual nuclei within the hypothalamus and communication between them. It is also well 
established that there is a network of communication between the gut, pancreas, adipose 
tissue, brainstem, and hypothalamus to signal energy balance. Additionally, there is further 
communication between the hypothalamus and higher cortical centres pertaining to food 
memory and rewarding aspects of food, resulting in overall co-ordinated control of appetite 
and food intake.  
 
1.4.1. Hypothalamic nuclei implicated in appetite control 
 
The arcuate nucleus (ARC), replaced by the infundibular nucleus in humans, is thought to be 
the main hypothalamic area controlling food intake. By virtue of lying close to the median 
eminence (a circumventricular organ where an incomplete blood-brain barrier is thought to 
allow peripheral signals to gain access to the CNS), the ARC is ideally positioned to co-
ordinate feeding. Lesions of the ARC result in hyperphagia and obesity in mice (Olney, 
1969). Within the ARC, two groups of neurons are pivotal in regulating food intake. One 
group of neurons contains neuropeptide Y (NPY) and the vast majority of these also contain 
agouti-related peptide (AgRP). Activation of these neurons enhances food intake; i.e. these 
neurons are orexigenic (Clark et al., 1984). The second group is formed by anorexigenic 
neurons containing pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated 
transcript (CART). POMC is the precursor of α-melanocyte stimulating hormone (α-MSH).  α-
MSH acts on melanocortin receptors (mainly MC4R) to reduce food intake (Schwartz et al., 
2000). AgRP is a competitive antagonist at melanocortin receptors (Rossi et al., 1998). 
CART is thought to have either orexigenic or anorexigenic effects depending on its site of 
action; central intracerebroventricular (ICV) administration of CART reduces food intake in 
rats (Kristensen et al., 1998), whereas administration of CART directly into the ARC 
increases food intake (Abbott et al., 2001).  
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Axons from NPY/AgRP and POMC/CART neurons project from the ARC to other areas of 
the hypothalamus such as the paraventricular nucleus (PVN). Destruction of the PVN leads 
to hyperphagia and obesity in rats (Leibowitz et al., 1981). In addition to the PVN, axons 
from the ARC also project to the ventromedial hypothalamus (VMH), dorsomedial nucleus 
(DMN), lateral hypothalamic area (LHA), and perifornical area (PFA) to modulate food 
intake.  
 
1.5. Role of the brainstem 
 
The brainstem has a well established role in the sensing of energy balance and modulation 
of food intake. Within the brainstem, the dorsal vagal complex (DVC) is the main organ 
responsible for facilitating the communication between peripheral signals of food intake and 
hypothalamic nuclei (Bailey, 2008). The DVC consists of the nucleus of the tractus solitarius 
(NTS), the area postrema (AP), and the dorsal motor nucleus of the vagus (DVN). Vagal 
nerve afferents carry sensory information relaying hunger and satiety from the gut directly to 
the NTS. Transection of these gut sensory vagal nerve afferents results in increased meal 
size and duration (Schwartz, 2000). The absence of a complete blood-brain barrier in the AP 
also allows the brainstem to directly receive metabolic signals of energy balance, such as 
hormones and nutrients carried by the blood.  
 
The brainstem is then able to process these sensory inputs and relay them to the 
hypothalamus and higher cortical centres. In keeping with this, it is well established that 
there are neural projections from the brainstem to the hypothalamus (Ter Horst et al., 1989). 
There are also descending, efferent pathways from the hypothalamus to the DVN (ter Horst 
et al., 1984). The DVN modulates efferent vagal nerve activity in the gastrointestinal tract 
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and can alter gastric emptying, gastric motility, and pancreatic secretions. This points to a 
role for the brainstem in modulating feeding related activity, as well as sensing energy 
balance.  
 
1.6. Hedonic brain regions modulating appetite and food intake 
 
The word ‘hedonic’ relates to pleasant (or unpleasant) sensations.  It is apparent that visual, 
smell, and taste signals can override satiety signals to maintain food intake despite neutral 
or even positive energy balance. For example, the sweet taste of certain foods is associated 
with positive emotions that motivate animals to find food and continue consumption. These 
sensory signals are conveyed from visual, smell, and taste receptors to the NTS in the 
brainstem, then relayed to cortical and limbic ‘reward centres’ implicated in appetite 
regulation. Past experience with specific foods also forms an important contributor to 
continued consumption (if the previous experience was pleasant) or early cessation of intake 
(if the previous experience was unpleasant), regardless of satiety and energy balance. This 
is referred to as conditioned preference or conditioned aversion respectively. From an 
emotional perspective, the evaluation of a stimulus for its motivational significance and 
cross-reference with the existing working memory occurs in multiple brain regions, 
particularly the dopaminergic limbic and prefrontal reward areas (Berthoud, 2011). In 
rodents, pharmacological studies suggest that dopaminergic D2-and D3 receptors play a 
critical role in reward; mice lacking D2-receptors have reduced sensitivity to the rewarding 
effects of addictive drugs such as cocaine (Welter et al., 2007) and opiates (Maldonado et 
al., 1997). Furthermore, administration of D3 receptor antagonists have been shown to 
reduce cocaine-seeking behaviour and reduce self-administration of nicotine in rats 
(Heidbreder et al., 2005). Key regions of this dopaminergic reward system are illustrated in 
figure 2, and include the amygdala, insula, striatum (comprising the nucleus accumbens, 
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caudate, putamen and globus pallidus), orbitofrontal cortex (OFC), ventral tegmental area 
(VTA), anterior cingulate cortex (ACC) and pre-frontal cortex. Those regions that form the 
focus of specific investigation within this thesis will now be introduced further: 
 
1.6.1. Amygdala 
 
This almond shaped limbic structure lies in each anterior temporal lobe. The amygdala is 
involved in a wide range of emotional processing and is particularly responsive to fear, 
positive and negative affect (Pessoa and Ungerleider, 2004). In keeping with this, bilateral 
lesions of the amygdalae in primates produce fearless animals, with impairments in 
emotional learning, impaired memory for emotional events and deficits in the perception of 
emotion (Cardinal et al., 2002). The amygdala receives afferent projections from the insular 
and visual cortices, with efferent projections to the OFC and nucleus accumbens (Amaral 
and Price, 1984, Morgane et al., 2005). Importantly, some of the functions of the amygdala 
are carried out in conjunction with the OFC, such as updating the values of expected 
outcomes stored in the OFC (Holland and Gallagher, 2004). Thus, communication between 
the amygdala and the OFC is thought to be important in the generation and maintenance of 
a working memory for food experiences (Verhagen, 2007). Furthermore, in rats trained to 
associate the availability of food with the presentation of a food cup (resulting in conditioned 
food intake even when satiated), elimination of amygdala-hypothalamus connections 
completely abolishes this conditioned food intake (Petrovich et al., 2002). This illustrates the 
importance of connections between the amygdala and other brain regions (both homeostatic 
and non-homeostatic) implicated in the control of food intake.  
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1.6.2. Insula 
 
The insula (or insular cortex) is located within the temporal and frontal cortices. It is 
comprised of a larger anterior and smaller posterior part. Considered to be the primary 
gustatory cortex, the insula is thought to be involved in sensory and rewarding aspects of 
taste processing in addition to taste aversion (James et al., 2009, Welzl et al., 2001). It is 
also suggested that the insula is responsible for generating representations of previous 
flavour and reward experience with food (de Araujo et al., 2003). The insula receives  
afferent inputs from the NTS, and sends efferent projections to the LHA, amygdala, nucleus 
accumbens and OFC (Van Vugt, 2009), indicating connections with both homeostatic and 
other reward regions modulating food intake.  
 
1.6.3. Striatum 
 
The striatum can be divided into ventral and dorsal components. The ventral striatum 
comprises the nucleus accumbens and olfactory tubercle, whereas the dorsal striatum 
comprises the caudate nucleus, putamen and globus pallidus. The striatum contains 
GABAergic and cholinergic neurons (Meredith, 1999), expressing D1-, D2- and D3-like 
dopamine receptors. It is well established that the striatum, in particular the nucleus 
accumbens, plays a key role in motivation and enabling the behavioural responses 
necessary for obtaining rewards (Berridge, 1996). Consistent with this, lesions of the nucleus 
accumbens have been shown to reduce the rewarding effects of addictive drugs such as 
cocaine and opiates (Kelsey et al., 1989), which normally elevate extracellular 
concentrations of dopamine in the ventral striatum (Kelley, 2004). There are established 
projections from the ventral striatum back to the midbrain (Carlezon and Thomas, 2009). 
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Furthermore, administration of an opioid µ-receptor agonist into the nucleus accumbens 
increases neuronal expression of orexin (which promotes food intake) in the hypothalamus 
(Zheng et al., 2007). This evidence implies links between the ventral striatum and 
homeostatic regions controlling food intake.  
 
1.6.4. Orbitofrontal cortex (OFC) 
 
Occupying the ventral surface of the frontal cortex, the OFC plays a key role in encoding 
taste, flavour, and food reward (Small et al., 2007). The OFC receives converging sensory 
input from olfactory, visual, gustatory, and somatosensory signals (Rolls et al., 2003, 
Verhagen, 2007, Verhagen and Engelen, 2006, de Araujo et al., 2003) and is in close 
contact with the amygdala, insula and hippocampus (Verhagen and Engelen, 2006), thought 
to be important in producing an overall co-ordinated response following integration of 
sensory inputs. The primary role for the OFC in encoding reward value of food is supported 
by the decrease in activation seen during repeated tasting of a food (‘sensory-specific 
satiety’) (Kringelbach and Rolls, 2004). During eating, distinct sensory inputs fuse into an 
overall perception of flavour; such olfactory and oral somatosensory inputs are thought to be 
encoded in the OFC (Small et al., 2007).  
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It is now widely accepted that with regard to appetite control, homeostatic and non-
homeostatic systems do not function independently; instead, there is extensive cross-
modulation between them, along with a complex integration of inputs before a final decision 
is made regarding food consumption. Figure 1.2 illustrates some of the major brain regions 
implicated in appetite control. 
OFC
VS
PFC
DLPFC
VTA
H
Am
Figure 1.2: Brain regions implicated in the control of appetite:  The hypothalamus (H), as a homeostatic 
gatekeeper, has numerous connections with the brainstem (BS) as well as with higher brain centres which 
process salience and reward.  The hypothalamus transmits to these higher centres information received from 
the periphery, such as nutritional status signalled via the postprandial release of gut hormones. Important 
higher brain centres include:  amygdala (Am) – emotional and aversive processing, ventral striatum (VS) and 
dorsal striatum (DS) – anticipatory reward processing, ventral tegmental area (VTA) – numerous dopaminergic 
projections to other limbic areas, anterior cingulate cortex (ACC) – decision making, orbitofrontal cortex (OFC) 
– reward encoding, prefrontal cortex (PFC) – translation of external and internal cues into behavioural 
responses, dorsolateral  prefrontal cortex (DLPFC) – self control.  Not shown is the insular cortex (a more 
lateral structure), which is also important in gustatory processing.  
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1.7. The role of PYY and GLP-1 in the control of food intake 
 
The gut is the largest endocrine organ in the body and secretes over 30 different regulatory 
peptide hormones. A number of these gut hormones are stimulated by gut nutrient content 
and interact with receptors at various points in the ‘gut-brain axis’ to affect short term 
feelings of hunger and satiety. This thesis will focus on two such hormones - PYY and GLP-
1. Both hormones are released together following a meal and are thought to mediate post-
prandial satiety.  
 
As discussed previously, gastric bypass surgery is one of the most effective treatments for 
obese patients, where sustained weight loss results from diminished appetite. Notably, 
gastric bypass patients demonstrate increased levels of PYY and GLP-1, especially post-
prandially (Borg et al., 2006, le Roux et al., 2006, le Roux et al., 2007). Significantly, 
inhibiting the PYY and GLP-1 responses results in return of appetite and increases food 
intake (le Roux et al., 2007). Therefore, it is likely that elevated levels of PYY and GLP-1 
play a key role in the sustained weight loss observed following gastric bypass surgery. It 
follows that investigation into the physiological interaction between these hormones and the 
CNS is of paramount importance in obesity research.  
 
 
 
 
 
 
29 
 
1.7.1. Peptide YY (PYY) 
 
PYY is a 36-amino acid peptide which belongs to the Pancreatic Polypeptide (PP) family. 
This family of peptides, comprising PP, PYY and NPY, share a common hair-pin-fold motif 
structure. PP, PYY and NPY bind to G-protein coupled receptors Y1, Y2, Y4, Y5 and Y6, 
displaying promiscuity in their interactions with these receptors by virtue of their shared hair-
pin-fold motif structure. 
 
PYY is produced by the L cells of the gut, with highest concentrations found in the large 
bowel and the rectum (Adrian et al., 1985). Two endogenous forms, PYY1-36 and PYY3-36, are 
released post-prandially into the circulation. PYY3-36 is further produced by cleavage of the 
Tyr-Pro amino terminal residues of PYY1-36 by the enzyme dipeptidyl peptidase IV (DPP-IV). 
PYY3-36 acts mainly via the Y2 receptor (Dumont et al., 1995). Indeed, PYY3-36 selectivity for 
the Y2 receptor is thought to be conferred by cleavage of the Tyr-Pro amino terminal 
residues of PYY1-36 (Dumont et al., 1995). In the fasted state, PYY1-36 predominates in the 
circulation, whereas post-prandially, PYY3-36 is the major circulating form (Grandt et al., 
1994). Following a meal, circulating levels of PYY3-36 rise within 15 minutes, peak at 
approximately 90 minutes and remain elevated for up to 6 hours (Adrian et al., 1985). The 
magnitude of the rise in PYY3-36 is in proportion to the calories ingested (Degen et al., 2005). 
When exogenously administered intravenously, its circulating half-life is approximately 8 
minutes (Lluis et al., 1989). 
 
Given that PYY3-36 is released within 15 minutes of food intake, this must occur before 
ingested nutrients reach the distal small intestine and colon (where the greatest 
concentrations of PYY3-36 are found). Therefore, initial post-prandial release of PYY3-36 is 
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likely to be under neural control. Further release of PYY3-36 is observed when the nutrients 
arrive in the distal gut and is particularly stimulated by a high fat diet (Essah et al., 2007). 
The protein content of the diet is thought to be influential for delayed PYY3-36 release 
approximately 2 hours post-prandially (Helou et al., 2008). PYY3-36 is likely to affect appetite 
via a direct central effect and also via its effects on gut motility – it acts as an ‘ileal brake’ 
and so leads to a sensation of fullness and satiety (Batterham et al., 2002, Batterham et al., 
2003). 
 
Studies by Batterham et al. have shown that peripheral administration of PYY3-36 to rodents 
and humans leads to marked inhibition of food intake (Batterham et al., 2002, Batterham et 
al., 2003). In humans, ad libitum food intake at a buffet meal served 2 hours after the 
completion of a 90 min intravenous infusion of PYY3-36 delivered at a dose of 0.8 
pmol/kg/min, was reduced by 36% compared with an infusion of saline. The PYY3-36 infusion 
generated plasma levels of PYY3-36 similar to those achieved physiologically after a meal 
(Batterham et al., 2002). Thus, it was suggested that PYY3-36 inhibits food intake 
physiologically. Energy intake measured over the subsequent 24 hours after the infusion of 
PYY3-36 was reduced by 33% compared with saline. This pointed towards a role for PYY3-36 in 
the intermediate control of food intake beyond the study test meal. Significantly, there was 
no reported nausea in subjects infused with PYY3-36.  
 
Some studies have reported that obese individuals have lower basal fasting levels of PYY3-36 
and have a smaller rise in postprandial levels (Batterham et al., 2003). Obesity does not 
appear to be associated with resistance to PYY3-36, as in obese subjects, there was a 30% in 
a reduction in ad libitum food intake at a buffet meal served 2 hours after completion of a 90 
minute infusion of PYY3-36 delivered at an unspecified dose based on body surface area 
(Batterham et al., 2003). This compared with a 31% reduction in food intake in a group of 
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lean subjects who also received a peripheral infusion of PYY3-36. Additionally, there was also 
a comparable reduction in 24 hour energy intake in both lean and obese subjects following 
PYY3-36 infusion.  
 
A similar study administered a 90 minute intravenous infusion of PYY3-36 to lean and 
overweight human subjects at a dose of 0.8 pmol/kg/min, with 19% reduction in ad libitum 
food intake at a buffet meal served 2 hours after completion of the infusion (Sloth et al., 
2007). However, in contrast to the studies by Batterham et al, significant nausea was 
experienced by subjects, culminating in only 4 of the first 9 being able to complete their 
infusion. This study also found that there was increased thermogenesis, lipolysis, post-
prandial insulin and glucose responses in those receiving PYY3-36, suggestive of increased 
sympathoadrenal activity and increased energy expenditure. However, the effect of nausea 
on these latter findings is a potential confounder.   
 
Significant problems with nausea and vomiting were also encountered when intra-nasal 
PYY3-36 was tested in obese human subjects as a weight-loss treatment (Gantz et al., 2007). 
In this study, placebo or intra-nasal PYY3-36 was administered at a dose of 200 mcg 3 times 
daily or 600 mcg 3 times daily for 12 weeks. Only 70% of subjects in the low-dose group 
completed the study and this figure was even lower (26%) in the high-dose group. The mean 
weight loss from baseline over the 12 weeks was 2.8 kg in the placebo group, 3.7 kg in the 
200 mcg PYY3-36 group, and only 1.4 kg in the 600 mcg PYY3-36 group (Gantz et al., 2007). 
Pharmacokinetics revealed rapid (Cmax 20 min) absorption of PYY3-36 to pharmacological 
plasma levels. This is likely to have been a major contributor to nausea.  
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Oral delivery of peptide hormones has been unsuccessful on the whole, due to the harsh 
environment of the gastrointestinal tract and thus failure of absorption across the intestinal 
wall. The subcutaneous route is therefore the established route for peptide hormone 
delivery; insulin being the classical example. However, it could be argued that oral 
administration of gut hormones better mimics the physiological post-prandial state (given 
that these peptides are naturally secreted from the gut, where they may act on local vagal 
afferents, in addition to being absorbed into the portal circulation before acting systemically). 
Subcutaneous administration does not allow for these potentially important local 
physiological gastrointestinal effects. Encouragingly, a recent study of oral delivery of PYY3-
36 with sodium N-caprylate (Emisphere Technologies, Cedar Knolls, NJ) to 12 healthy human 
subjects showed that there was effective absorption of the peptide from the gut (Steinert et 
al., 2010). Supraphysiological plasma levels were achieved, but despite this, no nausea was 
encountered with administration of oral PYY3-36 alone. Energy intake at a buffet meal served 
15 minutes later was reduced by 12% compared with placebo, although this was not found 
to be statistically significant. 24 hour energy intake was unchanged by oral PYY3-36 
administration. Emisphere’s sodium N-caprylate technology uses hydrophobic moieties on 
carrier molecules, which when in association with a peptide such as PYY3-36, allows for the 
creation of a more lipophilic complex. This facilitates absorption of the peptide across the 
intestinal wall.  
 
Batterham et al. performed a series of experiments in rodents which shed considerable light 
on the action of PYY3-36 on CNS appetite circuits (Batterham et al., 2002). Firstly, it was 
shown that chronic peripheral administration of PYY3-36 resulted in a decrease in food intake 
and body weight. Furthermore, a single peripheral injection of PYY3-36 resulted in induction of 
expression of the immediate-early gene c-fos (a marker of neuronal activation) in the 
hypothalamic ARC. This suggests that the ARC is an important site of action of the peptide. 
Furthermore, a single peripheral injection of PYY3-36 caused a decrease in expression of 
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hypothalamic NPY mRNA 6 hours later. A subsequent single injection of PYY3-36 directly into 
the ARC inhibited food intake. Inhibition of food intake was also observed with intra-arcuate 
administration of a Y2 receptor specific agonist. Significantly, this effect was absent in Y2 
receptor knock-out mice. Addition of PYY3-36 to ex-vivo hypothalamic explants inhibited 
release of NPY and stimulated release of α-MSH. This finding was further validated by 
electrophysiological studies, which demonstrated that POMC neurons showed disinhibition 
when exposed to PYY3-36. It therefore appears that circulating PYY3-36 inhibits appetite by 
acting directly on the ARC via the Y2 receptor, increasing the activity of anorexigenic 
POMC/α-MSH neurons, whilst suppressing orexigenic NPY neurons.  
 
In contrast to peripheral and intra-ARC injection, administration of PYY3-36 into the 3
rd 
ventricle or the PVN is orexigenic in mice (Morley et al., 1985, Stanley et al., 1985). This is 
thought to be due to action on Y1 and Y5 receptors in these regions. In contrast to the 
anorectic effect produced by Y2 receptor activation, Y1 and Y5 receptor activation promotes 
feeding (Kanatani et al., 2000). 
 
The Y2 receptor is abundantly distributed within the hypothalamic ARC, preoptic nucleus and 
DMN (Gustafson et al., 1997). Given the presence of an incomplete blood-brain-barrier in 
the hypothalamic median eminence, which lies close to the ARC, it is plausible that 
circulating PYY3-36 accesses the CNS at this level. Furthermore, the Y2 receptor is found in 
the NTS of the brainstem (Gustafson et al., 1997). In keeping with this, peripheral injection of 
PYY3-36 activates c-fos expression in the AP and the NTS (Blevins et al., 2008). Therefore, 
circulating PYY3-36 may access the brainstem via the incomplete blood brain barrier at the 
AP. Taking into account the presence of ascending and descending projections between the 
brainstem and hypothalamus (as discussed earlier), it is possible that there is 
communication between these areas with regard to PYY3-36 action.  
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Other forebrain areas that express the Y2 receptor include the posterior hypothalamic nuclei, 
medial nucleus of the amygdala, substantia nigra and parabrachial area (Dumont et al., 
1998).  Action on the limbic system (including the amygdala) may be of significance when 
considering modulation of hedonic pathways by PYY3-36.   
 
PYY3-36 may also act via the vagus-brainstem-hypothalamic pathway (Koda et al., 2005). 
Using vagal ligation studies, Koda et al. showed that Y2 receptors are transported to the 
peripheral terminals of vagal afferent neurons. Furthermore, peripheral administration of 
PYY3-36 led to afferent vagal discharges, while disruption of the vagus-brainstem-
hypothalamus pathway abolished its anorexigenic effect.  
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Table 1.1 summarises some of the major translational human studies investigating the role 
of PYY3-36 in the control of appetite. 
 
 
 
 
Table 1.1: Important translational human studies involving PYY3-36. 
 
Study Major findings 
Batterham et al. 
2002 
In lean subjects, 36% reduction (compared with 
placebo) in ad libitum food intake at meal served 2 
hours after 90 min intravenous infusion of PYY3-36.  
 
In the same group, 33% reduction (compared with 
placebo) in 24 hour food intake following 90 min 
intravenous infusion of PYY3-36. 
 
Batterham et al. 
2003  
In overweight subjects, 30% reduction (compared 
with placebo) in ad libitum food intake at meal 
served 2 hours after 90 min intravenous infusion of 
PYY3-36. 
 
Sloth et al. 2007 In lean and overweight subjects, 19% reduction 
(compared with placebo) in ad libitum food intake at 
meal served 2 hours after 90 min intravenous 
infusion of PYY3-36. 
 
Gantz et al. 2007 
 
Rapid absorption and significant nausea following 
prandial, intranasal administration of PYY3-36 to 
obese subjects over 12 weeks. 
 
Steinert et al. 2010 In lean subjects, effective absorption of oral PYY3-36 
when delivered with sodium N-caprylate. 12% 
reduction (compared with placebo) in ad libitum food 
intake at meal served 15 min after oral PYY3-36. 
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1.7.2. Glucagon-like peptide 1 (GLP-1) 
 
Proglucagon is a 160-amino acid prohormone that is produced in the -cells of the 
pancreatic islets, the L cells of the gut and within the CNS. Selective post-translational 
proteolysis of proglucagon by prohormone convertases 1 and 2 results in the tissue-specific 
production of a number of biologically-active fragments. In the gut and CNS, with respect to 
the regulation of appetite and food intake, the cleavage product GLP-1 will be the focus of 
this section. 
 
GLP-1 is an incretin hormone, enhancing endogenous insulin secretion in response to a 
post-prandial glucose load. GLP-1 is released post-prandially into the circulation from the 
gastrointestinal L cells in proportion to the calories ingested (Ghatei et al., 1983, Orskov et 
al., 1994). It has been shown that GLP-1 shows a biphasic response after a meal. As with 
PYY, the first peak occurs before nutrients enter the distal gut (Delzenne et al., 2010) and 
has been shown to be augmented by a high-carbohydrate meal (Smeets et al., 2008). This is 
presumably via the effect of carbohydrates absorbed in the proximal gut. It is thought that 
the second peak of secretion of GLP-1 is triggered by free fatty acids in the intestinal lumen, 
via activation of the G-protein coupled receptors GPR 40 (Edfalk et al., 2008), GPR 119 
(Chu et al., 2008, Lauffer et al., 2009) and GPR 120 (Hirasawa et al., 2005). The two forms 
synthesized are GLP-11-37 and GLP-11-36 amide. Further cleavage produces the bioactive 
fragments GLP-17-37 and GLP-17-36 amide, The major circulating bioactive species of GLP-1 is 
the truncated form GLP-17-36 amide (Orskov et al., 1994). It is rapidly broken down by DPP-IV 
and has a half-life of 2 minutes (Kieffer et al., 1995). 
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GLP-1 acts by binding to the G-protein coupled GLP-1 receptor (GLP-1R). GLP-17-37 and 
GLP-17-36 amide are equally potent at the GLP-1R (Thorens et al., 1993). The GLP-1R is 
expressed in pancreatic islets, where GLP-1 functions as an incretin hormone. This allows 
for enhanced glucose-dependent insulin release post-prandially (Kreymann et al., 1987). 
GLP-1 also inhibits glucagon secretion and delays gastric emptying (Gutniak et al., 1992, 
Willms et al., 1996). The GLP-1R is also present in a number of CNS areas implicated in 
appetite control. These include the ARC and PVN in the hypothalamus and the AP in the 
brainstem (Wei and Mojsov, 1995, Shughrue et al., 1996). Neurons containing GLP-17-36 amide 
are located in the AP and NTS. Furthermore, there are projections to the dorsomedial 
hypothalamus (Larsen et al., 1997).  
 
It is well established that administration of GLP-17-36 amide peripherally or centrally leads to 
reduced food intake in rodents, whereas co-administration of an antagonist of GLP-17-36 amide 
(exendin9-39) abolishes this effect (Turton et al., 1996). In the same study, single 
administration of exendin9-39 doubled food intake in satiated rats in addition to potentiating 
the feeding response to NPY administration, suggesting that GLP-17-36 amide regulates 
appetite physiologically.  
 
A range of studies has demonstrated that peripheral administration of GLP-17-36 amide to 
humans leads to a dose-dependent reduction in appetite and ad libitum energy intake. A 
meta-analysis of major studies (Verdich et al., 2001) revealed that intravenous infusion of 
GLP-17-36 amide reduces energy intake dose-dependently in both lean and overweight 
subjects. The protocols in the individual studies within the meta-analysis varied considerably, 
in addition to including a mixture of lean, overweight and obese subjects in the studies 
analysed. The duration of the infusions ranged between 0 and 240 minutes (spanning 60 
minutes in the majority of studies). Furthermore, the timing of the ad libitum buffet meal with 
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regard to the infusion varied between studies, such that in some, the meal was served with 
the infusion still running from the outset (Naslund et al., 1999, Long et al., 1999, Gutzwiller et 
al., 1999) whereas in others, the infusion was stopped 30 minutes before the meal was 
served and then restarted at the onset of the meal (Flint et al., 1998, Flint et al., 2001). In 
one study of 6 obese subjects, the meal was served at the beginning of the infusion 
(Naslund et al., 1998). Finally, individual protocols varied such that the dose of infused GLP-
17-36 amide in individual studies ranged between 0.375 pmol/kg/min and 1.5 pmol/kg/min. 
Amalgamating the individual study data in the meta-analysis revealed that the mean infusion 
rate was 0.89 pmol/kg/min across all subjects. In lean subjects, infusion of GLP-17-36 amide led 
to a 13.2% reduction in energy intake at the ad libitum buffet meal compared with saline 
infusion. When the 6 obese subjects who were served their meal at the beginning of the 
infusion were excluded from the analysis, the reduction in ad libitum energy intake for 
overweight / obese subjects by GLP-17-36 amide was comparable (10.5%) with that of lean 
subjects (Verdich et al., 2001). Data on nausea and other well-being scores were only 
included in 2 of the studies in the meta-analysis. Nausea was not encountered in either of 
these studies. In addition to the intravenous infusion studies described above, it was found 
that daily prandial subcutaneous injections of GLP-17-36 amide (76 nmol 4 times daily) to obese 
human subjects over 5 days led to a 15% mean reduction in energy intake at each meal 
compared with placebo. Over 5 days, this translated to a mean weight loss of 0.55 kg. 
(Naslund et al., 2004) However, feelings of sickness were reported in 8 out of 19 subjects 
receiving prandial subcutaneous injections of GLP-17-36 amide, compared with 2 out of 7 
subjects receiving placebo injections. 
 
The brainstem is thought to be an important site of action of peripheral GLP-17-36 amide. c-fos 
expression occurs in the brainstem only after the peripheral and not central injection of GLP-
17-36 amide. (Turton et al., 1996). In contrast, both peripheral and central injection of GLP-17-36 
amide induce c-fos in the PVN (Baggio et al., 2004). Furthermore, vagotomy or lesions of 
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projections from the brainstem to the hypothalamus reduce the appetite suppression 
mediated by peripheral GLP-17-36 amide (Abbott et al., 2005). Therefore, as seems to be the 
case with PYY3-36, peripheral GLP-17-36 amide may either act via the vagus, with projections to 
the brainstem and then hypothalamus, or alternatively may act directly on the brainstem 
(gaining access from the circulation at the AP) or hypothalamus (gaining access from the 
circulation at the median eminence). Furthermore, action on brain food reward regions (such 
as the pre-frontal cortex) is likely, either directly or through communication via homeostatic 
centres. 
 
The fact that circulating GLP-1 is rapidly broken down by DPP-IV has been a challenge to 
developing its use clinically. Exenatide (exendin-4) is a currently licensed DPP-IV resistant 
GLP-1R agonist that has enjoyed success in producing improved glycaemic control and 
promoting weight loss when administered subcutaneously to overweight patients with Type 2 
diabetes (Ratner et al., 2006, Riddle et al., 2006). Long acting analogues of GLP-1 such as 
liraglutide are also licensed for subcutaneous use in Type 2 diabetes as adjunctive therapy, 
following favourable efficacy and safety data (Nauck et al., 2009, Zinman et al., 2009, 
Garber et al., 2009, Marre et al., 2009). The half-life of liraglutide is prolonged by albumin 
binding. The fact that exenatide and liraglutide produce an incretin effect is favourable in 
enhancing endogenous insulin secretion in response to a post-prandial glucose load. 
Furthermore, their effects of suppressing food intake and causing weight loss (through 
reduction in gastric emptying and central effects on the CNS as discussed above) makes 
this line of treatment particularly attractive in treating overweight patients with Type 2 
diabetes. However, one major limitation surrounds their well-recognised side effect of 
nausea. Although it occurs commonly, the incidence of nausea declines with duration of 
treatment (Ratner et al., 2006, Riddle et al., 2006). 
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In order to avoid the need for injections, nonpeptidic GLP-1R agonists in oral form have 
been developed and tested in rodents (Knudsen et al., 2007, Chen et al., 2007). Recently, 
delivery of oral GLP-17-36 with sodium N-caprylate to healthy human subjects reduced energy 
intake by 13.6% during a meal served 15 minutes later, with marked effects on glucose 
homeostasis (Steinert et al., 2010). However, in this study, 24 hour energy intake was 
unaffected by GLP-17-36.  
 
In addition to GLP-1R agonism, oral DPP-IV inhibitors such as sitagliptin and vildagliptin are 
also currently licensed as adjunctive therapy in Type 2 diabetes. Although they confer the 
advantage of being available in oral form, unlike exenatide and liraglutide, they tend to be 
weight-neutral (Green et al., 2006). This may well be due to the fact that DPP-IV has a role 
in activating the anorectic gut hormone PYY3-36; DPP-IV inhibitors may therefore lead to 
reduced levels of active PYY3-36 and theoretically result in a lesser degree of appetite 
inhibition. Finally, although currently not licensed, GPR 119 agonists (i.e. GLP-1 
secretagogues) are under development for use in Type 2 diabetes (Lauffer et al., 2008). 
 
Outside of the context of Type 2 diabetes, liraglutide has proven successful in causing 
significant weight loss when administered over 20 weeks to obese, non-diabetic patients 
(Astrup et al., 2009). Administration of liraglutide subcutaneously at a dose of 3 mg once 
daily led to a mean weight loss of 7.2 kg, compared with 2.8 kg with placebo and 4.1 kg with 
orlistat 120 mg orally 3 times daily. 76% of participants on liraglutide 3 mg once daily lost 
>5% body weight (Astrup et al., 2009). Nausea and vomiting occurred more frequently in the 
liraglutide group than in the placebo group, but this rarely led to discontinuation of treatment. 
The results of this randomised, double-blind, placebo-controlled study hold promise for the 
licensing of GLP-1 analogues in obesity alone.  
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Table 1.2 summarises some of the major translational human studies investigating the role 
of GLP-1 in the control of appetite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2: Important translational human studies involving GLP-1 
 
 
 
 
Study Major findings 
Verdich et al. 2001 
(meta-analysis) 
In lean subjects, 13.2% reduction (compared with 
placebo) in ad libitum food intake at meal served 
following intravenous infusion of GLP-17-36 amide. 
Comparable 10.5% reduction in ad libitum food 
intake in overweight/ obese subjects. Individual 
study protocols within the meta-analysis varied.  
 
Naslund et al. 2004 In obese subjects, 15% mean reduction in ad libitum 
energy intake at each meal (compared with placebo) 
following prandial, subcutaneous administration of 
GLP-17-36 amide over 5 days. 
 
Steinert et al. 2010 In lean subjects, effective absorption of oral       
GLP-17-36 amide when delivered with sodium N-
caprylate. 13.6% reduction (compared with placebo) 
in ad libitum food intake at meal served 15 min after 
oral GLP-17-36 amide. 
 
Astrup et al. 2009 In obese, non-diabetic subjects, daily subcutaneous 
administration of liraglutide over 20 weeks led to a 
mean weight loss of 7.2 kg (compared with 2.8 kg 
with placebo) 
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1.7.3. Studies investigating combined administration of PYY3-36 and GLP-17-36 amide 
 
During and after a meal, a variety of hormones are released from the gut into the circulation. 
These are thought to act in concert in producing an overall satiety response, thus facilitating 
meal termination and increasing the period of time before the next meal is sought. 
Preliminary research has focused on deciphering the role and mode of action of individual 
gut hormones in appetite regulation. However, more recently, there has been an interest in 
investigating how these satiety factors act in concert to regulate appetite. This is particularly 
relevant when considering that in the physiological fed state, a multitude of gut hormones 
are released into the circulation. More effectively mimicking the physiological fed state using 
combination gut hormone analogues may prove promising for the future treatment of obesity.  
 
In the case of PYY3-36 and GLP-17-36 amide, it was shown (Neary et al., 2005) that in 10 
healthy, lean human subjects, co-administration of PYY3-36 and GLP-17-36 amide (each at 0.4 
pmol/kg/min over 120 min) produced a 27% reduction in ad libitum energy intake (compared 
with saline) during a buffet meal served 90 minutes into the infusion (the infusion was 
continued during the meal). Individually, single infusion of PYY3-36 and GLP-17-36 amide at the 
above doses did not produce a statistically significant reduction in energy intake compared 
with saline. Importantly, no nausea was experienced during any of the infusions, including 
the combined PYY3-36 and GLP-17-36 amide infusion.  
 
In the same paper (Neary et al., 2005), rodent studies were carried out and findings 
strengthened those of the human study; combination of peripheral PYY3-36 and GLP-17-36 amide 
led to reduction in food intake that was greater than that observed when either hormone was 
infused individually at twice the dose. In the hypothalamic ARC, no changes were observed 
43 
 
after low-dose PYY3-36 or GLP-17-36 amide individually, but co-administration led to c-fos 
expression.  
 
In a recent study of 12 healthy human subjects, co-administration of oral PYY3-36 and GLP-
17-36 amide in conjunction with sodium N-caprylate lead to a 21.5% reduction in energy intake 
during a meal served 15 minutes later (Steinert et al., 2010). Admittedly, 2 subjects 
experienced significant gastrointestinal side effects of nausea, abdominal discomfort and 
vomiting. Furthermore, 24 hour energy intake was no different compared with placebo. 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Figure 1.3 provides an overview of the likely major interactions between PYY, GLP-1, the 
hypothalamus, brainstem and non-homeostatic brain regions in the regulation of appetite 
and food intake.  
 
Higher brain centres
Cortico-limbic system
BRAINSTEM
HYPOTHALAMUS
PYY, GLP-1 VAGUS NERVE
ME AP
NTS
ARC
NPY/AgRP POMC/CART
↓ ↑
↓ FOOD INTAKE
 
 
 
 
 
 
 
 
Figure 1.3: An overview of the role of PYY and GLP-1 in the control of appetite and food intake. Gut 
hormones such as PYY and GLP-1 are released post-prandially into the peripheral circulation. They may 
interact with the CNS via local vagal afferents that project to the brainstem nucleus of the tractus 
solitaries (NTS). Alternatively, they may act directly on the brainstem NTS, via an incomplete blood-brain-
barrier at the area postrema (AP) or on the hypothalamic arcuate nucleus (ARC), via an incomplete blood-
brain-barrier at the median eminence (ME). Within the ARC, NPY/AgRP neurons are predominantly 
orexigenic, whereas POMC/CART/αMSH neurones are predominantly anorexigenic. AgRP is a competitive 
antagonist at central melanocortin receptors. There are connections between hypothalamus, brainstem, 
reward centres and mnemonic centres, important in the overall regulation of appetite and food intake.                 
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1.8. Other hormones implicated in the control of food intake 
 
This section introduces other hormones, discussed elsewhere in this thesis, that are 
implicated in the control of appetite and food intake.  
 
1.8.1. Ghrelin 
 
Ghrelin is the only known gut hormone that increases appetite. It was first discovered as an 
endogenous ligand to the growth hormone secretagogue receptor (GHS-R) in the stomach. 
It is primarily produced by the A-cells of gastric fundus. Its other actions include increase in 
gastric motility and stimulation of growth hormone release. Its metabolic effects include 
increased fat storage and decrease in fat use (van der Lely et al., 2004).  
 
Plasma ghrelin levels rise before meals and decline after eating (Cummings et al., 2001), 
implicating a role for ghrelin in controlling appetite. Peripheral administration of ghrelin 
increases food intake in humans (Wren et al., 2001, Druce et al., 2005) and ghrelin is now 
considered as one of the most powerful physiological orexigenic agents.  
 
Ghrelin mediates its effects on food intake via the GHS-R. GHS-R deficient mice are 
resistant to diet induced obesity (Zigman et al., 2005). The ARC NPY/AgRP neurons have 
been implicated in mediating ghrelin’s central orexigenic effects. Ghrelin may increase food 
intake by binding to the GHS-R on vagal afferent nerve terminals or in the neurones of the 
ARC to alter ARC NPY/AgRP neuronal activity (van der Lely et al., 2004).  
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Ghrelin levels are inversely correlated with body weight and may constitute a feedback 
mechanism to reduce appetite in obesity (Chaudhri et al., 2006a). Plasma ghrelin levels are 
also noted to increase upon weight loss (Chaudhri et al., 2006a). This may be a factor 
resulting in poor adherence to diets and tendency to regain weight after initial weight loss. 
 
1.8.2. Insulin 
 
Insulin is released by the beta cells of the pancreas in a glucose sensitive manner and binds 
to the insulin receptor. The primary role of insulin is to increase glucose uptake in peripheral 
tissues, decrease hepatic glucose production and maintain glucose levels. Its release peaks 
postprandially in proportion to the glucose influx following a meal. Similar to leptin, insulin 
levels are also influenced by the amount of adipose tissue in the body, with higher levels in 
more obese individuals. Therefore, insulin is also considered an adiposity signal (Woods et 
al., 2006).  
 
The most common effect on appetite mediated by insulin is seen in hypoglycemia following 
treatment with excess insulin in diabetes. In this situation, there is a marked increase in food 
intake. This effect is due to low blood glucose rather than due to insulin directly (see Section 
1.9.3.). Insulin itself crosses the blood brain barrier in a dose dependant manner and acts on 
ARC insulin receptors to decrease food intake (Marks et al., 1990). When insulin is centrally 
administered, a decrease in food intake and body weight is noted (Woods and Seeley, 
2001). The opposite is seen when insulin blocking antibodies are injected in the 
hypothalamus and when insulin receptor expression is selectively decreased in the ARC 
(McGowan et al., 1992, Obici et al., 2002). Insulin levels also augment the effect of other 
satiety signals, an effect seen with leptin as well (Woods et al., 2006). Therefore insulin 
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provides signals to the brain reflecting circulating energy in the form of glucose and stored 
energy in the form of adipose tissue. These signals interact with other satiety signals to 
reduce food intake.  
 
1.8.3. Leptin 
 
Leptin is a hormone produced largely in the adipose tissue, with levels proportional to fat 
stores and increased by overfeeding. Leptin provides a mechanism by which body fat can 
control food intake via a feedback system on the hypothalamus. This idea was initially 
proposed by Gordon Kennedy in 1953 as the ‘lipostatic theory’ (Kennedy, 1953). Friedman 
and colleagues demonstrated the absence of leptin in the inbred Ob/Ob strain of severely 
obese mice (Zhang et al., 1994). Subsequently, human congenital leptin deficiency was 
identified in 2 severely obese cousins (Montague et al., 1997). The peripheral administration 
of leptin in both Ob/Ob mice and human congenital deficiency, as well as central 
administration of leptin in Ob/Ob mice reversed the obese phenotype (Friedman and Halaas, 
1998, Farooqi et al., 1999). Therefore, leptin is a signal from the adipose tissue to the brain 
reflecting the state of energy stores and significantly influencing appetite (Farooqi and 
O'Rahilly, 2009). 
 
Leptin exerts its effects by acting on the leptin receptor (LepR). LepR mutations in mice 
(Db/Db strain mice) and humans are associated with severe obesity (Farooqi and O'Rahilly, 
2009). Leptin acts on ARC LepR to stimulate POMC neurons and inhibits NPY/AgRP 
neurons to decrease food intake (Farooqi and O'Rahilly, 2009). Downstream signalling of 
leptin occurs via the MC4R (Farooqi and O'Rahilly, 2009). Leptin also acts on leptin 
receptors in other parts of the brain and has important effects on reward pathways, energy 
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expenditure, pubertal development, fertility, and immune function (Farooqi and O'Rahilly, 
2009).  
 
Leptin levels are elevated in obese individuals and administration of leptin in common 
obesity has a variable effect on food intake (Farooqi and O'Rahilly, 2009). This failure of 
leptin to diminish appetite in obesity is termed leptin resistance and is not completely 
understood. 
 
1.9. Neural signals controlling food intake 
 
1.9.1. Orosensory and visual stimuli 
 
Orosensory and visual stimuli provide the brain with sensory information regarding the 
nature of food. These stimuli include appearance, taste, smell and texture. Visual information 
regarding the appearance of food is relayed via neural signals in the afferent optic fibres of 
cranial nerve II. Gustatory, olfactory, orosensory information about food in contact with the 
tongue and palate is transduced into neural signals by the gustatory fibres of cranial nerves 
VII, IX, and X, olfactory fibres of cranial nerve I, and sensory fibres of cranial nerve V. These 
neural signals are directly or indirectly relayed to areas of the brain important for taste, 
reward, flavour, and mnemonic representations, such as the limbic system and OFC (Rolls, 
2006). The information is used by the brain to continue or to stop eating. The stimuli of the 
food (e.g. sweet or bitter) and prior experience with eating the food (conditioned preferences, 
such as reward, or conditioned aversions, such as nausea) influence the decision to eat or 
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not to eat. The potency of these stimuli in promoting food intake during a meal is increased 
by food deprivation as well as other signals (Rolls, 2006).  
 
1.9.2. Gastric distension 
 
Volume related post-prandial gastric distension results in satiety during a meal. This is 
demonstrated in rats by the use of a chronic gastric fistula. Food intake is increased when 
gastric contents are continuously drained whilst these rats eat (Smith, 1998). Pyloric cuffs 
can reversibly close the pylorus, restrict the food to the stomach and prevent the passage of 
food downstream. Experiments utilising reversible pyloric cuffs in animals provide further 
support that gastric distension contributes to satiety during a meal (Smith, 1998, Ritter, 
2004). These satiety signals arise from mechanical distension of the stomach rather than 
nutrient sensing (Smith, 1998). Mechanoreceptors in the stomach wall sense stretch, 
volume, and tension during a meal. This information is transmitted to the brain by afferent 
fibres of the vagal and spinal visceral nerves (Cummings and Overduin, 2007). Earlier 
gastric distention and satiety during a meal resulting from a reduced stomach size forms the 
basis of ‘restrictive’ bariatric surgical treatments (e.g. laparoscopic adjustable gastric 
banding) that are used in the management of severe obesity.  
 
1.9.3. Glucose 
 
In addition to glucose exerting its effects on the gastrointestinal system by inducing the 
secretion of insulin, the level of glucose itself may be sensed by hypothalamic neurons in the 
brain involved in appetite regulation. This ‘glucostatic theory of feeding’ was first proposed 
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by Jean Mayer more than 50 years ago (Mayer, 1952). Although it has been noted for some 
time that peripheral and central glucoprivation (low glucose) can stimulate feeding, for 
example during hypoglycaemia, the role of central glucosensing in affecting day to day food 
intake and the mechanisms involved in regulating this have only been elucidated recently.  
Glucose alters the firing rate of neurons in the ARC, LHA, and NTS (Levin, 2006). The 
cellular influx of glucose alters the ratio of AMP: ATP within the neuronal cell. This may 
affect ATP-dependant membrane channels that may influence neuronal depolarisation or 
may alter the activity of important nutrient sensing enzymes, such as AMP-activated protein  
kinase, that have important roles in cellular processes relevant to energy homeostasis 
(Jordan et al., 2010). Some neurons, such as ARC POMC neurons, are excited by glucose 
whereas others, such as ARC NPY neurons, are inhibited by glucose (Levin, 2006). These 
glucose sensitive neurons also respond to other hormonal and metabolic signals, such as 
insulin, leptin, lactate, ketone bodies, and free fatty acids (Levin, 2006). Glucose sensitive 
neurons may represent focal points where signals converge to alter appetite and allow 
various signals to act in concert to influence the initiation and termination of meals.  
 
1.10. The use of imaging techniques to determine CNS neuronal activation in the 
regulation of feeding 
 
In humans, there is a need to further investigate the physiology of appetite control within the 
CNS in a non-invasive fashion. A deeper understanding of CNS pathways governing 
appetitive behaviour and in particular, shedding further light on interactions between gut 
hormones and key brain regions implicated in appetite control, holds promise for the 
development of pharmacotherapies to combat obesity. In recent years, functional 
neuroimaging techniques have formed important tools to investigate the above. Techniques 
such as positron emission tomography (PET) and single photon emission tomography 
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(SPECT) have been used to investigate patterns of brain activation associated with factors 
that underpin the regulation of feeding, but they have significant limitations in human 
research. Firstly, the above techniques are associated with exposure to ionising radiation. 
Additionally, SPECT suffers from low signal/noise ratio and the requirement for access to a 
cyclotron greatly limits the availability of PET. In addition, the spatial resolution offered by 
PET and SPECT is limited to several millimetres, which therefore permits the investigation of 
changes in neuronal activity at a regional level only (Tataranni and DelParigi, 2003). 
Magnetic resonance imaging (MRI) (and its adaptation to functional magnetic resonance 
imaging (fMRI)) exhibits clear advantages over PET and SPECT in that it offers better spatial 
resolution of tens of microns (Tataranni and DelParigi, 2003) and is relatively non-invasive. 
Furthermore, MRI does not require exposure to ionising radiation, thereby allowing for 
repeated measures in a given subject.  
 
1.11. Overview of fMRI 
 
MRI is based on the physical phenomenon of nuclear magnetic resonance. Nuclei that have 
an odd total number of protons and neutrons possess angular momentum (spin). The 
hydrogen nucleus is one such example, as it consists of a single proton. As soon as an 
external magnetic field (B0) is applied, the protons in tissue tend to align with this, causing 
their spins to precess about a circular path around B0. Here, they are in a low-energy state. 
Generation of MRI images requires application of a radiofrequency (RF) pulse at 90 degrees 
to B0. The protons will then ‘tip’ to align with the RF pulse. In doing so, they gain energy. 
After the RF pulse is switched off, the protons re-align with B0. Spins return to the low energy 
state by emitting the absorbed energy, also in the form of a radiowave. The emitted energy 
can be measured by the receiver coil and converted to images. By slightly altering the 
strength of the magnetic field (and therefore the frequency of the emitted radiation) using 
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gradient coils across the volume to be imaged, spatial information can be inferred. The T1 
relaxation time is a time constant referring to the realignment of spins with B0 in the 
longitudinal plane after the RF pulse is switched off. The T2 relaxation time, on the other 
hand, is a time constant referring to the de-phasing of spins in the transverse plane after the 
RF pulse is switched off (figure 1.4). T1 and T2 vary depending on the tissue being imaged. 
The strength of magnetic resonance signal obtained for a particular tissue depends primarily 
on the proton density. However, by altering the time between successive RF pulses and 
therefore the degree of T1 and T2 relaxation, the image can be weighted towards one or the 
other of these tissue-specific properties. It should be noted that, in practice, due to localised 
inhomogeneities in the externally applied magnetic field, T2 is shorter than expected for any 
particular tissue. This apparent T2 is referred to as T2*. fMRI utilises adaptations of this 
classical MRI technique, such that function of tissues can be analysed rather than structure 
alone. 
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Figure 1.4:  T1 and T2 relaxation.  MRI utilises the behaviour of protons within varying magnetic 
fields to produce signals which can be converted into images. Each hydrogen nucleus in the brain 
can be thought of as a vector (in the z and x-y planes) representing the strength and direction of 
its magnetic field as it spins on its axis.  The spins of the imaged protons try to align with the main 
external magnetic field of the scanner (referred to here as B0 and conventionally shown along the 
z axis in 3D coordinates). A second magnetic field (in the form of a short radiofrequency (RF) 
pulse) is applied, which flips all of the spins from alignment in the z plane into the x-y plane (figure 
1.4 a).  Before application of the RF pulse the amplitude in the z-plane is maximal while the 
amplitude in the x-y plane is zero. Just after application of the RF pulse the amplitude in the z-
plane is zero while the amplitude in the x-y plane is maximal (figure 1.4 a). During relaxation 
(figure 1.4 b) the amplitude in the z-plane will slowly increase while the amplitude in the x-y plane 
slowly decreases.  T1 relaxation is the time taken for the z vector to regain in strength, whereas T2 
relaxation is the time taken for the x-y vector to decay.  These changing magnetic vectors invoke 
their own RF signals, which are picked up by the receiver coils and interpreted into information 
about the proton density of the subject being scanned. 
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1.11.1. fMRI - Manganese-enhanced MRI (MEMRI) 
 
In animals, manganese-enhanced MRI (MEMRI) has been used to determine regions of the 
CNS activated following gut hormone administration. This technique utilises the fact that 
unpaired electrons in the outer shell of Mn2+ ions alter the relaxation properties of protons in 
a magnetic field, resulting in an increased T1 weighted signal (Mendonca-Dias et al., 1983).  
This is proportional to the concentration of Mn2+ in the tissue. Mn2+ can therefore be used as 
a contrast agent and has the advantage (compared with chelated gadolinium contrast 
agents) that its volume of distribution matches the intracellular volume (Crossgrove et al., 
2003). Additionally, Mn2+ ions biologically mimic Ca2+ ions, and are able to enter L-type 
voltage gated calcium channels. Normal depolarisation of neurons involves entry of Ca2+ 
through L-type voltage-gated calcium channels (Narita et al., 1990). Hence, administration of 
MnCl2 contrast allows a functional assessment of neuronal activity, given that Mn
2+ will mimic 
Ca2+, enter depolarising neurons and increase the T1 weighted signal. 
 
MEMRI without disruption of the blood-brain-barrier has been used to demonstrate an 
increase in hypothalamic T1 weighted signal in fasted compared with non-fasted rodents in 
the ARC, PVN and VMH (Kuo et al., 2006). With regard to gut hormone action, MEMRI 
without blood-brain-barrier disruption showed that peripherally administered ghrelin (an 
orexigenic gut hormone) increased hypothalamic signal intensity in the ARC and VMH in fed 
mice. On the other hand, peripherally administered PYY3-36 caused a reduction in 
hypothalamic signal intensity in the same regions (Kuo et al., 2006) in fasted mice. The 
effect of GLP-17-36 amide has also been studied using MEMRI; there was reduction in 
hypothalamic signal in the PVN and an increase in the VMH (Chaudhri et al., 2006b). 
Unfortunately, MEMRI cannot be used to study CNS activation in humans due to the toxicity 
conferred by Mn2+ ions.  
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1.11.2. fMRI - Blood-oxygen-level-dependent (BOLD) fMRI 
 
Virtually all human fMRI studies rely on a measure called blood-oxygenation-level dependent 
(BOLD) contrast, based on the fact that oxygenated and deoxygenated blood possess 
different magnetic properties. Increased neuronal activity in the brain elicits a local 
haemodynamic response, which causes an increase in blood flow greater than necessary for 
tissue demands. This results in a locally reduced ratio of deoxyhaemoglobin to 
oxyhaemoglobin concentrations and the ensuing differences in local magnetic field 
inhomogeneities can be detected on a T2*-weighted imaging protocol (Kwong et al., 1992, 
Ogawa et al., 1992); the locally reduced ratio of deoxyhaemoglobin to oxyhaemoglobin leads 
to a longer T2*, producing an increased image intensity. Such protocols typically use 
magnetic gradients to generate the MR signal (gradient-echo imaging) and, as scanner and 
computational hardwares have advanced, faster sequences have been developed to acquire 
large numbers of images in short spaces of time. Echo-planar imaging (EPI), for example, is 
a technique whereby an entire 2-dimensional image can be attained by the rapid alteration of 
spatial gradients following a single RF pulse. In this way, the entire brain can now be 
functionally imaged within the same timeframe as the physiological changes of interest. fMRI 
has thus provided hugely important insights in numerous disciplines. However, its use in the 
field of neuroendocrinology has been limited due to the inherent weakness of the technique 
at imaging the hypothalamus. This small (approximately 5-8 mm in diameter) brain structure 
lies close to the air-tissue boundaries of surrounding sinuses and is susceptible to signal 
loss due to resultant distortions of the external magnetic field, which is a particular issue for 
T2*-weighted images (Ojemann et al., 1997). 
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1.12. BOLD fMRI image reconstruction 
 
fMRI image reconstruction results in the selected brain area divided into thousands of 
voxels, each assigned a signal intensity. Statistical analysis of each voxel, or cluster of 
voxels, ascertains whether the signal intensity there is different compared with the signal 
intensity elsewhere. Whilst this approach may be useful for exploratory studies, most fMRI 
experiments perform ROI (region of interest) analyses whereby the functional properties of a 
pre-determined set of voxels (corresponding to a priori anatomical areas of the brain) are 
analysed. ROI analysis, with very many fewer degrees of freedom than whole brain voxel-
wise analysis, has a greater chance of finding statistically significant results but entails the 
inherent risk of missing activated areas of the brain that were not included in the original 
hypothesis. Resting state functional connectivity analyses investigate the activational inter-
relationships between different brain regions, allowing for the formation of distinct neuronal 
networks implicated in a co-ordinated brain response (Biswal et al., 1997). Resting state 
scans are performed when the subject is not performing any purposeful task and have 
recently reported on blood flow to the hypothalamus as an ROI with or without infusion of 
anorectic gut hormones (Batterham et al., 2007).  
 
1.13. Principles of fMRI in human appetite studies  
 
A commonly used approach in the area of functional imaging of appetite is to present the 
subject with images of food (with further subdivision into appetising, bland, high calorie or 
low calorie food) or non-food items. A subtraction analysis is performed to see whether the 
difference in regional brain activation between viewing images of food or non-food is altered 
in different physiological conditions (e.g. the fasted state, the fed state or in the presence of 
exogenously administered anorectic hormones). Several studies have utilised this approach; 
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these will be discussed in depth subsequently. Hypothalamic data remain an elusive goal 
with such whole brain task-based analyses; in addition to the aforementioned difficulties in 
hypothalamic imaging, activation of some nuclei within the hypothalamus promotes food 
intake, whereas other nuclei are appetite-inhibiting (Suzuki et al., 2010). Therefore, using the 
hungry, fasted state as an example, the overall hypothalamic signal resulting from the 
activation of orexigenic nuclei and inhibition of anorexigenic nuclei may in fact be negligable, 
due to the above opposing signals cancelling each other out. In addition to developing 
stronger magnetic fields to enhance spatial resolution, newer perfusion imaging techniques, 
which are T1 weighted, may provide better hypothalamic data which is not so affected by 
signal loss due to magnetic susceptibility artefacts (Wong et al., 1997). Arterial spin labelling 
(ASL) uses RF pulses to magnetically label protons in blood water molecules before they 
reach the tissue of interest which lies in the imaging plane from where data is acquired. It 
has favourable noise properties over BOLD (Wang et al., 2011), so may represent a better 
method of imaging the hypothalamus.  
 
1.14. fMRI studies in normal weight subjects - comparing the response to food cues in 
the fasted and fed states 
 
Before moving into the arena of functional brain imaging studies to specifically determine the 
neuroendocrinology of appetite control, it is useful to look at earlier studies which examined 
differences in brain activity in hunger and satiety. Such differences may be attributed to a 
number of physiological differences between the fed and fasted state, such as changes in 
concentrations of gut-derived neuropeptides (PYY, GLP-1, ghrelin and insulin) and vagal 
afferents conveying information about gut distension. These early studies into appetitive 
behaviour have led to our understanding of how images of food can trigger the brain’s 
reward system and how the motivational potency of this trigger is greater in the fasted state. 
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On the whole, these studies complemented earlier work which utilised PET scanning to 
assess the effects of hunger and satiety on regional cerebral blood flow differences, and 
which particularly implicated the OFC as a critical convergence zone for sensory information 
related to rewarding stimuli (Tataranni et al., 1999, Gautier et al., 2001, Small et al., 2001, 
Wang et al., 2004). 
 
Most of these fMRI studies have been task-based subtraction analyses, looking at 
differences in regional brain activation between when viewing images of food or non-food 
items. It is well understood that whilst taste provides an immediate reward (or punishment) 
for consumed foods, the visual characteristics of food are quickly learned and become 
powerful secondary reinforcers, capable of influencing subsequent food-seeking behaviour.  
Thus, showing food images is a useful way of examining the appetitive reward circuitry. 
 
In the first study of its kind in 2001, LaBar et al. reported on 9 healthy subjects, who 
underwent an initial whole brain fMRI after an 8 hour fast, followed by another post-meal 
scan one hour later. A follow up study was performed on 8 subjects who were fed a meal 
before the first of the two scans, to rule out the potential of habituation effects in the first 
group. The subjects were presented with food and non-food images during each scan and 
subtraction analysis was performed (LaBar et al., 2001). The authors’ hypothesis that 
variation in the state of hunger would modulate the response of the amygdala and 
anatomically related corticolimbic structures was borne out in a ROI analysis, which revealed 
satiety-induced reduction in activity in the amygdala, parahippocampal gyrus and fusiform 
gyrus. They suggested that the amygdala, with its extensive neural connections with the 
hypothalamus and higher brain centres, was in a pivotal position for integrating response to 
visual food stimuli in the context of nutritional status. However, it was noted that this study 
was under-powered to detect similar satiety-induced changes in many other ROIs studied.  
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In 2003, Killgore et al. used a different approach by scanning satiated recruits who were 
presented with pictures of high calorie, low calorie and non-food items. Irrespective of 
calorific content, food images caused greater activation than non-food images in the 
amygdala, hippocampus and ventromedial prefrontal cortex (Killgore et al., 2003). The 
authors point out the importance of these areas in the expectation and evaluation of reward. 
High calorie foods caused particular activation of the medial and dorsolateral prefrontal 
cortex, understood to be involved in evaluating stimulus relevance within the current 
affective state of the individual. In contrast, low calorie foods resulted in lesser activation of 
these reward areas per se, and greater activation in somatosensory areas, with a suggestion 
from the authors that this was due to a lesser cephalic phase response by classical 
conditioning to images of less appealing foods. In 2005, Killgore published a reanalysis of 
this study data, using an ROI approach (specifically, a sub-analysis of the OFC) and 
correlated BOLD activity with BMI. It was reported that for the high calorie food minus non-
food contrast, there was a significant negative correlation between BMI and BOLD signal in 
the OFC (Killgore and Yurgelun-Todd, 2005). This highlights the more subtle role of parts of 
the OFC not just in simply assigning reward value to certain stimuli, but in modifying 
stimulus-reward associations and accordingly redirecting feeding-related behaviour in 
response to new learning (Kringelbach, 2005). Of course, in this particular study, it was not 
possible to extend these findings to the obese population, since the subjects studied were all 
within the normal weight range.   
 
In 2005 St-Onge et al. published the only fMRI study to date where fasted individuals were 
exposed to four different stimuli: visual food, visual non-food, tactile food and tactile non-
food. In an uncorrected whole brain analysis, they reported that the anterior cingulate, 
superior temporal gyrus, hippocampus and insula were significantly activated to a greater 
extent during the presentation of foods (whether seen or felt) over non-food items (St-Onge 
et al., 2005). 
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In 2006, Porubska et al. published the results of an fMRI study of 12 normal-weight fasted 
subjects. Visual food stimuli (in contrast to non-food images) activated the insula and OFC, 
with a positive modulation of insular activity induced by subjective ratings of appetite 
(Porubska et al., 2006). These findings are consistent with the recognition of the insula as 
being an important region in establishing salience. Following on from this, Fuhrer et al. in 
2008 studied 12 healthy male volunteers undergoing two separate scanning sessions – one 
when fasted overnight and the other immediately after a large meal.  They performed a 
whole brain, uncorrected analysis of the data and particularly noted significantly enhanced 
activity within the OFC when hungry, again with reference to our understanding of this area 
as subjectifying the perceived pleasantness of food (Fuhrer et al., 2008). Furthermore, in 
2009, Goldstone et al. reported the findings from a fMRI study of twenty individuals in both 
the fed and fasted state; subjects viewed pictures of high calorie, low calorie and non-food 
items whilst rating the appeal value of these images. They found that when fasted, there was 
significantly greater activation to high calorie over low calorie food items in the ventral 
striatum, amygdala, anterior insula and OFC. They found that high calorie foods were 
consistently rated as more appealing, that this was augmented with fasting, and that the 
increase in appeal rating bias for high calorie over low calorie foods in the fasted state was 
positively correlated with activity in the OFC (Goldstone et al., 2009). In the same year, 
Schur et al. performed a study of ten normal weight, fed subjects viewing images of fattening 
food, non-fattening food and non-food items. These food images were specifically chosen 
based on whether the food was perceived to be compatible with an effort to lose weight. In a 
ROI analysis, this was the first study to report increased hypothalamic activation when 
viewing pictures of fattening food compared with non-food items, although this finding did not 
extend to other comparisons (ie fattening versus non-fattening or all food versus non-food).  
In concordance with other studies, they also found increased activation in the amygdala, 
insula and OFC when viewing fattening foods compared with non-food items (Schur et al., 
2009).  Also in agreement with previous findings were the results of Siep et al., who in 2009 
reported increased activity in the amygdala and OFC in response to viewing high calorie 
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versus low calorie food images, but only when their subjects were fasted (Siep et al., 2009). 
Their experimental protocol allowed for the further observation that this increased activity in 
the amygdala and OFC was only evident when participants explicitly evaluated foods but not 
when their concentration was diverted elsewhere.  
 
Recently, it was demonstrated (Fletcher et al., 2010) that the amygdala, hypothalamus and 
ventral striatum are all specifically responsive to viewing images of high calorie foods versus 
low calorie foods in the fasted state. Interestingly, the difference in ventral striatal activity 
between viewing high and low calorie food images was attenuated in the fed state, whereas 
the difference in hypothalamic and amygdala responses were unaffected by satiety.  
 
1.15. fMRI studies of hormones implicated in appetite control 
 
Having discussed the first generation of fMRI studies exploring the physiological responses 
to feeding, I will now turn to focus on research that has investigated the effects of appetite 
modulating hormones derived from the gastrointestinal tract and adipose tissue on the fMRI 
neuronal response. As alluded to earlier, such hormones are thought to be key mediators of 
both short term and longer term energy balance; in the post-prandial state, anorectic 
hormones (including PYY, GLP-1 and insulin) predominate, and in the longer term, high 
circulating levels of leptin and insulin correlate with nutritional status. In contrast, in the 
fasted, hungry state, the orexigenic hormone ghrelin is dominant amongst gut hormones. It 
is therefore interesting to observe the effects of exogenous administration of such hormones 
on the fMRI response, and compare these results with outcomes from earlier studies 
comparing the physiological fasted and fed states. It is worth noting that thus far, the majority 
of fMRI studies coupling the exogenous administration of appetite modulating hormones 
62 
 
(with the exception of studies of leptin) have been conducted in healthy, normal weight 
subjects, in order to investigate the action of such hormones in normal physiology.  
 
1.15.1. PYY and GLP-1 
 
PYY and GLP-1 are anorectic hormones, released by the enteroendocrine L cells of the gut 
following a meal; they lead to marked inhibition of food intake when administered to fasted 
human subjects (Verdich et al, 2001, Batterham et al. 2002; Sloth et al. 2007). In healthy 
human subjects, following intravenous infusion of PYY3-36, there was not only reduced food 
intake, but increased activity in the hypothalamus and OFC, as assessed by BOLD fMRI 
(Batterham et al., 2007). This study was conducted with subjects at rest, without 
engagement in a visual food-cue based task. Furthermore, during saline infusion visits, 
subjects’ caloric intake correlated positively with BOLD signal change in the hypothalamus, 
whereas this switched to a negative correlation between caloric intake and OFC signal on 
study visits when PYY3-36 was infused. It was postulated that the presence of PYY3-36 
switched regulation of food intake from a homeostatic brain region (hypothalamus) to a 
hedonic region (OFC).  
 
There have been no human studies to date investigating fMRI response to administration of 
GLP-1. A PET study has previously revealed that the endogenous post-prandial GLP-1 
response is positively associated with changes in neuronal activity in the prefrontal cortex 
and hypothalamus (Pannacciulli et al., 2007). 
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1.15.2. Ghrelin 
 
Ghrelin is a potent orexigenic gut hormone released from the stomach in response to fasting; 
administration of ghrelin to humans increases food intake (Wren et al., 2001, Druce et al., 
2005). A study by Malik et al. demonstrated that in normal-weight human subjects, 
intravenous ghrelin infusion increased hunger ratings and also increased the BOLD fMRI 
signal change (between food and non-food visual cues) compared with saline infusion in the 
amygdala, OFC, insula, visual areas and striatum (Malik et al., 2008).  
 
1.15.3. Insulin 
 
The central anorectic effect of insulin in normal physiology (Porte and Woods, 1981) must be 
distinguished from the secondary effect of hunger resulting from hypoglycaemia that may 
follow the exogenous administration of insulin (the associated over-compensatory eating 
may provide some explanation as to why patients with diabetes treated with insulin tend to 
gain weight). Therefore, human studies investigating the direct physiological action of insulin 
in the CNS have had to overcome the hurdle of maintaining euglycaemia during  insulin 
administration, for otherwise, it is the effect of hypoglycaemia (rather than the effect of 
insulin per se) that would manifest. Furthermore, to effectively study the action of insulin in 
the CNS, peripheral effects of the hormone should ideally be eliminated, hence even the use 
of a euglycaemic hyperinsulinaemic clamp technique is unsatisfactory in this regard. One 
group has used intranasal insulin administration as a method of overcoming this technical 
difficulty, demonstrating that insulin resulted in reduced BOLD fMRI activation (with respect 
to food images versus non-food images) in 9 healthy, normal weight adults compared with 
placebo in the right and left fusiform gyrus, the right hippocampus, right temporal superior 
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cortex, and the right frontal middle cortex (Guthoff et al., 2010). Notably, peripheral plasma 
glucose did not change following the intranasal insulin administration, thus validating their 
technique of observing the central effects of insulin.  
 
1.15.4. Leptin 
 
Leptin deficient individuals are obese and hyperphagic; replacement of leptin in these 
individuals reduces food intake (Williamson et al., 2005). However, the well recognised 
phenomenon of leptin resistance in obesity has precluded its development from a 
therapeutic viewpoint. However, fMRI studies of leptin administration are nevertheless 
interesting to shed further light on the physiological regulation of appetite.  
 
In 2 congenitally leptin deficient human subjects, daily subcutaneous leptin replacement 
reduced BOLD fMRI activation (in terms of the difference in activation between viewing food 
and non-food images) in the nucleus accumbens-caudate and putamen-globus pallidus 
regions compared with the control, leptin deficient state. Furthermore, before leptin 
treatment, activation in the nucleus accumbens-caudate correlated positively with liking of 
food images in both the fed and fasted states, whereas after leptin treatment, activation in 
the nucleus accumbens-caudate correlated positively with liking of food images only in the 
fasted state (Farooqi et al., 2007). Another study that year demonstrated that in 3 
congenitally leptin deficient human subjects, daily subcutaneous leptin replacement reduced 
the difference in BOLD fMRI activation (between viewing high calorie and low calorie food 
images) in regions implicated in the insula, temporal and parietal cortex compared with when 
subjects were not receiving leptin. On the other hand, leptin replacement increased the 
difference in BOLD fMRI activation (between viewing high calorie and low calorie food 
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images) in the prefrontal cortex compared with when subjects were not receiving leptin 
(Baicy et al., 2007). The authors postulated that the insula, temporal cortex and parietal 
cortex are hunger regions, therefore are inhibited by leptin, whereas the prefrontal cortex is a 
satiety region and is thus inhibited by weight loss and activated by leptin.  
 
Following this, a study by Rosenbaum et al. in 2008 showed that in 6 leptin replete obese 
human subjects who achieved an initial 10% weight loss (between 36 and 62 days) through 
dietary means, there was increased BOLD fMRI signal difference (between comparing food 
images and non-food images) in several regions including the brainstem and 
parahippocampal gyrus compared with the baseline state before weight loss. These changes 
were reversed by 5 weeks of subcutaneous leptin administration. Interestingly, other regions, 
including the hypothalamus and cingulate gyrus responded in the opposite direction 
following weight loss, but these changes remained sensitive to reversal by 5 weeks of 
subcutaneous leptin administration (Rosenbaum et al., 2008). This study reinforced the idea 
that weight loss leads to a state of relative leptin deficiency, which may be responsible for 
the rebound hyperphagia and subsequent weight gain in many dieters.  
 
1.16. Imaging before and after gastric bypass surgery  
 
The most effective treatment for obesity available at present is Roux-en-Y gastric bypass 
surgery, leading to sustained weight loss of approximately 30% and often a very prompt 
resolution of Type 2 Diabetes (Maggard et al., 2005). Although the mechanisms behind the 
weight loss seen following Roux-en-Y bypass surgery remain to be fully elucidated, they are 
unlikely to be solely due to restrictive or malabsorptive means alone. Roux-en-Y results in 
greater weight loss than adjustable gastric banding and this is thought to be due to a number 
of additional neurohormonal causes (Tice et al., 2008). These include elevated post-
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operative levels of endogenous anorectic gut hormones such as PYY and GLP-1 (Borg et 
al., 2006, le Roux et al., 2006, le Roux et al., 2007), increases in energy expenditure and 
metabolic rate (Nestoridi et al., 2012) changes in taste preference away from calorie dense 
foods (Bueter et al., 2011, le Roux et al., 2011), increased bile acid delivery to the ileum 
(Patti et al., 2009) and changes in gut microbiota (Li et al., 2011).  Recent studies imaging 
appetite in patients before and after weight loss are important in helping us to understand 
some of the CNS mediated effects.  
 
In 2011 van de Sande-Lee et al. performed fMRI studies on 8 lean control subjects and 13 
obese patients pre- and post- Roux-en-Y gastric bypass, by which an average 30% 
reduction in body weight had been achieved (van de Sande-Lee et al., 2011). They 
demonstrated that there was a reduction in hypothalamic signal seen 5-10 minutes following 
glucose ingestion in normal controls, but that was diminished in the obese (pre-operative) 
group. However, a recovery of this impaired hypothalamic response was seen post-
operatively when the obese group had lost weight following gastric bypass surgery.  
Interestingly, they also reported in lean subjects, a high level of functional connectivity 
between the hypothalamus and the orbitofrontal and somatosensory cortices. This was not 
seen in obese subjects, but post-operative weight loss was reported to re-establish these 
connectivity patterns (van de Sande-Lee et al., 2011). 
  
In the same year, a further ROI-based study of 10 obese female patients 1 month pre- and 
post- Roux-en-Y gastric bypass, there was attenuation of fMRI BOLD signal (when viewing 
high-calorie versus low-calorie food images) in the VTA, ventral striatum, putamen, lentiform 
nucleus, posterior cingulate and dorsomedial prefrontal cortex following the bypass 
procedure (Ochner et al., 2011). In this study, hunger was also reduced after surgery. 
Although circulating gut hormone levels were not measured, the authors speculated that 
post-surgical reductions in the orexigenic hormone ghrelin could have explained their 
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imaging observations. This would certainly be consistent with the previous fMRI findings 
(Malik et al., 2008) following exogenous ghrelin administration. The same imaging group 
have also recently published the results from a further fMRI study (Ochner et al., 2012), 
where 14 females were assessed 1 month pre- and one month post- Roux en-Y gastric 
bypass surgery. Results from this study confirmed significant postoperative reductions in 
striatal neural response, along with reductions in wanting and liking for high calorie relative 
to low calorie food cues.  
 
1.17. Summary 
 
The overall control of appetite and food intake is complex, resulting from integration of a 
variety of inputs in both homeostatic and hedonic brain regions. Obesity arises following an 
imbalance of energy homeostasis, where there is a relative excess of food intake in relation 
to energy expenditure. At present, there are no effective pharmacotherapies to tackle obesity 
that are licensed in the UK, and the only effective treatment of obesity is bariatric surgery, 
which is not without risk. Anorectic gut hormones, which are released post-prandially and 
known to exert effects on appetite centres in the brain, remain promising therapeutic targets. 
Two such hormones are PYY and GLP-1, both of which are secreted by the gut in response 
to a meal are thought to be important mediators of the satiety response. Acute administration 
of PYY3-36 and GLP-17-36 amide (the active form of the hormones) to humans is well established 
to inhibit appetite and reduce food intake, when the hormones are administered both singly 
and in combination. Thus, clarifying the neuroendocrinology of anorectic gut hormones such 
as PYY3-36 and GLP-17-36 amide, acting both independently and together, is hugely important 
for the development of effective obesity treatments. 
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In humans, fMRI offers an opportunity to safely study the effects of these hormones on the 
brain. fMRI studies have already established important differences in brain activation in 
response to food cues between the fed and fasted states in a variety of hedonic brain 
regions, although homeostatic brain regions have been more difficult to study. This has been 
followed by further fMRI studies investigating the action of orexigenic (ghrelin) and anorectic 
(leptin, insulin, and PYY3-36) hormones on brain regions implicated in appetite control. To 
date however, there have been no published human studies investigating the action of    
GLP-17-36 amide on brain regions implicated in appetite control, nor any studies investigating 
the combined action of PYY3-36 and GLP-17-36 amide on the brain fMRI response. Notably, 
following Roux-en-Y gastric bypass surgery, patients have elevated post-prandial levels of 
both PYY and GLP-1, and the combined action of these peptides is thought to be a key 
contributor to the greater and sustained weight loss observed following the intervention. In 
light of interesting recent fMRI data in patients pre- and post- bariatric surgery, it is all the 
more compelling to study the combined action of PYY3-36 and GLP-17-36 amide on the CNS in 
humans using fMRI. 
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1.18. Hypotheses and aims 
 
1.18.1. Hypotheses: 
 
I hypothesise that 
1. In subjects fasted overnight, mildly anorectic doses of PYY3-36 and GLP-17-36 amide, 
when infused in combination, will reduce ad libitum energy intake at a subsequent 
buffet meal compared with saline. 
 
2. There will be increased BOLD fMRI signal in the fasted state compared to the fed 
state when viewing food images versus non-food images in key CNS reward areas.  
 
3. The effect of combined infusion of PYY3-36 and GLP-17-36 amide in fasted subjects will 
reduce the BOLD fMRI signal in key CNS reward areas, similar to that observed in 
the fed state.  
 
1.18.2. Aims 
1. To establish doses of PYY3-36 and GLP-17-36 amide that are mildly anorectic alone but 
anorectic in combination compared with saline. 
 
2. To compare the BOLD fMRI response to food versus non-food images in the fed 
state and the fasted state during infusion of saline.  
 
3. In the fasted state, to investigate the BOLD fMRI response to PYY3-36 and            
GLP-17-36 amide, infused singly and in combination at doses determined in Aim 1.  
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CHAPTER 2 
 
Investigation of the effects of single and 
combined administration of PYY3-36 and       
GLP-17-36 amide on appetite and energy intake: 
Dose verification study 
(STUDY 1) 
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2.1. Introduction and rationale 
 
PYY3-36 and GLP-17-36 amide are well established to reduce food intake when administered 
intravenously to humans (Verdich et al., 2001, Batterham et al., 2002, Neary et al., 2005, 
Sloth et al., 2007). Varying degrees of nausea were encountered in the above studies. I 
therefore decided to perform a dose verification study in order to confirm doses of PYY3-36 
and GLP-17-36 amide that when administered in combination, would lead to a significant 
reduction in food intake without causing nausea which would prevent subjects from 
continuing in the study. I performed this initial dose verification study in order to guide doses 
of PYY3-36 and GLP-17-36 amide to be used in the subsequent fMRI study. 
 
Previous work by Neary et al. (Neary et al., 2005) had demonstrated that combined infusion 
of PYY3-36 & GLP-17-36 amide, each at a dose of 0.4 pmol/kg/min, reduced energy intake by 
27% compared to saline at an ad libitum buffet meal served 90 minutes into the infusion. 
Significantly, no nausea was reported in the group of 10 subjects. When GLP-17-36 amide was 
administered singly, there was only a 5% reduction in energy intake compared to saline at 
the ad libitum buffet meal. Taking this study by Neary et al. as an initial guide, I firstly 
decided to change the dose of infused GLP-17-36amide from 0.4 pmol/kg/min to 0.8 
pmol/kg/min. This is based on data from the meta-analysis by Verdich et al. in which the 
mean infusion rate of GLP-17-36 amide was 0.89 pmol/kg/min across all subjects in all studies 
and this led to a 13.2% reduction in energy intake at the ad libitum buffet meal compared 
with saline infusion (Verdich et al., 2001). A formal assessment of nausea ratings seems to 
have been made in only 2 of the studies included in Verdich’s meta-analysis; however, 
reassuringly, nausea was not observed in either of these individual studies.  
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Secondly, I decided to reduce the infused dose of PYY3-36 from 0.4 pmol/kg/min (used in the 
study by Neary et al.) to 0.3 pmol/kg/min in order to limit nausea. In the study by Neary et al., 
when PYY3-36 was administered singly, there was a 15% reduction in energy intake 
compared to saline at the ad libitum buffet meal. Other 90 minute infusion studies of PYY3-36 
have used varying doses between 0.2 pmol/kg/min and 0.8 pmol/kg/min. In one study (Sloth 
et al., 2007) found there to be no reduction in ad libitum energy intake with a dose of 0.2 
pmol/kg/min. In contrast, a dose of 0.8 pmol/kg/min led to a 19% reduction in ad libitum 
energy intake compared with saline in the subjects that managed to complete the study; in 
5/9 subjects, nausea and abdominal discomfort was so severe that the studies had to be 
terminated. This is in contrast to studies performed by Batterham et al., where a PYY3-36 
dose of 0.8 pmol/kg/min was reported to produce no nausea in 12 subjects (Batterham et al., 
2002). A further PYY3-36 dose-response study (Degen et al., 2005) in 16 subjects revealed 
that administering a dose of 0.2 pmol/kg/min did not produce nausea, whereas a dose of 0.4 
pmol/kg/min led to nausea in 2 subjects. Increasing the dose to 0.8 pmol/kg/min induced 
nausea in 4 subjects. As mentioned earlier, Neary et al. reported no nausea when PYY3-36 
0.4 pmol/kg/min was co-infused with GLP-17-36 amide at a dose of 0.4 pmol/kg/min. The 
therapeutic window for anorectic gut hormones, particularly that of PYY3-36, is narrow and the 
method of dose adjusting for the actual known peptide content of each vial had not been 
performed in previously published studies. This may form one source of discrepancy 
between the above studies in terms of induction of nausea with infusion of PYY3-36.  
 
It should be noted that Neary et al. continued the peptide infusion during the meal for a 
further 30 minutes. Although this is possible in a clinical investigation unit, I faced the 
additional practical issue of using an MRI-compatible injector system to deliver the peptide 
infusion during the subsequent fMRI study. This injector system cannot be easily moved out 
of the scanner room and furthermore, it would not possible for subjects to be served their 
test meal at the end of the study in the MRI scanner room. Hence, continuation of the 
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peptide infusion during the meal would have necessitated a change of injector systems 
during the infusion, which would have lead to inconsistency in peptide delivery and would 
have also required preparing a new infusion mid-way through the study.  
 
I was therefore initially guided by previous studies that administered individual infusions of 
PYY3-36 and GLP-17-36 amide to determine the timing of the test meal in relation to the peptide 
infusion as well as the duration of the infusion itself. Previous PYY3-36 infusion studies 
(Batterham et al., 2002, Sloth et al., 2007) had left an interval of 2 hours between termination 
of the infusion and timing of the test meal, yet demonstrated a significant reduction in food 
intake in response to the peptide. The duration of PYY3-36 infusion was 90 minutes in both 
these studies. Historically, GLP-17-36 amide infusion studies have allowed a shorter interval (if 
any at all) between termination of the infusion and serving the test meal. Some studies 
served the test meal whilst continuously running the peptide infusion (Naslund et al., 1999, 
Long et al., 1999, Gutzwiller et al., 1999), whereas in others, the infusion was stopped 30 
minutes before the meal was served and then restarted at the onset of the meal (Flint et al., 
1998, Flint et al., 2001). The duration of the infusion in many of these studies has been in 
the order of 60 minutes. The difference in protocols used between PYY3-36 and GLP-17-36 amide 
infusion studies in terms of the timing of the study meal probably stems from the differing 
circulating half-life of the two peptides; PYY3-36 has a circulating half-life of approximately 8 
minutes (Lluis et al., 1989), whereas that of GLP-17-36 amide is only 2 minutes (Kieffer et al., 
1995). Given that my protocol was to use a combination of PYY3-36 and GLP-17-36 amide, I 
decided to serve the test meal immediately after the termination of the 90 minute infusion. 
This was to better take into account the extremely short circulating half-life of GLP-17-36 amide. 
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2.2. Methods 
 
2.2.1. Peptides 
 
Human PYY3-36 and GLP-17-36 amide were purchased from Bachem (St. Helens, UK). The 
identity and purity of each peptide was confirmed by matrix assisted laser desorption 
ionisation-time of flight (MALDI-TOF) mass spectrometry, and by high-pressure liquid 
chromatography (HPLC) (Bachem).  
 
Sterile 0.9% saline was purchased from Bayer (Haywards Heath, UK). Using an aseptic 
technique in a laminar flow cabinet, the peptides were dissolved in 0.9% saline, aliquoted 
into vials and freeze dried. Vials were randomly selected for microbiological examination and 
for the Limulus Amoebocyte Lysate test for pyrogen. The vials were sterile on bacterial and 
extended fungal culture (Department of Microbiology, Hammersmith Hospital, London) and 
the Limulus Amoebocyte Lysate tests (Associates of Cape Cod, Liverpool, UK) were within 
the safe range for human infusion. Further representative vials were randomly selected and 
sent for amino acid analysis by Alta Bioscience (Birmingham, UK). These results were used 
to calculate the actual peptide content of the vials and therefore the correction factor when 
calculating the dose of peptide to be administered to subjects.  
 
Toxicity studies were also performed; PYY3-36 and GLP-17-36 amide, each at a dose greater 
than 10 times the maximum intended for humans (in pmol/kg body weight), were 
administered by intra-peritoneal injection to 20 mice, and saline was administered to a 
control group of 10 mice. Half the animals in each group were sacrificed by CO2 
75 
 
asphyxiation after 48 hours, and the other half after 14 days. The heart, lungs, kidneys, liver, 
spleen, pancreas, brain and gut were dissected, fixed and sent for examination by an 
independent histopathologist.  
 
2.2.2. Subjects 
 
Six healthy right-handed subjects (2 male and 4 female) of mean age 31.5 years (range 21 – 
45 years) and mean BMI 21.7 kg/m2 (range 19.1 - 24.6 kg/m2), were recruited by newspaper 
advertisement. Inclusion criteria for this research were: age 18 years or over; in good health, 
stable body weight for the preceding three months, and BMI 19 - 25 kg/m2. Exclusion criteria 
were: smokers, substance abuse; significant physical or psychiatric illness; regular 
medication other than contraceptives, and pregnancy. All subjects were screened and 
determined to be healthy by medical history, physical examination, full blood count, urea and 
electrolytes, liver function tests, bone profile, thyroid function tests and 12-lead 
electrocardiogram. Women of child-bearing age were advised to avoid pregnancy during the 
studies and underwent a urine test to exclude pregnancy prior to the start of each study visit. 
Potential subjects were screened to exclude those with disordered eating, as assessed by 
the SCOFF questionnaire (Morgan et al., 1999), and those with a high level of restrained 
eating, as assessed by the standard Dutch Eating Behaviour Questionnaire (Van Strien et 
al., 1986). A score of 1 point or greater on the SCOFF questionnaire, or a total score of 25 
points or greater on the first 8 questions of the Dutch Eating Behaviour Questionnaire 
warranted exclusion from participation in the study. Furthermore, women who reported 
significant alteration of eating behaviour during different phases of the menstrual cycle were 
excluded from participation. Subjects also completed a three day diet diary to determine their 
usual eating habits before acceptance into the studies. During the screening visit, a sample 
of the study meal was provided, and an assessment of palatability was made using a nine-
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point hedonic scale. Subjects who disliked the study meal, or rated the study meal as ‘like 
extremely’ were also excluded.  
 
The research was approved by the St Mary’s Research Ethics Committee (reference number 
09/H0712/4). The research was planned and performed in accordance with the Declaration 
of Helsinki. Full, informed consent was obtained from all subjects prior to enrolment in the 
study.  
 
2.2.3. Design 
 
Six healthy right-handed subjects (2 male and 4 female) each attended the clinical 
investigation unit for 5 study visits, each at least 3 days apart. Subjects fasted (they were 
permitted to drink only water) from 22:00 h the evening before each study visit. They were 
asked to standardise their diet (by eating the same evening meal at the same time the night 
before each study visit), abstain from alcohol and avoid strenuous exercise for 24 hours prior 
to each visit.  
 
The study was conducted in a single-blinded fashion. On their first visit, subjects always 
received an infusion of saline after an overnight fast. This protocol was an identical protocol 
to that used for the subsequent fasted visits, and was intended to acclimatise the subject to 
the clinical environment and to experimental procedures. Results from the first saline visit 
are not included in the analysis. Following the first saline visit, subjects were randomly 
assigned to receive each of the following after an overnight fast: 
 
 
77 
 
1. Saline infusion (control visit) 
2. PYY3-36 infusion at 0.3 pmol/kg/min 
3. GLP-17-36 amide infusion at 0.8 pmol/kg/min 
4. Combined PYY3-36  + GLP-17-36 amide infusion, at 0.3 pmol/kg/min and 0.8 pmol/kg/min 
respectively 
 
Subjects arrived for each visit at 09:30 h (t = - 60 min), then had peripheral intravenous 
cannulae inserted in both forearms; one for infusions and one for blood sampling. Subjects 
were studied up to a maximum of two per room and were separated by a screen when meals 
were served. They were encouraged to relax, but not fall asleep, by reading or watching a 
DVD. Time cues were removed from the study room to limit the potential effect of time 
awareness leading to food expectation and appetite alteration. 
 
2.2.4. Peptide preparation and delivery 
 
All syringes and lines used to deliver peptide were coated in gelofusin for 20 minutes prior to 
preparation, to minimise adsorption of peptide to the plastic walls. The vehicle for delivering 
peptide was a 10% solution of gelofusin in 0.9% saline. Vials of peptide were dissolved in 
2.5 ml vehicle, and drawn up in a single syringe up to a total volume of 60 ml. The amount of 
peptide added to the delivery syringe varied according to the dose each subject received, 
such that the infusion rate was kept constant throughout at 20 ml/hr (Graseby 3100 syringe 
driver, SIMS Graseby Ltd, Watford, UK). The first 10 ml were slowly (over 5 minutes) purged 
through the delivery line before it was attached to a subject’s infusion cannula. The 
intravenous infusion started at 10:30 h (t = 0 min) and was delivered over 90 minutes.   
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2.2.5. Blood sampling and processing 
 
Six ml blood samples were collected for gut hormone measurement at t = - 30, 0, 15, 30, 45, 
60, 75, 90 and 120 min into lithium heparin-coated tubes (International Scientific Supplies 
Ltd, Bradford, UK) containing 1500 kallikrein inhibitor units (0.15 ml) aprotinin (Trasylol, 
Bayer Schering Pharma, Berlin, Germany). Samples immediately underwent centrifugation 
(4000 rpm for 10 minutes at 4°C), after which, plasma was separated immediately and 
stored at - 20°C until analysis. Cannulae were flushed with 6 ml 0.9% saline after collecting 
each blood sample. Immediately prior to collection of the subsequent sample, 1 ml 
deadspace blood was collected and discarded. 
 
2.2.6. Visual analogue scale scores 
 
At t = - 30, 0, 30, 60, 90, and 120 min, subjects completed a series of visual analogue scales 
(VAS) that rated food-related sensations (hunger, nausea, fullness). The VAS scales 
consisted of 100 mm lines with text expressing the most positive and the most negative 
rating for each variable anchored at either end (Flint et al., 2000). 
 
2.2.7. Measurement of haemodynamic parameters and blood glucose 
 
The pulse and blood pressure of each subject was measured at t = - 30, 0, 15, 30, 45, 60, 
75, 90, and 120 min. A drop of blood was taken from the t = - 30, 0, 30, 60, 90 and 120 min 
samples to check blood glucose on an Optimum Exceed blood glucose monitor (Abbott 
Diabetes Care, Maidenhead, Berks). Haemodynamic parameters and blood glucose were 
measured primarily to ensure subjects’ safety during the studies.  
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2.2.8. Ad libitum test meal 
 
The infusion was terminated after 90 minutes. Immediately after stopping the infusion (i.e. t = 
90 min), subjects were offered an identical buffet meal at each visit that was provided in 
excess. Subjects were asked to ‘eat until comfortably full’. Water was freely available. The 
meal was served with the curtains drawn around each subject for 20 minutes and consisted 
of a mild chicken tikka curry with rice (628 kJ/ 100g) or a vegetarian option of tomato and 
mozzarella pasta (507kJ /100g). Each subject had previously decided on their choice of 
meal during their screening visit; they were subsequently served the same meal during each 
of their study visits. Food was weighed pre- and post-consumption. Energy intake was 
calculated from the weight of food consumed. At the end of the meal, subjects were asked to 
rate the palatability of the food using VAS. Subjects remained in the study room until t = 120 
min.  
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The protocol for Study 1 is summarised in figure 2.1 below. 
- 90 - 60 - 30 0 +30 +60 +90 +120
Subject 
arrives, 2 
cannulae
inserted
Start 
infusion
End 
infusion 
and buffet 
meal
Home
VAS
Blood 
sample
X
X
X X X X X X
X
X
X
Time 
(min)
X
X
XX
 
Figure 2.1: Protocol for Study 1. Healthy subjects underwent 90 minute infusions of saline, PYY 0.3 
pmol/kg/min, GLP-1 0.8 pmol/kg/min, combined PYY 0.3 pmol/kg/min + GLP-1 0.8 pmol/kg/min 
following an overnight fast. An ad libitum buffet meal was served immediately after the infusion in 
order to measure energy intake. Blood sampling and VAS analysis was performed as indicated. Study 
visits were single blinded and in randomised order.   
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2.2.9. Measurement of total PYY 
 
Total PYY immunoreactivity was measured with a specific and sensitive in-house 
radioimmunoassay (RIA), previously established (Adrian et al., 1985). Information regarding 
the priniciples of RIA can be found in Appendix 1. The antibody (Y21) was produced in 
rabbits against synthetic human PYY coupled to bovine serum albumin by glutaraldehyde 
and used at a final dilution of 1:50,000. The antibody cross reacted fully with both PYY3-36 
and PYY1-36, but not with pancreatic polypeptide, neuropeptide Y, or other known 
gastrointestinal hormones. Radiolabelled 125I-PYY was prepared by the iodogen method 
(Wood et al., 1981) and purified by HPLC. The specific activity of the 125I-PYY label was 54 
Bq/fmol. PYY standard was used at 1 pmol/ml and volumes ranging from 1 microlitre to 100 
microlitres were added to generate the standard curve. The assay was performed in total 
volume of 0.7 ml of 0.06 M phosphate buffer (pH 7.3) containing 0.3% bovine serum albumin 
(BSA). The assay was incubated for three days at 4ºC. Separation of the free and antibody 
bound radiolabel was by the addition of 0.1 ml sheep anti-rabbit antibody to each tube, along 
with 0.1 ml 10% polyethylene glycol (PEG) and 0.5 ml Triton X-100 in 0.05M phosphosaline, 
followed by centrifugation at 4ºC for 20 minutes at 2500 rpm. The detection limit of the assay 
was 2 pmol/L, with an intra-assay coefficient of variation of 5.8%. The inter-assay coefficient 
of variation was 9.8%. All samples were assayed in duplicate and in one assay to avoid 
inter-assay variation.  
 
2.2.10. Measurement of amidated GLP-1 
 
Amidated GLP-1 like immunoreactivity was measured by a specific and sensitive in-house 
RIA, previously established (Kreymann et al., 1987). The antibody was produced in rabbits 
against human GLP-1 coupled to BSA and used at a final dilution of 1:50,000. The antibody 
cross reacted 100% with all amidated forms of GLP-1 but did not cross react with glycine 
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extended forms [GLP-11-37 and GLP-17-37] or any other known pancreatic or gastrointestinal 
peptide. Radiolabelled 125I-GLP-1 was prepared by the iodogen method (Wood et al., 1981) 
and purified by HPLC. The specific activity of the 125I-GLP-1 label was 48 Bq/fmol. GLP-1 
standard was used at 0.5 pmol/ml and volumes ranging from 1 microlitre to 100 microlitres 
were added to generate the standard curve. The assay was performed in a total volume of 
0.7 ml of 0.06 M sodium barbitone buffer (pH 8) containing 0.3 % BSA and 0.02 % Tween. 
The assay was incubated for three days at 4ºC. Separation of the free and antibody bound 
radiolabel was by charcoal adsorption (charcoal and dextran were dissolved in 0.06 M 
phosphate buffer containing gelatine, and 0.3 ml of this solution was added to each tube). 
The limit of detection of the assay was 5 pmol/L with an intra-assay coefficient of variation of 
under 10%. The inter-assay coefficient of variation was also under 10%. All samples were 
assayed in duplicate and in one assay to avoid inter-assay variation. 
 
2.2.11. RIA set up for measurement of total PYY and amidated GLP-1 
 
Assay tubes were set up in duplicate according to the volumes described in table 2.1 below. 
All samples were added in duplicate. “Non-specific binding (NSB)” tubes, without primary 
antibody, were added at the beginning of the assay. Tubes containing half (1/2 X) and twice 
(2X) the standard volume of radiolabelled peptide were also included in order to confirm the 
quality of the radiolabel. Tubes with no sample (‘zero’ tubes) were placed at regular intervals 
throughout the assay, and standard (STD) curves (containing known quantities of unlabelled, 
pure peptide) were performed every 400 tubes, in order to calibrate the assay. Quality 
control (QC) samples, containing high, medium and low known concentrations of each 
peptide, were included at 3 points within each assay.  
The known QC values for each assay (pmol/L) were: 
PYY: High = 100 - 150 pmol/L, Medium = 50 - 100 pmol/L, Low = 10 - 40 pmol/L. 
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GLP-1: High = 120 - 180 pmol/L, Medium = 60 - 100 pmol/L, Low = 20 - 40 pmol/L. 
The measured QC values for each hormone were within the above ranges. At the end of the 
assay, two tubes contained excess antibody (XS), to ensure that the volume of antibody 
added during the assay was indeed limiting.  
 
TUBE 
IDENTITY 
BUFFER 
VOLUME 
(µL) 
LABEL 
VOLUME 
(µL) 
ANTIBODY 
VOLUME 
(µL) 
SAMPLE / 
STANDARD 
(µL) 
TOTAL 
VOLUME 
 (µL) 
NSB 600 100 0 0 700 
1/2 X 550 50 100 0 700 
2 X 400 200 100 0 700 
ZERO 500 100 100 0 700 
STD 1-15 500 100 100 1-15 701-715 
STD 20 480 100 100 20 700 
STD 30 470 100 100 30 700 
STD 50 450 100 100 50 700 
STD 100 400 100 100 100 700 
XS 
Sample  
QC 
0 
400 
400 
100 
100 
100 
600 
100 
100 
0 
100 
100 
700 
700 
700 
 
Table 2.1: Volumes of reactants for addition to PYY and GLP-1 in-house radioimmunoassay.  
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2.2.12. Statistical analysis of energy intake, VAS, haemodynamic parameters, blood 
glucose and gut hormone levels 
 
Grouped data are represented as the mean ± Standard Error of Mean (SEM). Comparisons 
of energy intake and ratings of meal palatability were by repeated measures Analysis of 
Variance (ANOVA) with Tukey’s multiple comparison post-test. VAS scores were adjusted 
for baseline and differences between t = 0 min and t = 90 min (the duration of the infusion) 
compared by repeated measures non-parametric Friedman’s test with Dunn’s multiple 
comparison post-test. Glucose levels were adjusted for baseline and differences between t = 
0 min and t = 90 min compared by repeated measures ANOVA with Tukey’s multiple 
comparison post-test. Comparisons of haemodynamic parameters between interventions 
were by one-way ANOVA with Tukey’s multiple comparison post-test. For each subject, the 
area under the curve (AUC) of plasma gut hormone levels was calculated during the infusion 
period (0 - 90 min) and the mean values during each of the interventions were compared by 
repeated measures ANOVA with Tukey’s multiple comparison post-test. The threshold for 
statistical significance in each case was set at p<0.05. Analyses were performed using 
Prism version 5.01 software (Graphpad Software, San Diego, CA, USA). 
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2.3. Results 
 
2.3.1 Peptides 
 
Microbiological examination and Limulus Amoebocyte Lysate testing of representative 
peptide vials was unremarkable. Analysis by Alta Bioscience (Birmingham, UK) revealed that 
a representative 25 nmol vial of PYY3-36 actually contained 18.6 nmol and a representative 
25 nmol vial of GLP-17-36 amide actually contained 25.4 nmol. Toxicity studies in mice showed 
no histological abnormalities (Appendix 2).  
 
2.3.2. Energy intake 
 
All subjects were fasted overnight before each study visit. For the 6 subjects in Study 1, the 
mean energy intake during the ad libitum buffet lunch was 3478 ± 838.4 kJ when they 
received saline, 3726 ± 804.5 kJ when they received the single infusion of PYY3-36 0.3 
pmol/kg/min, 3334 ± 961.3 kJ when they received the single infusion of GLP-17-36 amide 0.8 
pmol/kg/min and 2359 ± 825.7 kJ when they received the combined infusion of PYY3-36 0.3 
pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min. This is illustrated in figure 2.2 below. The 
difference in mean energy intake was statistically significant between the 4 visits (p<0.05 for 
PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min vs. Fasted saline and GLP-17-36 
amide 0.8 pmol/kg/min, p <0.01 for PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
vs. PYY3-36 0.3 pmol/kg/min). 
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Figure 2.2: Mean ad libitum energy intake in Study 1. Six healthy subjects underwent 90 minute infusions of 
saline (Fast sal), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 
0.3 pmol/kg/min + GLP-17-35 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. An ad libitum buffet 
meal was served immediately after the infusion in order to measure energy intake. * denotes p<0.05 for 
PYY+GLP-1 vs. Fast sal and GLP-1, **denotes p <0.01 for PYY+GLP-1 vs. PYY. 
 
2.3.3. Ratings of meal palatability 
 
For the 6 subjects in Study 1, mean rating (at t = 120 min) of how tasty they found the buffet 
lunch on a 100 mm VAS scale was 61 ± 9.4 mm when they received saline, 65.2 ± 8.7 mm  
when they received the single infusion of PYY3-36 0.3 pmol/kg/min, 64.8 ± 7.8 mm when they 
received the single infusion of GLP-17-36 amide 0.8 pmol/kg/min and 56.7 ± 12.0 mm when they 
received the combined infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min. 
This is illustrated in figure 2.3 below. There was no significant difference between visits (p = 
0.48). 
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Figure 2.3: Meal rating following ad libitum meal in Study 1. Six healthy subjects underwent 90 minute 
infusions of saline (Fast sal), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. 
An ad libitum buffet meal was served immediately after the infusion and subjects rated this meal on a scale of 
0 - 100. 
 
2.3.4. Hunger, nausea and fullness scores 
For the 6 subjects in Study 1, combined infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 
0.8 pmol/kg/min resulted in a mean increase in nausea score by 22.5 mm from t = 0 min to   
t = 90 min (figure 2.4). This was statistically significant when compared with the mean 
change in nausea score between t = 0 min and t = 90 min in other groups (p<0.05) (figure 
2.5). Analysis of the mean change in hunger and fullness scores between t = 0 min and t = 
90 min revealed no significant difference between the control saline infusion, PYY3-36 
infusion, GLP-17-36 amide infusion or combined PYY3-36 + GLP-17-36 amide infusion (p = 0.68) 
(figure 2.5).  
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Figure 2.4: Hunger, nausea and fullness ratings during Study 1. Six healthy subjects underwent 90 minute 
infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. 
On each day, the infusion was administered between t = 0 and t = 90 min. During the study, subjects 
completed 100 mm VAS questionnaires relating to hunger (A), nausea (B) and fullness (C) 
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Figure 2.5: Change in hunger, nausea and fullness ratings during Study 1. Six healthy subjects underwent 90 
minute infusions of saline (Fast sal), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. 
On each day, the infusion was administered between t = 0 and t = 90 min. During the study, subjects 
completed 100 mm VAS questionnaires relating to hunger, nausea and fullness.  The change in hunger (A), 
nausea (B) and fullness (C) from t = 0 to t = 90 min is shown.  
* denotes p<0.05 for PYY+GLP-1 vs. all other groups. 
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2.3.5. Haemodynamic parameters 
For the 6 subjects in Study 1, blood pressure (systolic and diastolic BP) and pulse were not 
significantly different between infusions, as shown in figure 2.6 (p = 0.23 for systolic blood 
pressure, p = 0.97 for diastolic blood pressure and p = 0.11 for pulse) 
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Figure 2.6: Haemodynamic parameters during Study 1. Six healthy subjects underwent 90 minute infusions of 
saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined 
PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. On each 
day, the infusion was administered between t = 0 and t = 90 min. During each study, systolic blood pressure 
(A), diastolic blood pressure (B) and pulse (C) were recorded. 
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2.3.6. Blood glucose 
For the 6 subjects in Study 1, infusion of GLP-17-36 amide 0.8 pmol/kg/min, in addition to 
combined infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min, led to a 
greater fall in blood glucose between 0 and 90 min compared with infusion of saline or 
infusion of PYY3-36 0.3 pmol/kg/min alone (figure 2.7). 
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Figure 2.7: Blood glucose during Study 1. Six healthy subjects underwent 90 minute infusions of saline (Fast 
sal), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 
pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. On each day, the 
infusion was administered between t = 0 and t = 90 min. During the study, the change in blood glucose from 
baseline was measured (figure 2.7 A). Figure 2.7 B shows the change in blood glucose from 0 - 90 min. 
* denotes p<0.05 for GLP-1 and PYY+GLP-1 vs. Fast sal. 
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2.3.7. Plasma PYY levels in Study 1 
 
Mean plasma concentration of total PYY (from time points t = 15 min to t = 90 min) was 27.5 
± 1.7 pmol/L when saline was infused, 66.8 ± 9.0 pmol/L when PYY3-36 0.3 pmol/kg/min was 
infused,  20.5 ± 0.4 pmol/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 87.3 ± 8.8 
pmol/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
was infused. 
 
Peak mean plasma concentration of total PYY (during the entire study) was 33.3 ± 6.8 
pmol/L during the saline study visit (occurring at t = 30 min), 91.0 ± 11.2 pmol/L during the 
PYY3-36 0.3 pmol/kg/min study visit (occurring at t = 90 min), 33.3 ± 3.7 pmol/L during the 
GLP-17-36 amide 0.8 pmol/kg/min study visit (occurring post-prandially at t = 120 min), and 
106.5 ± 12.6 pmol/L during the PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
study visit (occurring at t = 90 min).  
 
The mean AUC of total PYY levels (between 0 - 90 min) was 2553 ± 330 pmol min/L when 
saline was infused, 5464 ± 743 pmol min/L when PYY3-36 0.3 pmol/kg/min was infused,  1882 
± 224 pmol min/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 7267 ± 716 pmol 
min/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min was 
infused. There was no significant difference between the mean AUC of total PYY levels 
between saline and GLP-17-36 amide 0.8 pmol/kg/min infusions. When PYY3-36 was infused in 
combination with GLP-17-36 amide, the mean AUC of total PYY levels was higher than when 
PYY3-36 was infused singly (p<0.05). 
Figure 2.8 shows the variation of plasma total PYY levels with time in Study 1. 
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Figure 2.8: Variation of plasma total PYY levels with time during Study 1.  Following an overnight fast, 6 
healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-
17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1). On each study visit, the infusion was administered between t = 0 and t = 90 min. An ad libitum 
buffet lunch was served immediately after the infusion. Blood samples were taken for measurement of total 
PYY during each study at the time-points indicated.         
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2.3.8. Plasma GLP-1 levels in Study 1 
 
Mean plasma concentration of amidated GLP-1 (from time points t = 15 min to t = 90 min) 
was 19.8 ± 0.2 pmol/L when saline was infused, 17.2 ± 0.5 pmol/L when PYY3-36 0.3 
pmol/kg/min was infused, 58.9 ± 6.0 pmol/L when GLP-17-36 amide 0.8 pmol/kg/min was 
infused, and 59.4 ± 5.7 pmol/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 
amide 0.8 pmol/kg/min was infused. 
 
Peak mean plasma concentration of amidated GLP-1 (during the entire study) was 32.4 ± 
4.7  pmol/L during the saline study visit (occurring post-prandially at t = 120 min), 26.3 ± 4.0  
pmol/L during the PYY3-36 0.3 pmol/kg/min study visit (occurring post-prandially at t = 120 
min), 73.3 ± 6.7 pmol/L during the GLP-17-36 amide 0.8 pmol/kg/min  study visit (occurring at t = 
90 min), and 73.0 ± 9.4 pmol/L during the PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 
pmol/kg/min study visit (occurring at t = 90 min).  
 
The mean AUC of amidated GLP-1 levels (between 0 - 90 min) was 1790 ± 248 pmol min/L 
when saline was infused, 1574 ± 268 pmol min/L when PYY3-36 0.3 pmol/kg/min was infused,  
4897 ± 508 pmol min/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 4928 ± 585 
pmol min/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 
pmol/kg/min was infused. There was no significant difference between the mean AUC of 
amidated GLP-1 levels between saline and PYY3-36  0.3 pmol/kg/min infusions. Furthermore, 
there was no significant difference between the mean AUC of amidated GLP-1 levels when 
GLP-17-36 amide was infused singly or in combination with PYY3-36. 
Figure 2.9 shows the variation of plasma amidated GLP-1 levels with time in Study 1. 
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Figure 2.9: Variation of plasma amidated GLP-1 levels with time during Study 1.  Following an overnight fast, 
6 healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-
17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1). On each study visit, the infusion was administered between t = 0 and t = 90 min. An ad libitum 
buffet lunch was served immediately after the infusion. Blood samples were taken for measurement of 
amidated GLP-1 during each study at the time-points indicated.       
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2.4. Discussion 
 
My dose verification study involved investigating the effect PYY3-36 0.3 pmol/kg/min and  
GLP-17-36 amide 0.8 pmol/kg/min both singly and in combination, infused intravenously over 90 
minutes to a group of 6 subjects. The ad libitum test meal was served immediately after the 
termination of the infusion. Combined infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 
pmol/kg/min led to a statistically significant reduction (32% reduction compared with the 
control saline visit) in ad libitum energy intake during the test meal, which is similar to the 
findings of Neary et al., 2005. Single infusion of PYY3-36 0.3 pmol/kg/min led to non-
significantly increased food intake (7% increase compared with the control saline visit), 
whereas single infusion of GLP-17-36 amide led to a small reduction in ad libitum energy intake 
during the test meal (4% reduction compared to the control saline visit). There was no 
significant modulation of meal rating in response to either single or combined infusions.  
 
The combined infusion was associated with a degree of nausea (the mean increase in 
nausea rating from baseline to that at the peak of the infusion was 22.5 mm), although 
interestingly, there was no change in hunger or fullness ratings. Furthermore, although a 
degree of nausea outlined above was established through VAS questioning, at no stage did 
any subjects report to the investigators that they felt nauseated outside of the context of VAS 
analysis. Therefore, it could be argued that the degree of nausea induced by the combined 
infusion of PYY3-36 0.3 pmol/kg/min and GLP-17-36 amide 0.8 pmol/kg/min was tolerable.  
 
Haemodynamic parameters were not significantly different between infusion of saline,   
PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min or combined infusion of PYY3-36 0.3 
pmol/kg/min and GLP-17-36 amide 0.8 pmol/kg/min. The infusion of GLP-17-36 amide, as well as 
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the combined infusion of PYY3-36 and GLP-17-36 amide led to a small but statistically significant 
fall in blood glucose compared with infusion of saline. This would be expected, given the well 
established incretin effect of GLP-1.  
 
A peak mean total PYY concentration of 106.5 pmol/L during the combined PYY3-36 0.3 
pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min infusion, and peak mean total PYY  
concentration of 91.07 pmol/L during the single PYY3-36 0.3 pmol/kg/min infusion, were 
similar to the circulating PYY concentrations achieved by Neary et al. (Neary et al., 2005), 
when PYY3-36 0.4 pmol/kg/min + GLP-17-36 amide 0.4 pmol/kg/min were co-infused. 
Interestingly, Batterham et al. achieved a peak mean total circulating PYY concentration of 
43.5 pmol/L when administering a single infusion of PYY3-36 0.8 pmol/kg/min (Batterham et 
al., 2002). This may provide an explanation for why Batterham et al. did not report any 
nausea as a result of their PYY3-36 infusion. Despite this modest elevation in circulating 
concentrations of PYY, 24 hour energy intake was reduced by 33% compared to saline in 
the study by Batterham et al.  A degree of inter-assay variation in measurement may explain 
these differences. Variation between true and estimated peptide content of vials may also 
account for this mis-match. As outlined in the methods section, after the aliquotting process, 
I randomly selected representative vials of each peptide and sent them for amino acid 
analysis. These results were used to calculate the actual peptide content of the vials and 
therefore the correction factor when calculating dose. In the case of PYY3-36, each 
representative 25 nmol vial was in fact found to contain 18.6 nmol, whereas in the case of 
GLP-17-36 amide, each 25 nmol vial contained a near exact quantity of peptide (25.4 nmol). 
Given that previous research may not have taken into account amino acid analysis, it is 
plausible that a dose of PYY3-36 thought to be 0.8 pmol/kg/min by Batterham et al. may in fact 
have been a lower dose.  
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Analysis of circulating amidated GLP-1 levels in response to infusion in my study showed 
that compared with a previous study (Neary et al., 2005), peak circulating levels of amidated 
GLP-1 were similar in my study. Notably, I infused GLP-17-36amide at a higher dose than 
Neary’s group. Inter-assay variation could have explained these differences.  
 
Interestingly, when PYY3-36 was infused in combination with GLP-17-36 amide, circulating levels 
of PYY were higher than when the same dose of PYY3-36 was infused singly. This may have 
influenced the results for energy intake and nausea. Reasons for this are unclear, but may 
be due to possible interactions between PYY3-36 and GLP-17-36 amide in the infusion system.  
 
My dose verification study established doses of PYY3-36 and GLP-17-36amide that were sub-
anorectic when infused singly, but anorectic in combination. Additionally, these doses 
reduced food intake without causing intolerable nausea. This was of particular importance 
when planning the fMRI study, given that in the claustrophobic environment within the MRI 
scanner, nausea was likely to be accentuated. Furthermore, whilst nausea is relatively easy 
to tackle in a clinical investigation unit, it is more problematic if it occurs within the confines 
of an MRI scanner, with risk of aspiration pneumonia if the subject were to actually vomit 
when recumbent. Therefore, it was reassuring that my dose verification study identified 
doses of PYY3-36 and GLP-17-36amide that when administered in combination, produced 
significant reduction in food intake without causing intolerable nausea. As a result, these 
doses (0.3 pmol/kg/min for PYY3-36 and 0.8 pmol/kg/min for GLP-17-36amide) were taken 
forward into the fMRI study (Study 2). 
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CHAPTER 3 
 
Investigation of the effects of single and 
combined administration of PYY3-36 and      
GLP-17-36 amide on appetite, energy intake and 
neuronal activity in brain appetite centres  
(Study 2) 
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3.1. Introduction and rationale 
 
BOLD fMRI has recently been used as a tool to investigate the changes in brain activity in 
response to nutritional status in humans. It has been demonstrated that brain activity within 
reward systems is increased in the fasted state compared to the fed state (La Bar et al., 
2001, Goldstone et al., 2009, Fletcher et al., 2010). However, the use of BOLD fMRI to 
determine brain activity following peripheral administration of hormones affecting appetite in 
humans has been limited to a few studies (Batterham et al., 2007, Farooqi et al., 2007, Baicy 
et al., 2007, Rosenbaum et al., 2008, Malik et al., 2008). It has been shown that intravenous 
infusion of PYY3-36 to human subjects results in reduced food intake and changes in brain 
activity in appetite regions (Batterham et al., 2007). However, there have been no human 
fMRI studies investigating the effect of administration of GLP-1 or co-administration of PYY 
and GLP-1 on brain activity in humans.  
 
Following Roux-en-Y gastric bypass surgery (the most effective current treatment for 
obesity), patients demonstrate increased levels of the gut hormones PYY and GLP-1 (Borg 
et al., 2006, Le Roux et al., 2006). It is thought that elevated levels of these hormones act 
via the CNS to cause the reduced appetite and sustained weight loss observed following this 
intervention. It is therefore important to understand the CNS mechanisms by which the gut 
hormones PYY and GLP-1 mediate their combined anorectic effect in humans.  
 
Together, these important unanswered questions formed the rationale for my investigation of 
the single and combined anorectic effects of peripherally administered PYY3-36 and           
GLP-17-36 amide to healthy humans, using BOLD fMRI as a tool to assess the effect of these 
hormones on neuronal activation in brain regions implicated in appetite control. 
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3.2. Methods 
 
3.2.1. Peptides 
 
Freeze dried vials of PYY3-36 and GLP-17-36 amide used in this study were from the same batch 
of peptide vials as used in Study 1 (Section 2.2.1.). Based on the results of study 1, I 
decided to use PYY3-36 at a dose of 0.3 pmol/kg/min and GLP-17-36 amide at a dose of 0.8 
pmol/kg/min.  
 
3.2.2. Subjects 
 
Sixteen healthy right-handed subjects (11 male, 5 female) of mean age 29.5 years (range 21 
- 36 years) and mean body mass index 22.1 kg/m2 (range 18.3 - 25.1 kg/m2) were recruited 
by newspaper advertisement. It was predicted that a sample size of 16 will have 90% power 
to detect a difference in mean food intake of 950 kJ assuming a standard deviation of 
differences of 1140 kJ, using a paired Student t test with a 0.05 two sided significance level. 
Ethical Approval, subject screening, consent, inclusion and exclusion criteria were as per 
Study 1 (Section 2.2.2.). Additionally, subjects who were claustrophobic, had any metal 
implants, or those who had undergone recent dental work were excluded, as this would have 
precluded the subject entering the MRI scanner. One male subject was excluded from the 
study after recruitment due to excessive head movement during the MRI scans, resulting in 
complete data from 15 subjects for analysis. 
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3.2.3. Design 
 
Sixteen right-handed subjects (11 male, 5 female) each attended for 6 study visits, each at 
least 3 days apart. Overnight fasting from 22:00 h the night before and other preparation 
before each study visit was identical to Study 1 (Section 2.2.3.). 
 
The study was conducted in a single-blinded fashion. On their first visit, subjects always 
received an infusion of saline after an overnight fast. This protocol was an identical protocol 
to that used for the following fasted visits, and was intended to acclimatise the subject to the 
clinical environment and to experimental procedures. At the start of this acclimatisation visit, 
the nature of the MRI scan experience was explained to the volunteers. The rest of this first 
visit was run in an identical fashion to the following visits with an additional structural brain 
scan (5 minutes duration) at the end of the scanning run to exclude organic disease. Results 
from the first saline visit are not included in the imaging analysis.  
 
Following the first saline visit, subjects were randomly assigned to receive each of the 
following: 
 
1. Overnight fast followed by saline infusion (the fasted, control visit) 
2. Overnight fast followed by a set breakfast, then saline infusion (the fed visit) 
3. Overnight fast followed by PYY3-36 infusion at 0.3 pmol/kg/min 
4. Overnight fast followed by GLP-17-36 amide infusion at 0.8 pmol/kg/min  
5. Overnight fast followed by combined PYY3-36 and GLP-17-36 amide infusion, at 0.3 
pmol/kg/min and 0.8 pmol/kg/min respectively 
 
Subjects arrived for each visit at 09:00 h (t = - 90 min). Peripheral venous cannulae were 
inserted in both forearms at t = - 90 min, and subjects could relax and read in a room next to 
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the scanner until the preparation for the study had been completed. At that stage, a 100 cm 
long extension line was attached to the larger cannula so that blood samples could be taken 
without disturbing the subject during the scan.   
 
 
3.2.4. Peptide preparation and delivery 
 
All syringes and lines used to deliver peptide were coated in gelofusin for 20 minutes prior to 
preparation, to minimise adsorption of peptide to the plastic walls. The vehicle for delivering 
peptide was a 10% solution of gelofusin in 0.9% saline, as per Study 1 (Section 2.2.4.). Vials 
of peptide were dissolved in 2.5 ml vehicle, and drawn up in a single syringe up to a total 
volume of 90 ml. The amount of peptide solution added to the delivery syringe varied 
according to the dose each subject received. The first 10 ml were slowly (over 5 minutes) 
purged through the delivery line before it was attached to a subject’s infusion cannula. A 
MEDRAD MR Injector Spectris Solaris EP (Siemens UK, Camberley, Surrey) pump was 
used to deliver the infusions at a constant rate of 36 ml/hr. The intravenous infusion started 
in the MRI scanning room at 10:30 h (t = 0 min) and was delivered over 90 minutes.   
 
3.2.5. Blood sampling and processing 
 
Six ml blood samples were collected for gut hormone measurement at t = - 60, 0, 15, 30, 45, 
60, 75, 90 and 120 min and processed and stored as already described for Study 1 in 
Section 2.2.5. Three ml deadspace blood was collected and discarded at each sample point 
to account for the 100 cm long extension line.  
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3.2.6. Visual analogue scale scores 
 
At t = - 60, 0, 90, and 120 min, subjects completed a series of VAS questionnaires. These 
comprised five food-related sensations (hunger, nausea, pleasantness to eat, how much one 
could eat, fullness) and additionally four non-food related sensations (warmth, irritability, 
anxiety, sleepiness). The VAS scales consisted of 100 mm lines with text expressing the 
most positive and the most negative rating for each variable anchored at either end (Flint et 
al., 2000). 
 
 
3.2.7. Measurement of haemodynamic parameters and blood glucose 
 
The pulse and blood pressure of each subject was measured at t = - 60, 0, 15, 30, 60, 75, 
90, and 120 min. A drop of blood was taken from the t = - 60, 0, 30, 60, 90 and 120 min 
samples to check blood glucose. Measurement of these parameters was as per Study 1 
(Section 2.2.7.). 
 
3.2.8. Study meals 
 
The ad libitum lunch buffet meal was as per Study 1 (Section 2.2.8.). On their fed visit, 
subjects received a set breakfast (2500 kJ), served in a private area between 09:30 – 09:50 
h (t = - 60 to - 40 min). The set breakfast served to subjects during one of the fMRI study 
visits (2500 kJ) consisted of 2 medium slices of wholemeal bread, 20 g strawberry jam, 20 g 
margarine, 2 slices of Leerdammer Swiss cheese, 40 g Bran flakes, 170 g semi-skimmed 
milk, and 220 g orange juice. Subjects were asked to consume the above breakfast within 20 
minutes.  
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3.2.9. Functional MRI scan  
 
At 10:30 h (t = 0 min), the subject was taken into the scanning room and the 90 minute 
infusion started. Twenty minutes after the start of the infusion (i.e. t = 20 min), the 60 minute 
fMRI scan began. T2*-weighted, dual echo, EPI images sensitive to BOLD contrast were 
acquired continuously on a 3 Tesla Siemens Tim Trio scanner with a 32-channel head coil 
(Siemens Healthcare, Erlangen, Germany). Each scan session consisted of 501 volumes of 
36-slice acquisition, angled ~30º coronally to the anterior-posterior commissural plane to 
minimize signal dropout in orbitofrontal and medial temporal regions (Repitition time (TR) = 
2000 ms; dual echo times (TEs) = 13 and 31 ms; flip angle = 80º, slice thickness = 3.0 mm, 
matrix size = 64  64, field of view = 225  225 mm, voxel size = 3.51  3.51  3.0 mm). 
High-resolution T1-weighted anatomical scans (ADNI MPRAGE (Jack et al., 2008)) were 
acquired with whole-brain coverage (208 slices) for each participant to facilitate fMRI image 
co-registration, and ROI definition (TR = 3000 ms, TE = 3.66 ms, flip angle = 9º, voxel size = 
1 x 1 x 1 mm). 
 
During the fMRI scan, subjects were asked to watch and rate a series of colour images in a 
picture processing task. These visual stimuli were viewed via an angled mirror, which 
reflected images back-projected from a screen positioned in the bore of the magnet behind 
the subject’s head. During the fMRI picture processing task, 75 images were shown, divided 
into 50 images of foods and 25 non-food items (Beaver et al., 2006). There were two sets of 
75 images, alternated between each scanning session. Images from each category were 
presented in counterbalanced order across participants and sessions. The images appeared 
for 5 seconds, interspersed with periods of rest (fixation on a blue octagon), with each block 
lasting 25 seconds.   
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At the end of the scan, subjects were helped to sit up slowly, and stayed in the scanner room 
for a further 10 minutes until the infusion was stopped at t = 90 min. The subject was then 
immediately led into a private dining area where an ad libitum buffet meal (as previously 
described in Section 2.2.8.) was served. Subjects were allowed to go home at t = 120 min.  
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The protocol for Study 2 is summarised in figure 3.1 below. 
- 90 - 60 - 30 0 +30 +60 +90 +120
Subject 
arrives, 2 
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Figure 3.1: Protocol for Study 2.  Following an overnight fast, sixteen healthy, normal-weight 
subjects each received the following interventions, in random order, over 5 separate study days in a 
single-blinded fashion: 
1.  90 minute saline infusion (fasted saline, control visit) 
2.  Standard breakfast, then 90 minute saline infusion (fed saline) 
3.  90 minute PYY3-36 infusion at 0.3 pmol/kg/min 
4.  90 minute GLP-17-36 infusion at 0.8 pmol/kg/min 
5. 90 minute combined PYY3-36 and GLP-17-36 infusion, at 0.3 pmol/kg/min and 0.8 pmol/kg/min 
respectively 
On each visit, subjects underwent a 60 min fMRI scan, which commenced 20 min after the start of 
the infusion. During the fMRI scan, a picture processing task was performed where images of food 
and non-food were shown. The mean % change in BOLD signal in pre-specified brain regions of 
interest when viewing images of food compared to non-food were determined for each study day. 
An ad libitum buffet meal was served immediately after the infusion on all study days in order to 
measure energy intake. Blood sampling (for PYY and GLP-1) and assessments of appetite (based on 
VAS after direct questioning) was performed.  
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3.2.10. Measurement of total PYY 
 
Total PYY immunoreactivity was measured with a specific and sensitive in-house RIA, as 
previously described in Section 2.2.9. The RIA set up was as described in Section 2.2.11.  
 
 
3.2.11. Measurement of PYY3-36 
 
Active PYY (PYY3-36) immunoreactivity was measured with a specific and sensitive 
commercial RIA (Cat. # PYY-67HK, Millipore Corporation, MA, USA) (King et al., 2011). The 
antibody was produced in Guinea Pigs against human PYY. The antibody cross reacted 
100% with PYY3-36, but 0% PYY1-36 (for concentrations up to 247 pmol/L). PYY3-36 standard 
was used at 2800 pg/ml (0.69 pmol/ml) and serially diluted for use in the standard curves, 
which were included every 200 tubes in the assay. The assay was performed in total volume 
of 0.4 ml of 0.08% sodium azide buffer (0.1 ml) with treated human serum matrix (0.1 ml). A 
sample volume of 0.1 ml and antibody volume of 0.1 ml were used. The assay tubes 
containing sample (or standard), antibody, buffer and matrix were incubated for 24 hours at 
4ºC, following which 125I-PYY was added to each tube (0.1 ml) and the assay incubated for a 
further 24 hours. Separation of the free and antibody bound radiolabel was by the addition of 
0.01 ml of Guinea Pig serum and 1 ml of precipitating reagent to each tube (containing goat 
anti-Guinea Pig IgG Serum, 3% PEG and 0.05% Triton X-100 in 0.05M phosphosaline, 
0.025M EDTA, 0.08% sodium azide) followed by centrifugation at 4ºC for 20 minutes at 2500 
rpm. The assay results in pg/ml were divided by 4049.52 (the molecular weight of 1 mole of 
PYY3-36) and multiplied by 1000 in order to convert to pmol/L. The detection limit of the assay 
was 5 pmol/L, with an intra-assay coefficient of variation of 6.4% (for high levels of 54 
pmol/L) and 11% (for low levels of 21 pmol/L). The inter-assay coefficient of variation was 
7% (for high levels of 54 pmol/L) and 15% (for low levels of 21 pmol/L). All standard curve 
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tubes were assayed in duplicate, whereas all sample tubes were assayed in singlet. All 
samples were assayed in one assay to avoid inter-assay variation. The value of the QCs 
used were: high = 84 - 174 pmol/L; low = 24 - 50 pmol/L and measured QC values were 
within the above ranges.  
 
Full details of the commercial RIA protocol for measurement of PYY3-36 can be found at 
http://www.millipore.com/catalogue/item/pyy-67hk  
 
3.2.12. Measurement of amidated GLP-1 
 
Amidated GLP-1 like immunoreactivity was measured by a specific and sensitive in-house 
RIA, as previously described in Section 2.2.10. The RIA set up was as described in Section 
2.2.11. 
 
3.2.13. Measurement of active GLP-1 (GLP-17-36 amide & GLP-17-37) 
 
Active GLP-1 immunoreactivity was measured with a specific and sensitive commercial 
enzyme-linked immunosorbent assay (ELISA) kit (Cat. # EGLP-35K, Millipore Corporation, 
MA, USA) (Adam et al., 2005). Information regarding the principles of ELISA can be found in 
Appendix 1. Microtiter plates (96 well) were used to set up the assay, which had been pre-
coated in anti-GLP-1 monoclonal antibody. The antibody cross reacted 100% with active 
forms of GLP-1 (GLP-17-36 amide & GLP-17-37) but undetectably with other forms of GLP-1 
(GLP-11-36 amide, GLP-11-37). Volumes of 0.1 ml from GLP-17-36 ELISA standard vials ranging 
from 2 pmol/L to 100 pmol/L were used to generate the standard curves, which were placed 
throughout the assay at the beginning of each 96 well microtiter plate. The assay was 
performed in total volume of 0.2 ml. This comprised 0.1 ml of sample added to 0.1 ml of 
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phosphate buffered saline (pH 6.8), containing proprietary protease inhibitors, with Tween 
20, 0.08% sodium azide and 1% BSA. Following addition of sample, plates were covered 
with a plate sealer and incubated for 24 hours at 4ºC. Plates were washed to remove 
unbound materials, following which 0.2 ml detection conjugate (containing anti-GLP-1-
alkaline phosphatase conjugate) was added to each well and the plates further incubated at 
room temperature for 2 hours. Plates were then washed again to remove unbound 
conjugate, following which 0.2 ml 4-methylumbelliferyl phosphate was added to each well. 
Plates were incubated at room temperature in the dark for at least 20 minutes, following 
which 0.05 ml stop solution was added to each well. The plates were read on a fluorescence 
plate reader with an excitation / emission wavelength of 355 nm / 460 nm. The detection limit 
of the assay was 2 pmol/L, with an intra-assay coefficient of variation of 9% (for high levels 
of 76 pmol/L) and 8% (for low levels of 4 pmol/L). The inter-assay coefficient of variation was 
<1% (for high levels of 76 pmol/L) and 13% (for low levels of 4 pmol/L). All samples were 
assayed in duplicate and in one assay to avoid inter-assay variation. The value of the QCs 
used were: high = 24 - 50 pmol/L; low = 4.4 - 9.2 pmol/L and measured QC values were 
within the above ranges.  
 
Full details of the commercial ELISA protocol for measurement of active GLP-1 (GLP-17-36 
amide & GLP-17-37) can be found at http://www.millipore.com/catalogue/item/eglp-35k  
 
3.2.14. Statistical analysis of energy intake, VAS, haemodynamic parameters, blood 
glucose and gut hormone levels 
 
Grouped data are represented as the mean ± SEM. Comparisons of energy intake, ratings of 
meal palatability, VAS scores, glucose levels, haemodynamic parameters and gut hormone 
levels during the infusion period were as per Study 1 (Section 2.2.12.). Comparison of 
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energy intake between the fasted acclimatisation saline visit (visit 1) and the control, fasted 
saline visit was by paired Student t-test. The effect of visit number on energy intake was 
analysed using two-way ANOVA, with the intervention as the column factor and visit number 
as the row factor. Linear regression analysis was performed to assess correlation between 
nausea and energy intake for the combined infusion of PYY3-36 and GLP-17-36 amide. The 
threshold for statistical significance in each case was set at p<0.05. Analyses were 
performed using Prism version 5.01 software (Graphpad Software, San Diego, CA, USA). 
 
3.2.15. fMRI analysis: pre-processing of data  
 
All fMRI data processing was carried out using FEAT (fMRI Expert Analysis Tool) version 
5.98. fMRI data were preprocessed with FSL software (www.fmrib.ox.ac.uk/fsl/) in order to 
correct for motion, to register the echo planar functional images to the high-resolution 
anatomical (T1-weighted) scan of each individual, and to overlay images on a standardized 
Montreal Neurological Institute (MNI) atlas in order to allow for comparisons across 
individuals. Correction for slice timing was performed in view of the fact that each slice was 
acquired at a slightly different time within the TR; 36 slices were acquired within the TR of 
2000 ms. Data were high-pass temporally filtered in order to remove low frequency drifts 
(e.g. drifts due to the cardiac and respiratory cycle) in image acquisition. Data were spatially 
smoothed (5mm Full Width Half Maximum Gaussian kernel) to allow for gyral variability 
across subjects and to improve signal-to-noise ratio at the intra-subject level. Using the 
MCFLIRT tool within FSL (Jenkinson et al., 2002), individual subjects sessions with greater 
than 3.5 mm absolute head motion or severe stimulus-correlated motion (as exhibited by 
marked rim artefacts in intra-subject statistic maps) were excluded from further analysis. 
This led to a total of fifteen usable subjects with complete data from all infusion groups.  
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3.2.16. fMRI analysis: whole-brain activation with presentation of food-salient visual 
stimuli 
 
For the fasted saline and fed saline visits, a whole-brain map of brain regions activated by 
food images (compared with non-food images) was created. Clusters were thresholded by 
means of parametric testing at the level of spatially contiguous clusters of voxels, 
simultaneously controlling the family-wise probability of type 1 error at p<0.05, corrected for 
multiple comparisons.  
 
3.2.17. fMRI analysis: generation of whole brain maps of effect of feeding, PYY3-36 and 
GLP-17-36 amide administration on brain activation by food images 
 
Whole brain maps of the difference in BOLD signal between viewing images of food versus 
non-food were generated for each infusion (fasted saline, fed saline, PYY3-36 0.3 
pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min, PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 
pmol/kg/min). Comparison was made between the difference in BOLD signal between 
viewing images of food versus non-food for each of the above interventions, against the 
difference in BOLD signal between viewing images of food versus non-food during the fasted 
saline infusion. Clusters were thresholded by means of parametric testing at the level of z > 
1.6, simultaneously controlling the family-wise probability of type 1 error at p<0.05, corrected 
for multiple comparisons. 
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3.2.18. fMRI ROI analysis: effect of feeding, PYY3-36 and GLP-17-36 amide administration 
on brain activation by food images  
 
During each infusion (fasted saline, fed saline, PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 
pmol/kg/min, PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min) the difference in 
regional mean BOLD signal intensity between periods of subject exposure to food images 
compared with non-food images was estimated at each of 6 pre-specified ROIs bilaterally- 
amygdala, caudate, insula, nucleus accumbens, OFC, and putamen. These were chosen 
based on previous studies (Batterham et al., 2007, Farooqi et al., 2007, Fletcher et al., 2010, 
LaBar et al., 2001, Malik et al., 2008) using an in-house MRI atlas (Tziortzi et al., 2011). All 
ROI signal change was defined as the conjunction between the full group main effect of task 
(food vs. non-food, using parametric testing at the level of spatially contiguous clusters of 
voxels, while controlling the family-wise probability of type 1 error at p<0.05, corrected for 
multiple comparisons) at the relevant atlas region. The accuracy of registration of ROIs on 
the BOLD functional data was confirmed by visual inspection of their overlay in relation to 
the functional images i.e. in subject space. Image acquisition for this ROI analysis was 
weighted towards the 2nd echo (TE = 31 ms).  
 
These estimates of % BOLD signal change were then averaged over right and left 
homologous regions of amygdala, caudate, insula, nucleus accumbens, OFC, and putamen. 
For each study intervention (i.e. feeding or gut hormone infusion), I tested the null 
hypothesis that the within-subject difference between fasted saline, fed saline, PYY3-36 
infusion, GLP-17-36 amide infusion or combined PYY3-36 + GLP-17-36 amide infusion in regional 
BOLD response to food images vs. non-food images was zero, i.e. [the gut hormone infusion 
or fed saline infusion BOLD response to food images] – [fasted saline BOLD response to 
food images] = ΔBOLD = 0. The statistical model used to test this was a repeated measures 
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analysis of difference of means, with Dunnett’s post-test between control (fasted saline) and 
each infusion session BOLD data. A separate analysis of left and right sides for each of the 
6 ROIs was also performed. This was followed by an analysis of the effects of feeding, PYY3-
36 infusion, GLP-17-36 amide infusion and combined PYY3-36 & GLP-17-36 amide infusion on 
changes in mean % BOLD signal change between viewing images of food vs. non-food in 
the total brain volume represented by the 6 a priori selected ROIs. Statistical analysis was by 
repeated measures ANOVA and Tukey’s multiple comparison post-test. 
For each subject undergoing the combined infusion of PYY3-36 & GLP-17-36 amide, linear 
regression analysis of the change in nausea score from 0 - 90 min against the reduction in % 
BOLD signal change from the control saline infusion was performed for each ROI, averaged 
over right and left sides.  
 
3.2.19. fMRI analysis: effect of feeding, PYY3-36 and GLP-17-36 amide administration on 
hypothalamic and brainstem activation by food images 
 
In a separate voxel-wise analysis, I examined the mean % change in BOLD signal when 
viewing food images versus non-food images in the hypothalamus and brainstem (midbrain) 
in subjects after feeding, PYY3-36, GLP-17-36 amide or combined PYY3-36 & GLP-17-36 amide 
infusion. I compared this with the mean % change in BOLD signal when viewing food images 
versus non-food images in the hypothalamus and brainstem (midbrain) when subjects were 
fasted and received saline (control). Voxels were thresholded by means of parametric testing 
at the level of z > 1.6, simultaneously controlling the family-wise probability of type 1 error at 
p<0.05, corrected for multiple comparisons. Image acquisition for this hypothalamic and 
brainstem response used a combined echo analysis, weighted towards the 1st echo (TE = 
13 ms). 
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3.3. Results 
 
3.3.1. Comparison of energy intake between acclimatisation visit and fasted saline 
visit 
 
For the 15 subjects in Study 2, energy intake during the ad libitum buffet lunch during the 
fasted saline acclimatisation study visit (visit 1) and the control, fasted saline visit (randomly 
distributed across the remaining 5 study visits was analysed (figure 3.2). This revealed there 
to be significantly lower energy intake during the ad libitum buffet lunch during the 
acclimatisation study visits compared with the control saline study visits (energy intake at ad 
libitum buffet lunch (kJ): fasted acclimatisation saline, 3715 ± 419.4 vs fasted (control) 
saline, 4039 ± 399, p = 0.049) (Figure 3.2). 
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Figure 3.2: Mean ad libitum energy intake during acclimatisation visit and control saline visit in Study 2. 
Fifteen healthy subjects underwent an initial acclimatisation visit where they received a 90 minute infusion of 
saline following an overnight fast (acclimatisation), followed by 5 further randomised visits, one of which 
comprised a 90 minute infusions of saline following an overnight fast. An ad libitum buffet meal was served 
immediately after each infusion in order to measure energy intake. Energy intake during the acclimatisation 
visit and control fasted saline visit is shown.  * denotes p<0.05 for acclimatisation vs fasted saline.  
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3.3.2. Analysis of visit order effects on energy intake 
 
For the 15 subjects in Study 2, following the acclimatisation visit, where subjects received 
saline only, the remaining 5 study visits were randomised in terms of the infusion 
administered (fasted saline, fed saline, PYY3-36, GLP-17-36 amide, PYY3-36 + GLP-17-36 amide). 
Analysis of the mean energy intake during the ad libitum lunch across the 5 randomised 
visits revealed that there were no order effects across study visits and that subjects did not 
eat progressively less during each subsequent visit as a result of habituation to the study 
meal: mean energy intake at ad libitum buffet lunch (kJ): visit 2 3798 ± 498; visit 3 3229 ± 334; 
visit 4 3531 ± 330; visit 5 3354 ± 411; visit 6 3116 ± 323. The effect of the interventions on 
energy intake was not significantly different between visits (p = 0.16). Furthermore, energy 
intake did not change significantly with visit number (p = 0.74). This is illustrated in figure 
3.3. 
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Figure 3.3: Visit order effects on energy intake in Study 2. Following an acclimatisation visit, 15 healthy 
subjects underwent 90 minute infusions of saline, PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min following an overnight fast. On one visit, 
after an overnight fast, they received a set breakfast followed by a 90 minute saline infusion. The interventions 
were administered in randomised order. On each study visit, each subject received the same ad libitum buffet 
meal immediately after the infusion in order to measure energy intake. There were no effects on energy intake 
of subjects by visit number (p = 0.74). 
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3.3.3. Effects of feeding, PYY3-36 and GLP-17-36 amide administration on subsequent 
energy intake 
 
Following saline, PYY or GLP-1 (either as single or combined administration) in 15 fasted 
healthy human subjects, ad libitum energy intake was measured during a buffet lunch. The 
effects of PYY and GLP-1 were compared to those seen naturally following a breakfast 
meal. Consumption of a standard breakfast by subjects before saline infusion led to a 23.5% 
± 8.3% reduction in energy intake during the subsequent ad libitum buffet lunch, compared 
to when subjects received only saline infusion (energy intake at ad libitum buffet lunch (kJ): 
fasted (control), 4039 ± 399 vs. fed, 3090 ± 335, p<0.01) (Figure 3.4 A). Infusion of PYY3-36, 
GLP-17-36 amide or combined PYY3-36 and GLP-17-36 amide to fasted subjects resulted in 12.3% ± 
11.2%, 15.7% ± 7.5% and 27.0% ± 9.4% reductions in energy intake, respectively, at the 
subsequent ad libitum buffet lunch compared to when subjects received saline infusion 
(energy intake at ad libitum buffet lunch (kJ): fasted saline 4039 ± 399; PYY3-36 3542 ± 452; 
GLP-17-36 amide 3407 ± 302; PYY3-36 + GLP-17-36 amide 2950 ± 378).  The reduction in energy 
intake was significantly lower (p<0.001) relative to fasted saline only for the combined 
administration of hormone (Figure 3.4 A). 
 
The additive effects of single infusions of PYY3-36 and GLP-17-36 amide were compared with 
combined infusion of PYY3-36 and GLP-17-36 amide on energy intake at the ad libitum lunch. The 
summed reduction in energy intake by each of the single peptide infusions was comparable 
with the reduction after the combined infusion (p = 0.86) (Figure 3.4 B).  
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Figure 3.4: Mean ad libitum energy intake in Study 2. Fifteen healthy subjects underwent 90 minute infusions 
of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined 
PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (Combined PYY+GLP-1) following an overnight fast. 
On one visit, after an overnight fast, they received a set breakfast followed by a 90 minute saline infusion (Fed 
saline). An ad libitum buffet meal was served immediately after the infusion in order to measure energy intake 
(figure 3.4 A).Figure 3.4 B shows the reduction in energy intake during the buffet meal for each infusion versus 
the fasted saline infusion and also the sum of the individual effects of PYY and GLP-1 in reducing energy intake 
(sum of PYY and GLP-1). ** denotes p<0.01 vs. fasted saline.  *** denotes p = 0.0001 vs. fasted saline.  
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3.3.4. Ratings of meal palatability 
 
For the 15 subjects in Study 2, mean rating (at t = 120 min) of how tasty they found the 
buffet lunch on a 100 mm VAS scale was 71.6 ± 4.1 mm when they received saline, 66.3 ± 
3.4 mm when they received saline after a set breakfast, 68.7 ± 3.9 mm when they received 
the single infusion of PYY3-36 0.3 pmol/kg/min, 67.8 ± 3.5 mm when they received the single 
infusion of GLP-17-36 amide 0.8 pmol/kg/min and 64.4 ± 4.1 mm when they received the 
combined infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min. This is 
illustrated in figure 3.5 below. There was no significant difference between visits (p = 0.11). 
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Figure 3.5: Meal rating following ad libitum meal in Study 2. Fifteen healthy subjects underwent 90 minute 
infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (Combined PYY+GLP-1) following an 
overnight fast. On one visit, after an overnight fast, they received a set breakfast followed by a 90 minute 
saline infusion (Fed saline). An ad libitum buffet meal was served immediately after the infusion and subjects 
rated this meal on a scale of 0 - 100. 
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3.3.5. Analysis of the effect of feeding and gut hormone infusion on food related VAS 
parameters  
For the 15 subjects in Study 2, during the course of each study day, food related VAS 
parameters varied as shown in figure 3.6. 
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B: How pleasant would it be to eat right now?
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C: How much can you eat right now?
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D: How full do you feel right now?
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E: How nauseated do you feel right now?
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Figure 3.6: Food related VAS parameters during Study 2. During each study, 15 subjects completed 100 mm 
VAS questionnaires relating to hunger (A), pleasantness to eat (B), anticipated food consumption (C), fullness 
(D) and nausea (E).   
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VAS scores of appetite by subjects confirmed that consumption of the standard breakfast 
reduced hunger, reduced perceived pleasantness of eating more food and reduced 
anticipated further consumption, as well as increasing a sense of “fullness” (figure 19). 
Similarly, in fasted subjects, combined infusion of PYY3-36 and GLP-17-36 amide led to a small 
but significant reduction in hunger, perceived pleasantness of eating and anticipated food 
consumption, as well as increased “fullness” (figure 3.6). By contrast, the single infusions of 
PYY3-36 or GLP-17-36 amide were not associated with significant changes in subjective feelings 
of hunger, perceived pleasantness of eating, anticipated food consumption, “fullness” or 
nausea (figure 3.6). The mean change in each VAS parameter during the course of each 
infusion is shown in table 3.1.  
Change in 
VAS (mm) 
Fasted saline Fed saline PYY GLP-1 PYY+GLP-1 
Hunger -2.27 ± 6.4 13.43 ± 4.9 3.40 ± 5.6 7.47 ± 5.8 -16.20 ± 9.1 a 
Pleasantness 
to eat 
0.13 ± 5.7 10.07 ± 6.1 2.27 ± 6.1 3.53 ± 5.4 -20.73 ± 9.1 b 
How much 
one could eat 
2.00 ± 4.9 12.36 ± 3.4 -0.93 ± 4.5 -3.47 ± 5.0 -18.67 ± 8.7 c 
Fullness -2.47 ± 4.9 -9.21 ± 4.7 -0.07 ± 3.6 7.07 ± 2.7 24.07 ± 7.5 d 
Nausea 0.20 ± 0.2 1.14 ± 0.7 1.53 ± 1.5 0.60 ± 1.9 22.73 ± 5.9 e 
Table 3.1: Analysis of food related VAS parameters from t = 0 to t = 90 min during each infusion in Study 2. 
Fifteen healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min 
(PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 
pmol/kg/min (PYY+GLP-1) following an overnight fast. On one visit, after an overnight fast, they received a set 
breakfast followed by a 90 minute saline infusion (Fed saline). On each day, the infusion was administered 
between t= 0 and t= 90 min. During the study, subjects completed 100 mm VAS questionnaires relating to 
hunger, nausea, pleasantness to eat, how much they could prospectively eat and fullness. The change in VAS 
scores from baseline (t=0 min) to the end of the infusion (t= 90 min) are shown. 
a 
denotes p = 0.03 for 
PYY+GLP-1 vs Fed saline.
 b
 denotes p = 0.02 for PYY+GLP-1 vs Fed saline.  
c 
denotes p = 0.007 for PYY+GLP-1 vs 
Fed saline. 
d 
denotes p = 0.0002 for PYY+GLP-1 vs Fed saline and p<0.01 for PYY+GLP-1 vs Fasted saline and 
PYY.   
e 
denotes p<0.0001 for PYY+GLP-1vs all other groups. p = ns for Fasted saline vs. Fed saline. 
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3.3.6. Correlation of nausea with energy intake 
For the 15 subjects in Study 2, for the combined infusion of PYY3-36 and GLP-17-36 amide, there 
was no significant correlation between nausea and energy intake during the ad libitum buffet 
lunch (p =0.19, r2 = 0.13, figure 3.7).  
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Figure 3.7: Correlation of nausea with energy intake during combined PYY3-36 and GLP-17-36 amide infusion 
during Study 2. For each subject, the change in VAS nausea scores from baseline (t = 0 min) to the end of the 
combined infusion of PYY3-36 and GLP-17-36 amide (t = 90 min) are shown, correlated against ad libitum energy 
intake during the buffet lunch. p = 0.19, r
2
 = 0.13.  
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3.3.7. Analysis of the effect of feeding and gut hormone infusion on non-food related 
VAS parameters  
For the 15 subjects in Study 2, alteration of non-food related VAS parameters (warmth, 
irritability, anxiety and sleepiness) during the course of the studies is shown in figure 3.8.  
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B:How irritable do you feel right now?
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C: How anxious do you feel right now?
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D: How sleepy do you feel right now?
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Figure 3.8: Non-food related VAS parameters during Study 2. During each study, 15 subjects completed 100 
mm VAS questionnaires relating to warmth (A), irritability (B), anxiety (C) and sleepiness (D).   
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The change in non-food VAS ratings during the period of infusion (0 - 90 min) were not 
significantly different between infusion of saline, PYY3-36, GLP-17-36 amide, combined infusion 
of PYY3-36 + GLP-17-36 amide, or infusion of saline following a standard breakfast (p = 0.64 for 
warmth, p = 0.67 for irritability, p = 0.31 for anxiety, p = 0.90 for sleepiness, figure 3.9) 
A: Change in subjective warmth rating 0-90 min
F
a
s
te
d
 s
a
li
n
e
F
e
d
 s
a
li
n
e
P
Y
Y
G
L
P
-1
P
Y
Y
+
G
L
P
-1-10
-5
0
5
10
15
C
h
a
n
g
e
 f
ro
m
 0
-9
0
 m
in
 (
m
m
)
B: Change in irritability rating 0-90 min
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C: Change in anxiety rating 0-90 min
F
a
s
te
d
 s
a
li
n
e
F
e
d
 s
a
li
n
e
P
Y
Y
G
L
P
-1
P
Y
Y
+
G
L
P
-1-4
-2
0
2
4
6
C
h
a
n
g
e
 f
ro
m
 0
-9
0
 m
in
 (
m
m
)
D: Change in sleepiness rating 0-90 min
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Figure 3.9: Change in non-food related VAS parameters during Study 2. During each study, 15 subjects 
completed 100 mm visual analogue scale questionnaires relating to warmth (A), irritability (B), anxiety (C) and 
sleepiness (D).  The change in VAS scores from baseline (t = 0 min) to the end of each infusion (t = 90 min) are 
shown. 
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3.3.8. Haemodynamic parameters 
For the 15 subjects in Study 2, blood pressure (systolic and diastolic BP) and pulse were not 
significantly different between infusions, as shown in figure 3.10 (p=0.66 for systolic blood 
pressure, p=0.56 for diastolic blood pressure and p= 0.40 for pulse). 
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Figure 3.10: Haemodynamic parameters during Study 2. Fifteen healthy subjects underwent 90 minute 
infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. 
On one visit, after an overnight fast, they received a set breakfast followed by a 90 minute saline infusion (Fed 
saline). On each day, the infusion was administered between t = 0 and t = 90 min. During each study, systolic 
blood pressure (A), diastolic blood pressure (B) and pulse (C) were recorded. 
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3.3.9. Blood glucose 
 
For the 15 subjects in Study 2, infusion of GLP-17-36 amide 0.8 pmol/kg/min or combined 
infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min did not lead to a 
significant change in blood glucose between 0 and 90 min compared with infusion of saline 
or PYY3-36 0.3 pmol/kg/min alone (figure 3.11). Feeding subjects breakfast at t = - 60 min led 
to an intial rise in blood glocuse by t = 0 min, which returned to baseline during the course of 
the 90 min saline infusion (figure 3.11) 
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Figure 3.11: Blood glucose during Study 2. Fifteen healthy subjects underwent 90 minute infusions of saline 
(Fasted sal), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 
pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. On one visit, after an 
overnight fast, they received a set breakfast at t = -60 min followed by a 90 minute saline infusion (Fed saline). 
On each day, the infusion was administered between t = 0 and t = 90 min. During the study, the change in 
blood glucose from baseline was measured (figure 3.11 A). Figure 3.11 B shows the change in blood glucose 
from 0 - 90 min. 
*** denotes p<0.001 for Fed saline vs Fasted saline and PYY. 
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3.3.10. Total PYY levels in Study 2 
 
Mean plasma concentration of total PYY (from time points t = 15 min to t = 90 min) was 31.5 
± 0.9 pmol/L during the fasted saline infusion, 33.2 ± 0.7 pmol/L during the fed saline 
infusion, 65.0 ± 4.8 pmol/L during the PYY3-36 infusion, 30.0 ± 1.5 pmol/L during the        
GLP-17-36 amide infusion, and 69.8 ± 7.5 pmol/L during the combination infusion of PYY3-36 and 
GLP-17-36 amide (figure 3.12). 
 
Peak mean plasma concentration of total PYY (during the entire study) was 42.3 ± 6.2 
pmol/L during the fasted saline study visit (occurring post-prandially at t = 120 min), 42.5 ± 
3.9 pmol/L during the fed saline study visit (occurring post-prandially at t= 120 min), 78.8 ± 
6.7 pmol/L during the PYY3-36 study visit (occurring at t = 90 min), 37.5 ± 5.6 pmol/L during 
the GLP-17-36 amide study visit (occurring post-prandially at t = 120 min), and 93.5 ± 8.4 pmol/L 
during the combination PYY3-36 and GLP-17-36 amide study visit (occurring at t = 90 min).  
 
The mean AUC of total PYY levels (between 0 - 90 min) was 2892 ± 525 pmol min/L when 
saline was infused in the fasted state, 3010 ± 346 pmol min/L when saline was infused after 
the set breakfast, 5519 ± 402 pmol min/L when PYY3-36 0.3 pmol/kg/min was infused, 2713 ± 
533 pmol min/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 5821 ± 482 pmol 
min/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min was 
infused. There was no significant difference between the mean AUC of total PYY levels 
between fasted saline, fed saline and GLP-17-36 amide 0.8 pmol/kg/min infusions. Furthermore, 
there was no significant difference between the mean AUC of total PYY levels when PYY3-36 
was infused singly or in combination with GLP-17-36 amide. 
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Figure 3.12: Variation of plasma total PYY levels with time during Study 2.  Following an overnight fast, 15 
healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-
17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1). On one visit, after an overnight fast, they received a set breakfast at t = -60 min followed by a 90 
minute saline infusion (Fed saline). On each study visit, the infusion was administered between t = 0 and t = 90 
min. An ad libitum buffet lunch was served immediately after the infusion. Blood samples were taken for 
measurement of total PYY during each study at the time-points indicated.   
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3.3.11. PYY3-36 levels in Study 2 
 
Mean plasma concentration of PYY3-36 (from time points t = 15 min to t = 90 min) was 18.3 ± 
0.6 pmol/L during the fasted saline infusion, 20.6 ± 0.5 pmol/L during the fed saline infusion, 
49.2 ± 4.2 pmol/L during the PYY3-36 infusion, 16.6 ± 0.6 pmol/L during the GLP-17-36 amide 
infusion, and 51.2 ± 4.8 pmol/L during the combination infusion of PYY3-36 and GLP-17-36 amide 
(figure 3.13). 
 
Peak mean plasma concentration of PYY3-36 (during the entire study) was 22.7 ± 2.5 pmol/L 
during the fasted saline study visit (occurring post-prandially at t = 120 min), 27.3 ± 3.1 
pmol/L during the fed saline study visit (occurring post-prandially at t = 0 min), 59.8 ± 3.7 
pmol/L during the PYY3-36 study visit (occurring at t = 90 min), 23.1 ± 3.0 pmol/L during the 
GLP-17-36 amide study visit (occurring post-prandially at t = 0 min), and 63.6 ± 2.7 pmol/L during 
the combination PYY3-36 and GLP-17-36 amide study visit (occurring at t = 90 min).  
 
The mean AUC of PYY3-36 levels (between 0 - 90 min) was 1668 ± 194 pmol min/L when 
saline was infused in the fasted state, 1914 ± 127 pmol min/L when saline was infused after 
the set breakfast, 4132 ± 201 pmol min/L when PYY3-36 0.3 pmol/kg/min was infused, 1558 ± 
193 pmol min/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 4257 ± 127 pmol 
min/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min was 
infused. There was no significant difference between the mean AUC of PYY3-36 levels 
between fasted saline, fed saline and GLP-17-36 amide 0.8 pmol/kg/min infusions. Furthermore, 
there was no significant difference between the mean AUC of PYY3-36 levels when PYY3-36 
was infused singly or in combination with GLP-17-36 amide. 
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Figure 3.13: Variation of plasma PYY3-36 levels with time during Study 2.  Following an overnight fast, 15 
healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-
17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1). On one visit, after an overnight fast, they received a set breakfast at t = -60 min followed by a 90 
minute saline infusion (Fed saline). On each study visit, the infusion was administered between t = 0 and t = 90 
min. An ad libitum buffet lunch was served immediately after the infusion. Blood samples were taken for 
measurement of PYY3-36 during each study at the time-points indicated.   
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3.3.12. Amidated GLP-1 levels in Study 2 
 
Mean plasma concentration of amidated GLP-1 (from time points t = 15 min to t = 90 min) 
was 18.3 ± 0.2 pmol/L during the fasted saline infusion, 22.4 ± 0.4 pmol/L during the fed 
saline infusion, 18.2 ± 0.5 pmol/L during the PYY3-36 infusion, 40.6 ± 3.2 pmol/L during the 
GLP-17-36 amide infusion, and 42.8 ± 2.8 pmol/L during the combination infusion of PYY3-36 and 
GLP-17-36 amide (figure 3.14). 
 
Peak mean plasma concentration of amidated GLP-1 (during the entire study) was 33.0 ± 5.8 
pmol/L during the fasted saline  study visit (occurring post-prandially at t = 120 min), 42.9 ± 
7.4 pmol/L during the fed saline study visit (occurring post-prandially at t = 120 min), 35.9 ± 
7.4 pmol/L during the PYY3-36  study visit (occurring post-prandially at t = 120 min), 47.2 ± 
5.2 pmol/L during the GLP-17-36 amide study visit (occurring at t = 75 min), and 51.2 ± 5.0 
pmol/L during the combination PYY3-36 and GLP-17-36 amide study visit (occurring at t = 90 min).  
 
The mean AUC of amidated GLP-1 levels (between 0 - 90 min) was 1667 ± 334 pmol min/L 
when saline was infused in the fasted state, 2059 ± 388 pmol min/L when saline was infused 
after the set breakfast, 1655 ± 307 pmol min/L when PYY3-36 0.3 pmol/kg/min was infused, 
3457 ± 440 pmol min/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 3622 ± 387 
pmol min/L when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 
pmol/kg/min was infused. There was no significant difference between the mean AUC of 
amidated GLP-1 levels between fasted saline, fed saline and PYY3-36 0.3 pmol/kg/min 
infusions. Furthermore, there was no significant difference between the mean AUC of 
amidated GLP-1 levels when GLP-17-36 amide was infused singly or in combination with PYY3-
36. 
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Figure 3.14: Variation of plasma amidated GLP-1 levels with time during Study 2.  Following an overnight fast, 
15 healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), 
GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1). On one visit, after an overnight fast, they received a set breakfast at t = -60 min followed by a 90 
minute saline infusion (Fed saline). On each study visit, the infusion was administered between t = 0 and t = 90 
min. An ad libitum buffet lunch was served immediately after the infusion. Blood samples were taken for 
measurement of amidated GLP-1 during each study at the time-points indicated.   
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3.3.13. Active GLP-1 levels (GLP-17-36 amide & GLP-17-37) in Study 2 
 
Mean plasma concentration of active GLP-1 (from time points t = 15 min to t = 90 min) was 
3.9 ± 0.5 pmol/L during the fasted saline infusion, 3.9 ± 0.4 pmol/L during the fed saline 
infusion, 2.9 ± 0.2 pmol/L during the PYY3-36 infusion, 9.7 ± 1.0 pmol/L during the            
GLP-17-36 amide infusion, and 11.8 ± 1.1 pmol/L during the combination infusion of PYY3-36 and 
GLP-17-36 amide (figure 3.15). 
 
Peak mean plasma concentration of active GLP-1 (during the entire study) was 5.3 ± 1.7 
pmol/L during the fasted saline study visit (occurring at t = 15 min), 8.7 ± 3.4 pmol/L during 
the fed saline study visit (occurring post-prandially at t = 120 min), 6.5 ± 2.3 pmol/L during 
the PYY3-36 study visit (occurring post-prandially at t = 120 min), 13.2 ± 2.6 pmol/L during the 
GLP-17-36 amide study visit (occurring at t = 75 min), and 14.5 ± 2.0 pmol/L during the 
combination PYY3-36 and GLP-17-36 amide study visit (occurring at t = 75 min).  
 
The mean AUC of active GLP-1 levels (between 0 - 90 min) was 341 ± 115 pmol min/L when 
saline was infused in the fasted state, 341 ± 97 pmol min/L when saline was infused after the 
set breakfast, 264 ± 77 pmol min/L when PYY3-36 0.3 pmol/kg/min was infused, 819 ± 194 
pmol min/L when GLP-17-36 amide 0.8 pmol/kg/min was infused, and 986 ± 164 pmol min/L 
when the combination of PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min was 
infused. There was no significant difference between the mean AUC of active GLP-1 levels 
between fasted saline, fed saline and PYY3-36 0.3 pmol/kg/min infusions. Furthermore, there 
was no significant difference between the mean AUC of active GLP-1 levels when GLP-17-36 
amide was infused singly or in combination with PYY3-36. 
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Figure 3.15: Variation of plasma active GLP-1 levels with time during Study 2.  Following an overnight fast, 15 
healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-
17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1). On one visit, after an overnight fast, they received a set breakfast at t =-60 min followed by a 90 
minute saline infusion (Fed saline). On each study visit, the infusion was administered between t = 0 and t = 90 
min. An ad libitum buffet lunch was served immediately after the infusion. Blood samples were taken for 
measurement of active GLP-1 (GLP-17-36 amide and GLP-17-37) during each study at the time-points indicated.   
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3.3.14. Brain activation with presentation of food-salient visual stimuli 
 
Brain activation with presentation of food-salient images was assessed using BOLD fMRI. 
For this, a whole-brain cluster wise analysis was used. I found that when subjects infused 
with saline (in either the fasted or fed state) viewed images of food, there was greater BOLD 
signal in several brain regions compared with when non-food images were viewed (Figure 
3.16  and table 3.2).  
 
 
Figure 3.16: Brain regions where ∆ BOLD (when subjects viewed images of food compared with when they 
viewed images of non-food) was significantly greater than zero in Study 2. Fifteen healthy subjects 
underwent 90 minute infusions of saline, PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min following an overnight fast. On one visit, 
after an overnight fast, they received a set breakfast followed by a 90 minute saline infusion. During each 
infusion, a BOLD fMRI scan was performed, incorporating a picture processing task where images of food and 
non-food were shown. For the fasted saline and fed saline infusions, a whole brain map of brain regions 
activated (z-statistics) by food images (compared with non-food images) is shown. Z indicates distance (mm) 
superior or inferior to the inter-commissural plane in standard stereotactic space. Clusters were thresholded 
by means of parametric testing at the level of spatially contiguous clusters, simultaneously controlling the 
family-wise probability of type 1 error at p<0.05, corrected for the number of comparisons. 
 
Z    -16                         -10                       -8                         -4                        16 
0 5 
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I then a priori chose to test 6 ROIs (amygdala, caudate, insula, nucleus accumbens, OFC 
and putamen) based on previous research in the field (LaBar et al., 2001, Batterham et al., 
2007, Farooqi et al., 2007, Malik et al., 2008, Fletcher et al., 2010). The whole-brain cluster-
wise analysis supported the selection of these ROIs (Table 3.2). 
Brain region MNI co-ordinates of local maxima (mm) Max z 
  X Y Z   
R Occipital 14 -96 10 6.41 
R Occipital 6 -86 -8 6.2 
L Occipital -12 -100 8 6.19 
L Occipital -8 -86 -8 6.13 
L Occipital -46 -68 -8 5.93 
R Occipital 16 -98 20 5.78 
L Inferior frontal gyrus/ frontal 
pole 
-38 34 10 5.63 
L Inferior frontal gyrus/ frontal 
pole 
-44 38 12 5.42 
L Insula -38 -6 4 5.09 
R Insula 40 8 -12 5.07 
L Insula -40 -4 0 5.02 
R Insula 40 -2 -2 4.88 
Posterior cingulate 0 -32 20 4.75 
Posterior cingulate 0 -34 26 4.51 
Paracingulate gyrus 8 12 42 4 
Paracingulate gyrus -8 18 40 3.87 
L Superior frontal gyrus -18 2 54 3.79 
Posterior cingulate -4 -14 24 3.78 
R Lateral occipital 32 -62 36 5.16 
R Lateral occipital 32 -66 34 5.11 
R Posterior supramarginal gyrus 44 -40 44 3.98 
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R Angular gyrus 36 -54 38 3.95 
R Anterior supramarginal gyrus 52 -30 42 3.92 
R Angular gyrus 32 -48 32 3.91 
R Postcentral gyrus 50 8 28 4.41 
R Inferior frontal gyrus 48 8 14 4.05 
R Inferior frontal gyrus 56 10 12 3.91 
R Postcentral gyrus 56 8 40 2.9 
R Middle frontal gyrus 48 14 42 2.38 
L Amygdala -24 -4 -18 3.73 
R Amygdala 22 0 -18 3.76 
L Caudate -18 14 10 2.53 
R Caudate 18 4 20 3.33 
L Orbitofrontal cortex -34 34 2 3.8 
R Orbitofrontal cortex 26 36 -14 4.12 
L Insula -38 -6 4 5.09 
R Insula 40 8 -12 5.07 
L Putamen -20 4 8 3.01 
R Putamen 18 16 -6 3.42 
L Nucleus accumbens -14 16 -6 2.42 
R Nucleus accumbens 16 16 -8 3 
 
Table 3.2: Local maxima where ∆ BOLD (when subjects viewed images of food compared with when they 
viewed images of non-food) was significantly greater than zero in Study 2. Fifteen healthy subjects 
underwent 90 minute infusions of saline, PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min and 
combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min following an overnight fast. On one visit, 
after an overnight fast, they received a set breakfast followed by a 90 minute saline infusion. During each 
infusion, a BOLD fMRI scan was performed, incorporating a picture processing task where images of food and 
non-food were shown and the difference in brain activation compared. Imaging measures (cluster peaks 
meeting a criterion of p<0.05 for food images > non-food images, z >1.6) for saline infusion (in the fed and 
fasted state) are shown. The response of each of the a priori ROIs to the picture processing task for saline 
infusion (in the fed and fasted state) is highlighted in bold in the second half of the table. 
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3.3.15. Effect of feeding, PYY3-36 and GLP-17-36 amide administration on brain activation 
by food images: whole brain analysis.  
 
The difference in BOLD signal between viewing images of food versus non-food was 
reduced in the insula, nucleus accumbens, inferior frontal gyrus and post-central gyrus when 
subjects were fed breakfast (figure 3.17).  
 
Figure 3.17: Whole brain map showing attenuation of BOLD fMRI signal with feeding. Following an overnight 
fast, 15 healthy subjects underwent 90 minute infusions of saline, PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 
pmol/kg/min and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 0.8 pmol/kg/min. On one visit, after an 
overnight fast, they received a set breakfast followed by a 90 minute saline infusion. A BOLD fMRI scan was 
performed during each infusion, which comprised a picture processing task, where images of food and non-
food were shown. During the fasted saline infusion, when subjects viewed images of food, there was greater 
activation in several brain regions compared with non-food images were viewed. This difference was reduced 
on the day when subjects were fed a set breakfast prior to the saline infusion. Green areas highlight brain 
regions where eating breakfast led to a reduction in the mean BOLD fMRI signal difference between viewing 
images of food versus non-food compared with the fasted saline infusion. 1= Insula. 2 = Nucleus accumbens.   
3 = Inferior frontal gyrus. 4 = Post-central gyrus. Clusters were thresholded by means of parametric testing at 
the level of z > 1.6, simultaneously controlling the family-wise probability of type 1 error at p<0.05, corrected 
for the number of comparisons. 
1 
2 
3 
4 
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The difference in BOLD signal between viewing images of food versus non-food was 
reduced in the caudate, insula, nucleus accumbens, OFC, putamen and post-central gyrus 
when subjects were infused with PYY3-36 (figure 3.18),  
 
Figure 3.18: Whole brain map showing attenuation of BOLD fMRI signal with infusion of PYY3-36. Following an 
overnight fast, 15 healthy subjects underwent 90 minute infusions of saline, PYY3-36 0.3 pmol/kg/min, GLP-17-36 
amide 0.8 pmol/kg/min and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 0.8 pmol/kg/min. On one visit, after 
an overnight fast, they received a set breakfast followed by a 90 minute saline infusion. A BOLD fMRI scan was 
performed during each infusion, which comprised a picture processing task, where images of food and non-
food were shown. During the fasted saline infusion, when subjects viewed images of food, there was greater 
activation in several brain regions compared with non-food images were viewed. This difference was reduced 
on the day when subjects were administered a 90 minute infusion of PYY3-36 0.3 pmol/kg/min. Yellow areas 
highlight brain regions where infusion of PYY3-36 led to a reduction in the mean BOLD fMRI signal difference 
between viewing images of food versus non-food compared with the fasted saline infusion. 1 = Caudate. 2 = 
Insula. 3 = Nucleus Accumbens. 4 = OFC. 5 = Putamen. 6 = Post-central gyrus. Clusters were thresholded by 
means of parametric testing at the level of z > 1.6, simultaneously controlling the family-wise probability of 
type 1 error at p<0.05, corrected for the number of comparisons. 
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The difference in BOLD signal between viewing images of food versus non-food was 
reduced in the insula when subjects were infused with GLP-17-36 amide (figure 3.19). 
 
 
Figure 3.19: Whole brain map showing attenuation of BOLD fMRI signal with infusion of GLP-17-36 amide. 
Following an overnight fast, 15 healthy subjects underwent 90 minute infusions of saline, PYY3-36 0.3 
pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 0.8 
pmol/kg/min. On one visit, after an overnight fast, they received a set breakfast followed by a 90 minute saline 
infusion. A BOLD fMRI scan was performed during each infusion, which comprised a picture processing task, 
where images of food and non-food were shown. During the fasted saline infusion, when subjects viewed 
images of food, there was greater activation in several brain regions compared with non-food images were 
viewed. This difference was reduced on the day when subjects were administered a 90 minute infusion of GLP-
17-36 amide 0.8 pmol/kg/min. Red areas highlight brain regions where infusion of GLP-17-36 amide led to a reduction 
in the mean BOLD fMRI signal difference between viewing images of food versus non-food compared with the 
fasted saline infusion. 1 = Insula. Clusters were thresholded by means of parametric testing at the level of z > 
1.6, simultaneously controlling the family-wise probability of type 1 error at p<0.05, corrected for the number 
of comparisons. 
 
 
1 
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The difference in BOLD signal between viewing images of food versus non-food was 
reduced in the amygdala, insula, inferior frontal gyrus, OFC, post-central gyrus and occipital 
cortex when subjects were infused with a combination of PYY3-36 & GLP-17-36 amide (figure 
3.20).  
 
Figure 3.20: Whole brain map showing attenuation of BOLD fMRI signal with combined infusion of PYY3-36 
and GLP-17-36 amide. Following an overnight fast, 15 healthy subjects underwent 90 minute infusions of saline, 
PYY3-36 0.3 pmol/kg/min, GLP-17-36 amide 0.8 pmol/kg/min and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 0.8 
pmol/kg/min. On one visit, after an overnight fast, they received a set breakfast followed by a 90 minute saline 
infusion. A BOLD fMRI scan was performed during each infusion, which comprised a picture processing task, 
where images of food and non-food were shown. During the fasted saline infusion, when subjects viewed 
images of food, there was greater activation in several brain regions compared with non-food images were 
viewed. This difference was reduced on the day when subjects were administered a 90 minute infusion of 
PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min. Pink areas highlight brain regions where infusion of 
PYY3-36 and GLP-17-36 amide led to a reduction in the mean BOLD fMRI signal difference between viewing images 
of food versus non-food compared with the fasted saline infusion. 1 = Amygdala. 2 = Insula. 3 = Inferior frontal 
gyrus. 4 = OFC. 5 = Post-central gyrus. 6 = Occipital cortex. Clusters were thresholded by means of parametric 
testing at the level of z > 1.6, simultaneously controlling the family-wise probability of type 1 error at p<0.05, 
corrected for the number of comparisons. 
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3.3.16. Effect of feeding, PYY3-36 and GLP-17-36 amide administration on brain activation 
by food images: ROI analysis 
 
I examined each of the individual a priori selected ROIs, noting the cluster peaks where 
there was greatest difference in mean % change in BOLD signal (when viewing images of 
food versus non-food) in subjects after feeding, PYY3-36, GLP-17-36 amide or combined PYY3-36 
& GLP-17-36 amide infusion, all compared with fasted saline infusion. This is illustrated for the 
amygdala (table 3.3 A), caudate (table 3.3 B), insula (table 3.3 C), nucleus accumbens (table 
3.3 D), OFC (table 3.3 E) and putamen (table 3.3 F).  
 
AMYGDALA  
(FOOD MINUS NON-FOOD) 
CLUSTER 
PEAK 
MNI CO-ORDINATES OF CLUSTER 
PEAK (mm) 
 COMPARISON Voxels (n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 94 -12 -2 -20 2.48 
Fed saline>Fasted saline 6 14 0 -18 2.28 
Fed saline<Fasted saline 0 n/a n/a n/a n/a 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 2 -20 -7 -16 1.81 
PYY>Fasted saline 0 n/a n/a n/a n/a 
PYY<Fasted saline 5 -21 0 -18 1.92 
3.3 A 
CAUDATE 
(FOOD MINUS NON-FOOD) 
CLUSTER 
PEAK 
MNI CO-ORDINATES OF CLUSTER 
PEAK (mm) 
 COMPARISON Voxels (n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 11 -1 -5 19 2.08 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 9 2 19 4 1.96 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 13 5 0 16 2.23 
PYY>Fasted saline 7 -16 -11 22 1.77 
PYY<Fasted saline 46 15 20 4 2.45 
3.3 B 
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INSULA 
(FOOD MINUS NON-FOOD) 
CLUSTER 
PEAK 
MNI CO-ORDINATES OF CLUSTER 
PEAK (mm) 
 COMPARISON Voxels (n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 796 2 4 -5 3.13 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 734 0 9 -2 3.07 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 265 16 7 -6 2.43 
PYY>Fasted saline 4 -17 -13 14 1.86 
PYY<Fasted saline 1198 4 7 4 3.15 
3.3 C 
NUCLEUS ACCUMBENS 
(FOOD MINUS NON-FOOD) 
CLUSTER 
PEAK 
MNI CO-ORDINATES OF CLUSTER 
PEAK (mm) 
 COMPARISON Voxels (n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 5 -11 12 -11 1.88 
Fed saline>Fasted saline 0 n/a n/a n/a n/a 
Fed saline<Fasted saline 26 -4 12 -10 3.02 
GLP-1>Fasted saline 0 n/a n/a n/a n/a 
GLP-1<Fasted saline 0 n/a n/a n/a n/a 
PYY>Fasted saline 0 n/a n/a n/a n/a 
PYY<Fasted saline 53 -7 14 -9 2.91 
3.3 D 
ORBITOFRONTAL CORTEX 
(FOOD MINUS NON-FOOD) 
CLUSTER 
PEAK 
MNI CO-ORDINATES OF CLUSTER 
PEAK (mm) 
 COMPARISON Voxels (n) X Y Z Max z 
PYY+GLP-1>Fasted saline 22 -7 63 -12 1.91 
PYY+GLP-1<Fasted saline 628 -12 30 -18 2.83 
Fed saline>Fasted saline 305 -12 48 -16 2.38 
Fed saline<Fasted saline 207 -10 21 -12 2.35 
GLP-1>Fasted saline 133 -21 53 -12 2.31 
GLP-1<Fasted saline 90 23 25 -7 2.56 
PYY>Fasted saline 24 -32 29 -18 2.06 
PYY<Fasted saline 594 -2 26 -13 2.72 
3.3 E 
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PUTAMEN 
(FOOD MINUS NON-FOOD) 
CLUSTER 
PEAK 
MNI CO-ORDINATES OF CLUSTER 
PEAK (mm) 
 COMPARISON Voxels (n) X Y Z Max z 
PYY+GLP-1>Fasted saline 0 n/a n/a n/a n/a 
PYY+GLP-1<Fasted saline 3 10 9 -11 1.87 
Fed saline>Fasted saline 5 8 -15 2 1.76 
Fed saline<Fasted saline 200 -11 11 -4 2.83 
GLP-1>Fasted saline 5 32 -8 2 1.75 
GLP-1<Fasted saline 5 6 3 1 1.79 
PYY>Fasted saline 10 30 -13 4 1.94 
PYY<Fasted saline 269 4 12 -5 2.76 
3.3 F 
Table 3.3:  Cluster peaks within the 6 a priori ROIs where ∆ BOLD (when subjects viewed images of food 
compared with when they viewed images of non-food) was significantly greater than zero in Study 2. Fifteen 
healthy subjects underwent 90 minute infusions of saline (Fasted saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-
17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min 
(PYY+GLP-1) following an overnight fast. On one visit, after an overnight fast, they received a set breakfast 
followed by a 90 minute saline infusion (Fed saline). During each infusion, a BOLD fMRI scan was performed, 
incorporating a picture processing task where images of food and non-food were shown. Cluster peaks 
(meeting a criterion of p<0.05, z >1.6 corrected) for treatment contrasts versus Fasted saline are shown within 
the amygdala (3.3 A), caudate (3.3 B), insula (3.3 C), nucleus accumbens (3.3 D), OFC (3.3 E) and putamen (3.3 
F).  
 
Following this, I examined the mean % change in BOLD signal in subjects after feeding, 
PYY3-36, GLP-17-36 amide or combined PYY3-36 & GLP-17-36 amide infusion across the individual a 
priori selected ROIs and compared this with the mean % change in BOLD signal when 
subjects were fasted and received saline (control). There were similar reductions in mean % 
change in BOLD signal for all of the ROIs studied following feeding or gut hormone 
administration, compared to when subjects were fasted and received saline (figure 3.21).  
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Figure 3.21: Modulation of BOLD signal across brain ROIs by feeding, or either individual or combined gut 
hormone infusions.  
Fifteen healthy subjects underwent a 90 minute infusion of saline (Fasted saline) as a control. They also had 4 
further infusions - saline after a standard breakfast (figure 3.21 A), PYY3-36 after an overnight fast (figure 3.21 
B), GLP-17-36 amide after an overnight fast (figure 3.21 C) and combined PYY3-36 + GLP-17-36 amide after an overnight 
fast (figure 3.21 D). During each infusion, a BOLD fMRI scan was performed, incorporating a picture processing 
task where images of food and non-food were shown. The mean % BOLD signal change when subjects viewed 
images of food compared with when they viewed images of non-food is shown for each of the infusions 
administered as a comparison with the fasted saline infusion. Data are shown for individual ROIs (amygdala, 
insula, caudate, nucleus accumbens (N Acc), OFC and putamen), combined for left and right hemispheres and 
grouped for all 15 subjects. PYY denotes PYY3-36, GLP-1 denotes GLP-17-36 amide. 
* denotes p = 0.015 for Fed saline < Fasted saline and p = 0.012 for PYY+GLP-1 < Fasted saline.                            
** denotes p = 0.005 for PYY < Fasted saline.  
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Analysis of left and right hemisphere ROIs individually (figure 3.22) showed that reductions 
in mean % BOLD signal change (when subjects viewed images of food compared to when 
they viewed images of non-food) were significant for the following comparisons in the 
following ROIs: 
Fed saline vs. fasted saline in:  
left insula (p = 0.016) 
right insula (p = 0.034) 
PYY3-36 vs. fasted saline in: 
 left insula (p = 0.007) 
 right insula (p = 0.005) 
 left nucleus accumbens (p = 0.013) 
 left OFC (p = 0.019)  
GLP-17-36 amide vs. fasted saline in: 
right insula (p = 0.049) 
Combined PYY3-36 & GLP-17-36 amide vs. fasted saline in: 
  left insula (p = 0.014) 
  right insula (p = 0.014) 
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Figure 3.22: Modulation of BOLD signal across brain ROIs by feeding, or either individual or combined gut 
hormone infusions- left and right sided analysis.  
Fifteen healthy subjects underwent a 90 minute infusion of saline (Fasted saline) as a control. They also had 4 
further infusions - saline after a standard breakfast (figure 3.22 A), PYY3-36 after an overnight fast (figure 3.22 
B), GLP-17-36 amide after an overnight fast (figure 3.22 C) and combined PYY3-36 + GLP-17-36 amide after an overnight 
fast (figure 3.22 D). During each infusion, a BOLD fMRI scan was performed, incorporating a picture processing 
task where images of food and non-food were shown. The mean % BOLD signal change when subjects viewed 
images of food compared with when they viewed images of non-food is shown for each of the infusions 
administered as a comparison with the fasted saline infusion. Data are shown for individual ROIs and for left 
and right sides (amygdala, insula, caudate, nucleus accumbens (N Acc), OFC and putamen), grouped for all 15 
subjects.  PYY denotes PYY3-36, GLP-1 denotes GLP-17-36 amide. 
* denotes p<0.05 vs. fasted saline. ** denotes p<0.01 vs. fasted saline. 
 
 
 
 
 
149 
 
The reduction in mean % BOLD signal change with the combined infusion of PYY3-36 and 
GLP-17-36 amide was similar to the summed reduction in mean % BOLD signal changes after 
individual administrations of the two hormones (figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: Summed reduction in mean % BOLD signal change in ROIs with individual administration of 
PYY3-36 and GLP-17-36 amide, compared with the reduction in mean % BOLD signal change after combined 
administration of PYY3-36 and GLP-17-36 amide.  
The reduction in mean % BOLD signal change when subjects viewed images of food compared with when they 
viewed images of non-food compared with Fasted saline is expressed as a sum of the individual effect of PYY3-
36 and GLP-17-36 amide (grey bars). This is compared with the reduction in mean % BOLD signal change when 
subjects viewed images of food compared with when they viewed images of non-food compared with Fasted 
saline for the combination infusion of PYY3-36 & GLP-17-36 amide (hatched bars). Data are shown for individual 
ROIs (amygdala, insula, caudate, nucleus accumbens (N Acc), OFC and putamen), combined for left and right 
hemispheres and are grouped for all 15 subjects. PYY denotes PYY3-36, GLP-1 denotes GLP-17-36 amide. p = ns for 
all ROIs. 
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I then tested the effects of feeding, PYY3-36 infusion, GLP-17-36 amide infusion and combined 
PYY3-36 & GLP-17-36 amide infusion on changes in mean % BOLD signal in the total brain 
volume represented by the 6 a priori selected ROIs (Figure 3.24). When fasted subjects 
viewed images of food compared with when they viewed images of non-food, there was a 
significant reduction (p<0.001) in the mean % BOLD fMRI signal change after administration 
of PYY3-36 or after co-administration of PYY3-36 and GLP-17-36 amide, compared to when 
subjects were fasted and received saline infusion (control). There was a non-significant 
reduction in the mean % BOLD signal change in the selected ROIs following feeding or after 
GLP-17-36 amide administration compared to when subjects were fasted and received saline 
infusion.  
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Figure 3.24: Modulation of BOLD signal across collective brain ROIs by feeding, or either individual or 
combined gut hormone infusions. Fifteen healthy subjects underwent 90 minute infusions of saline (Fasted 
saline), PYY3-36 0.3 pmol/kg/min (PYY), GLP-17-36 amide 0.8 pmol/kg/min (GLP-1) and combined PYY3-36 0.3 
pmol/kg/min + GLP-17-36 amide 0.8 pmol/kg/min (PYY+GLP-1) following an overnight fast. On one visit, after an 
overnight fast, they received a set breakfast followed by a 90 minute saline infusion (Fed saline). During each 
infusion, a BOLD fMRI scan was performed, incorporating a picture processing task where images of food and 
non-food were shown. The mean % BOLD signal change (food images minus non-food images) across all 6 ROIs 
studied (amygdala, insula, caudate, nucleus accumbens, OFC and putamen), is shown for each of the 
interventions. 
 ** p<0.01, *** p<0.001.  
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To investigate the possible effect of nausea on the MRI findings, I analysed whether there is 
any significant correlation between change in nausea score from 0 - 90 min (the time of the 
infusion) and the reduction in % BOLD signal change from the control saline infusion for all 
subjects in each of the 6 ROIs (averaged over left and right hemispheres) during the 
combined infusion of PYY3-36 and GLP-17-36 amide. There was significant correlation between 
the change in nausea score and reduction in % BOLD signal change in the amygdala (r2 = 
0.35, p = 0.02), but not in the caudate (r2 = 0.02, p = 0.62), insula (r2 = 0.05, p = 0.44), 
nucleus accumbens (r2 = 0.06, p = 0.36), OFC (r2 = 0.05, p = 0.45) or putamen (r2 = 0.09, p 
= 0.28). This is shown in figure 3.25.  
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Figure 3.25: Correlation of nausea with reduction in % BOLD signal change during combined PYY3-36 and GLP-
17-36 amide infusion for each ROI. For each subject, the change in VAS nausea scores from baseline (t = 0 min) to 
the end of the combined infusion of PYY3-36 and GLP-17-36 amide (t = 90 min) are shown, correlated against 
reduction in % BOLD signal change (% BSC) from the control fasted saline infusion. This was done separately 
for each of the 6 ROIs (amygdala (A), caudate (B), insula (C), nucleus accumbens (D), OFC (E) and putamen (F), 
with % BSC data combined for left and right hemispheres. * denotes p<0.05  
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3.3.17. Effect of feeding, PYY3-36 and GLP-17-36 amide administration on brain activation 
by food images: analysis of hypothalamic and brainstem responses 
 
The whole brain cluster-wise analysis of brain regions responsive to the picture processing 
BOLD fMRI task (table 3.2) revealed that for the fasted saline and fed saline visits, the 
hypothalamus and brainstem (midbrain) BOLD signal was not significantly greater when 
subjects viewed images of food compared with non-food.  
 
Following this, in a voxel-wise analysis, I examined the mean % change in BOLD signal in 
subjects after feeding, PYY3-36, GLP-17-36 amide or combined PYY3-36 & GLP-17-36 amide infusion 
in the hypothalamus and brainstem (midbrain) and compared this with the mean % change 
in BOLD signal when subjects were fasted and received saline (control). This revealed that 
in the hypothalamus and brainstem, there was no effect of feeding or gut hormone 
administration on mean % change in BOLD signal (between viewing images of food 
compared with non-food) compared with the fasted saline infusion (figure 3.26).  
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Figure 3.26: Modulation of BOLD signal in the hypothalamus and brainstem (midbrain) by feeding, or either 
individual or combined gut hormone infusions.  
Fifteen healthy subjects underwent a 90 minute infusion of saline (Fasted saline) as a control. They also had 4 
further infusions - saline after a standard breakfast (A), PYY3-36 after an overnight fast (B), GLP-17-36 amide after 
an overnight fast (C) and combined PYY3-36 + GLP-17-36 amide after an overnight fast (D). During each infusion, a 
BOLD fMRI scan was performed, incorporating a picture processing task where images of food and non-food 
were shown. The mean % BOLD signal change when subjects viewed images of food compared with when they 
viewed images of non-food is shown for each of the infusions administered as a comparison with the fasted 
saline infusion. Data are shown for the midbrain and hypothalamus and grouped for all 15 subjects. PYY 
denotes PYY3-36, GLP-1 denotes GLP-17-36 amide. p = ns for all interventions compared with fasted saline.  
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3.4. Discussion 
 
3.4.1. Discussion of the effects of single and combined administration of PYY3-36 and 
GLP-17-36 amide on appetite, energy intake and neuronal activity in brain appetite 
centres. 
 
By means of this study (Study 2), I examined the independent and combined effects of 
PYY3-36 and GLP-17-36 amide on appetite, subsequent food intake and neuronal activity in 
regions of the brain contributing to appetitive processing and behaviour. Fifteen healthy, lean 
subjects underwent BOLD fMRI scanning on five separate occasions at least 3 days apart, 
during which they received each of the following 90 minute infusions in random order: a 
saline infusion following an overnight fast (the fasted, control visit); a saline infusion following 
a large breakfast (the fed visit); an infusion of PYY3-36 at 0.3 pmol/kg/min; an infusion of 
GLP-17-36 amide at 0.8 pmol/kg/min; a combined infusion of PYY3-36 0.3 pmol/kg/min + GLP-17-
36 amide 0.8 pmol/kg/min (all the gut hormone infusions were performed after an overnight 
fast). The subjects were then served a free intake buffet lunch at the end of each infusion, in 
order to assess effects on food intake.  
 
Prior to the 5 randomised visits detailed above, each subject underwent an initial 
acclimatisation visit, where they received a 90 minute infusion of saline following an 
overnight fast, underwent a BOLD fMRI scan and were then served an ad libitum buffet 
lunch. The protocol was almost identical to that of the subsequent randomized visits (the 
only difference being that during the acclimatisation visit, an extra 5 minute structural MRI 
scan was performed at the end of the BOLD fMRI picture processing task). The purpose of 
the acclimatization visit was to ensure that subjects were comfortable with the research 
environment and study protocol prior to the randomized study visits. The value of this visit is 
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illustrated by the fact that subjects consumed 8% fewer calories at lunch during the 
acclimatization visit compared to the control, fasted saline visit later on.  
 
Analysis of the mean energy intake during the ad libitum lunch during the 5 randomised 
study visits revealed that when subjects consumed breakfast, they consumed 24% fewer 
calories at lunch than if they had continued fasting through the morning. Administering either 
of the gut hormones PYY3-36 or GLP-17-36 amide to fasted subjects also reduced the amount of 
food they consumed at lunch, although to a smaller extent (administration of PYY3-36 reduced 
ad libitum food consumption at lunch by 12% compared to saline, whereas administration of 
GLP-17-36 amide reduced ad libitum food consumption at lunch by 16% compared to saline). 
Notably, when PYY3-36 and GLP-17-36 amide were co-administered to fasted subjects, the 
reduction in food consumption at lunch (27%) was comparable to that observed in subjects 
who had eaten breakfast and received saline (24%). Whilst my experimental procedure was 
not designed to draw conclusions about dose-response relationships for the effects of these 
hormones, the effects of combined gut hormone infusion appeared to be additive, with no 
loss of potency when the hormones were administered in combination. I postulate that 
administration of these anorectic gut hormones in combination induces the satiety similar or 
identical to that of a meal, but without the associated caloric load. This is consistent with 
expectations based on endogenous physiological responses observed post-prandially, 
whereby several anorectic gut hormones are co-secreted and are thought to act together to 
limit further food intake.  
 
The same ad libitum study lunch was served during all visits. To investigate the possibility of 
subjects being progressively less enticed by the meal, resulting in lower energy intake at 
each subsequent visit, I performed analysis of the mean energy intake (of the 15 subjects) 
during the ad libitum lunch across the 5 randomised visits. This analysis provided 
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reassurance that subjects did not eat progressively less during each subsequent visit as a 
result of habituation to the study meal.  
 
Haemodynamic parameters and non-food related VAS parameters were not significantly 
different between infusion of saline, PYY3-36, GLP-17-36 amide, combined infusion of PYY3-36 & 
GLP-17-36 amide or infusion of saline following consumption of breakfast. The effect of eating 
breakfast was as expected, to cause a rise in blood glucose levels, which then subsequently 
fell back towards baseline during the course of the saline infusion that followed. Interestingly, 
in contrast to Study 1, the infusion of GLP-17-36 amide or the combined infusion of PYY3-36 and  
GLP-17-36 amide did not lead to a significant reduction in blood glucose compared with infusion 
of saline after an overnight fast. In Study 1, the blood glucose during the control saline 
infusion rose slightly, whereas the blood glucose during the GLP-17-36 amide infusion and the 
combined PYY3-36 & GLP-17-36 amide infusion fell, perhaps creating a statistical artefact.  
 
During the course of each of the infusions described above, using BOLD fMRI, I tested for 
differences in relative activation in several pre-selected brain ROIs when subjects viewed 
images of food compared with images of non-food items. The a priori selected ROIs 
comprised the amygdala, caudate, insula, nucleus accumbens, OFC and putamen. These 
regions were selected based on the basis of previous studies of satiety and appetitive 
hormone responses, and have been hypothesized to contribute to the brain network for 
control of appetite (Batterham et al., 2007, Farooqi et al., 2007, Fletcher et al., 2010, LaBar 
et al., 2001, Malik et al., 2008). As predicted, my data demonstrated that in each of the 6 
brain reward ROIs, viewing images of food was associated with a greater BOLD fMRI signal 
than viewing non-food images in the fasted state. Consumption of a standard breakfast 
reduced this brain activation, extending earlier observations where a similar protocol was 
used (LaBar et al., 2001). Notably, I did not observe a fed-fasted difference within the 
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amygdala, in contrast to the earlier study by La Bar et al. Activation of the insula was most 
sensitive to modulation by consumption of a meal, with similar trends in the caudate and 
putamen (dorsal striatum), nucleus accumbens (ventral striatum) and OFC. My findings are 
also largely consistent with recent studies demonstrating that fasting selectively increases 
BOLD fMRI activation to pictures of high-calorie food compared with pictures of low calorie 
food in similar ROIs and that this activation is attenuated in the fed state (Goldstone et al., 
2009, Fletcher et al., 2010) 
 
I then assessed the change in BOLD signal following infusion of PYY3-36 and GLP-17-36 amide, 
either singly or in combination, in fasted subjects. When PYY3-36 alone was infused in the 
fasted state, the pattern of signal change in brain reward ROIs was similar to that observed 
after feeding, with consistent reductions in mean % BOLD signal change across all brain 
reward ROIs. Reductions in signal change were prominent in the insula, left nucleus 
accumbens and the left OFC.  
 
My work formed the first published study to describe effects of GLP-17-36 amide infusion on 
brain activation in humans. Infusion of GLP-17-36 amide alone led to consistent reductions in 
mean % BOLD signal change compared with fasted saline across all of the selected ROIs, 
with the greatest change in the right insula.  
 
I also characterized the combined effects of infusion of PYY3-36 and GLP-17-36 amide on brain 
activity for the first time. I found consistent reductions in mean % BOLD signal change 
relative to infusion of saline across all of the selected ROIs, similar to those observed 
following a meal. As with GLP-17-36 amide alone, the insula appeared particularly sensitive to 
hormonal modulation. Consistent with effects on ad libitum energy intake, summation of the 
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effect of each single hormone in reducing mean % BOLD signal change was comparable 
with the reduction in mean % BOLD signal change after the combined infusion of PYY3-36 
and GLP-17-36 amide. This provides novel evidence in humans that the actions of PYY3-36 and 
GLP-17-36 amide on brain responses to food-salient stimuli are additive, explaining the way in 
which gut hormones co-secreted physiologically after meals may work in concert to limit 
further food intake and cause satiety. 
 
This insight into the neuroendocrinology of appetite highlights numerous new questions for 
future studies. The functional anatomical localizations of brain activations after hormone 
administration suggest that ascending connections from vagal nuclei modulate the 
dopaminergic reward system: it was in the insular cortex (which is situated at an interface of 
homeostatic and cognitive systems with activity related to establishing salience of external 
stimuli for appropriate behavioural reactions (Menon and Uddin, 2010) that I observed brain 
activity to be most significantly modulated by both feeding and gut hormone infusion. 
Another region where I observed changes was in the nucleus accumbens (forming the major 
part of the ventral striatum); this area is thought to play an important role in the mediation of 
hedonic drive and action (e.g., food-seeking behaviours) (Baldo and Kelley, 2007). 
 
Recent evidence has identified a role for the OFC in linking food memory with food reward. 
Connectivities of the OFC with the hippocampus, amygdala and insula (Kringelbach, 2005) 
may facilitate a central role in coordinating appetitive behaviour. Changes in OFC activation 
were also reported in an earlier investigation of PYY3-36 effects (Batterham et al., 2007). In 
that study, subsequent food intake was predicted by the modulation of OFC signal with 
PYY3-36 infusion, but not with saline infusion after fasting, when subsequent food intake was 
better correlated with changes in hypothalamic signal. It was postulated that the presence of 
PYY3-36 switches regulation of food intake from a homeostatic brain region (hypothalamus) to 
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a hedonic region (OFC). However, differences in methodology used (my study used task-
activated BOLD fMRI data, whereas Batterham et al. tested for changes in resting state 
BOLD fMRI) confounds direct comparisons between the studies. 
 
Whereas single infusion of PYY3-36 to fasted subjects led to greatest modulation of BOLD 
signal in the left and right insula, left OFC and left nucleus accumbens, single infusion of 
GLP-17-36 amide infusion led to significant modulation of signal only in the right insula. This may 
in part be due to fundamental differences in the way in which these anorectic gut hormones 
act to mediate post-prandial satiety. However, notably, combined infusion of PYY3-36 and 
GLP-17-36 amide led to significant modulation of BOLD signal in the insula alone, suggesting 
that the study was somewhat underpowered to detect differences in BOLD signal due to 
considerable inter-subject variance of this parameter. Furthermore, despite the fact that 
GLP-17-36 amide infusion led to relatively modest changes in BOLD signal compared with 
infusion of PYY3-36, the reduction in energy intake during the ad libitum meal was greater for 
GLP-17-36 amide. This may be due to additional effects of GLP-17-36 amide in mediating fullness by 
inhibiting gastric emptying.  
 
Although there was no modulation of subjective ratings of meal palatability by either single or 
combined administration of the gut hormones, the combined infusion of PYY3-36 and GLP-17-
36 amide was associated with a mild increase in VAS nausea and fullness scores, along with a 
corresponding reduction in hunger, pleasantness of prospective food consumption and 
planned prospective food consumption. Significantly, at no stage did any subjects report to 
the investigators that they felt nauseated outside of the context of VAS analysis. Therefore, 
the degree of nausea induced by the combined infusion of PYY3-36 and GLP-17-36 amide was 
tolerable. Furthermore, the absence of significant correlation between nausea and ad libitum 
energy intake at lunch during the combined infusion of PYY3-36 and GLP-17-36 amide provides 
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reassurance that PYY3-36 and GLP-17-36 amide do not inhibit food intake merely by inducing 
nausea. Analysis of the effect of nausea on BOLD signal change revealed that there was a 
significant correlation between the change in nausea score during the combined PYY3-36 and 
GLP-17-36 amide infusion and the reduction in % BOLD signal change compared to the control 
saline infusion only in the amygdala, and not in any of the other ROIs. This may reflect the 
general role of the amygdala in processing of emotion. Notably, there was no significant 
correlation between nausea and reduction in % BOLD signal change in the insula, which 
was the brain region that showed greatest modulation with the combined infusion of PYY3-36 
and GLP-17-36 amide. 
 
3.4.2. Comparison of the effects of PYY3-36 and GLP-17-36 amide on neuronal activity 
related to appetite with those of other appetite-modulating hormones. 
 
It is of interest to interpret my results in the context of similar human fMRI studies 
investigating neuronal effects of other appetite-modulating hormones. Consistent trends can 
be found in reports of modulation of the BOLD fMRI signal when viewing food-related 
images in the presence or absence of these hormones, with the directionality of neuronal 
effects seemingly dependent on whether the hormone under scrutiny is anorectic or 
orexigenic.  
 
Leptin, a hormone secreted by adipocytes, is thought to form part of the feedback loop for 
maintaining long term energy homeostasis; when fat stores are replete, increased levels of 
leptin signal to the brain to reduce subsequent food intake in order to maintain weight 
neutrality. However, whilst this is an oversimplification, given the well known phenomenon of 
leptin resistance in obesity, in global terms, we may consider leptin to be an anorectic 
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hormone. In an fMRI study testing for brain activation contrasts between viewing high and 
low calorie food images (i.e. slight methodological differences to my study, as I used the 
signal contrast between all food and non-food images), subcutaneous leptin replacement in 
congenitally leptin deficient individuals resulted in reduced BOLD activation in the insula, 
temporal and parietal cortex (Baicy et al., 2007). Therefore, my results for PYY3-36 and GLP-
17-36 amide administration, showing attenuation of signal in the insula, caudate, putamen and 
nucleus accumbens, are consistent with this previous study of leptin. In another fMRI study 
that used a protocol similar to mine, when leptin was replaced subcutaneously in individuals 
with congenital leptin deficiency, BOLD activation contrast between viewing food and non-
food images was reduced in the caudate, putamen, globus pallidus and nucleus accumbens 
(Farooqi et al., 2007). I found similar activation changes following infusion of PYY3-36 and 
GLP-17-36 amide.  However, in my study the most significant reduction in mean % BOLD signal 
change following infusion of PYY3-36 and / or GLP-17-36 amide was in the insula, left nucleus 
accumbens and the left OFC. This implies that leptin, compared with PYY3-36 or GLP-17-36 
amide, modulates distinct neural networks. I speculate that this may be related to the longer-
term anorectic signaling by the adipokine leptin, relative to the more acute anorectic effects 
of post-prandially released gut hormones.  
 
It is also interesting to consider my results in relation to the effects of the hormone insulin on 
cue-induced brain activation. Although exogenous insulin therapy often leads to weight gain 
when administered to patients with diabetes (which may be consequential to its overall 
peripheral anabolic effects and also due to the stimulation of appetite secondary to a fall in 
blood glucose), endogenous insulin release is postprandial and central anorectic effects limit 
further food intake. In a study where insulin was administered intranasally whilst maintaining 
euglycaemia, BOLD fMRI activation (in response to food versus non-food images) was 
reduced in the fusiform gyri, right hippocampus, right temporal superior cortex and right 
frontal middle cortex (Guthoff et al., 2010). The attenuation of BOLD signal in higher cortical 
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centres by insulin is consistent with my data. I speculate that subtle differences in brain 
responses between insulin and the anorectic gut hormones PYY3-36 and GLP-17-36 amide may 
reflect the different roles of these hormones in energy homeostasis: anorectic gut hormones 
are thought to mediate short term signalling, whereas insulin may be implicated both in short 
and longer term signalling of energy homeostasis.  
 
My results are also interesting in relation to a previous study investigating the effects of 
ghrelin, the only known gut hormone which acutely increases food intake, on brain activity in 
normal-weight humans (Malik et al., 2008). Intravenous ghrelin infusion increased BOLD 
activation when subjects viewed images of food compared to when they viewed images of 
non-food in the amygdala, OFC, insula, visual areas and striatum. By contrast, in my study, 
the gut hormones PYY3-36 and GLP-17-36 amide, which acutely inhibit food intake, resulted in a 
reduction in mean % BOLD signal change in these ROIs. These results suggest that these 
ROIs form CNS networks, which when activated by ghrelin, mediate hunger and when 
inhibited by the anorectic gut hormones PYY3-36 and GLP-17-36 amide, mediate satiety.  
 
To investigate the effects of hypoglycaemia (another orexigenic stimulus), a recent study 
reported increased BOLD activation in the insula and striatum, along with increased hunger 
after mild hypoglycaemia was induced (Page et al., 2011). Thus my work, along with other 
fMRI studies, suggests that whilst anorectic hormones attenuate activity in brain regions 
supporting salience and reward, orexigenic stimuli enhance activation in these same areas. 
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3.4.3. Comparison of the effects of PYY3-36 and GLP-17-36 amide on neuronal activity 
related to appetite with those observed after gastric bypass surgery. 
 
Here, I have reported both total and active concentrations of PYY, in addition to amidated 
and active concentrations of GLP-1. In contrast to study 1, there was no significant 
difference in plasma levels of PYY achieved between single infusion of PYY3-36 compared 
with combined infusion of PYY3-36 and GLP-17-36 amide. Following the exogenous infusion of 
PYY3-36, the profile of total and active hormone levels in plasma was similar. Furthermore, 
following the exogenous infusion of GLP-17-36 amide, the profile of amidated and active 
hormone levels in plasma was similar. This suggests that the standard practice of measuring 
total PYY concentrations and amidated GLP-1 concentrations is valid. Total PYY 
concentrations and amidated GLP-1 concentrations are more commonly reported in the 
literature; review of the corresponding hormone levels in my study thus allows for meaningful 
comparison with existing relevant data. My results revealed that during the combined 
infusion of PYY3-36 and GLP-17-36 amide, the mean total PYY concentration achieved was 70 
pM and the mean amidated GLP-1 concentration was 43 pM. Interestingly, the mean 
circulating levels of total PYY and amidated GLP-1 following breakfast were 33 pM and 22 
pM, respectively. Although levels of total and active hormone levels were slightly higher after 
breakfast than when subjects continued to fast through the morning, this did not reach 
statistical significance. This is surprising, given that we would expect increased levels of both 
hormones post-prandially. One explanation for this may have been that the set breakfast 
was served between t = -60 and t = -40 min and the next plasma sample was not taken until         
t = 0 min, thereby missing the early peak of post-prandial PYY and GLP-1.  
 
Although my infused circulating total PYY and amidated GLP-1 levels were slightly higher 
than those observed physiologically after breakfast, there was a comparable reduction in ad 
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libitum energy intake at lunch following combined infusion of PYY3-36 and GLP-17-36 amide and 
following infusion of saline after breakfast. I hypothesize that this may reflect the combined 
effects of several other gut hormones and satiety factors in addition to PYY3-36 and GLP-17-36 
amide that are thought to play a role in mediating satiety as part of the physiological response 
to feeding. 
 
The plasma concentrations of total PYY and amidated GLP-1 that I have explored are 
pertinent when considering the levels observed after Roux-en-Y gastric bypass, the most 
effective current treatment for obesity. Gastric bypass patients demonstrate exaggerated 
post-prandial levels of total PYY and amidated GLP-1 (Borg et al., 2006, le Roux et al., 
2006). In the study by Le Roux et al., a mean 90 min post-prandial total PYY level of 40 pM 
was observed following Roux-en-Y gastric bypass. In the same study, a mean 30 min post-
prandial amidated GLP-1 level of 47 pM was observed. These levels are comparable to 
plasma levels of total PYY and amidated GLP-1 that were observed in my study. Therefore, 
although circulating levels achieved in my study may be regarded as somewhat 
supraphysiological within the normal population, they are of direct functional relevance for 
understanding the effects of PYY and GLP-1 in patients who have undergone gastric bypass 
surgery. PYY and GLP-1 appear to be the most important gut hormones implicated in 
mediating reduced appetite and promoting weight loss following gastric bypass (le Roux et 
al., 2007) although there are likely to be changes in other gut hormones that are not routinely 
measured.  
 
It is therefore of interest to compare my imaging results in healthy, lean individuals to those 
found in a fMRI studies of obese individuals pre- and post- gastric bypass surgery. In a 
recent study, reductions in striatal neural response, along with reductions in wanting and 
liking for high- relative to low-calorie food cues, were observed one month post- Roux en-Y 
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gastric bypass surgery compared with pre-surgery (Ochner et al., 2012). In a previous study 
by the same group (Ochner et al., 2011) post-surgery (compared with pre-surgery), there 
was attenuation of high calorie food cue associated fMRI BOLD signal in the VTA, ventral 
striatum, putamen, lentiform nucleus, posterior cingulate and dorsomedial prefrontal cortex. 
Hunger also was reduced after surgery (Ochner et al., 2011). These results are striking, 
given that I also found similar attenuation of BOLD signal in reward areas when I 
administered PYY3-36 and GLP-17-36 amide. Although circulating gut hormone levels were not 
measured in the gastric bypass study (Ochner et al, 2011), the authors postulated post-
surgical reductions in ghrelin levels as an explanation for their imaging observations. 
Alternatively, I speculate that elevated levels of PYY and GLP-1 post-bypass would explain 
their findings. Thus, whilst fMRI is at present used only as a research tool in endocrinology, 
these studies imply translation for the pre-operative work-up of obese patients; it may help 
highlight those patients who are more susceptible to the anorectic effects of gut hormones 
and who may therefore benefit most from surgery. Although there are as yet no published 
studies as such, a recent study of fMRI response to viewing high-calorie food versus control 
pictures in obese individuals before and after a 12 week psychosocial weight loss program 
revealed that obese individuals who were least successful in losing weight during the 
treatment displayed greater pre-treatment BOLD activation to high calorie food vs. control 
pictures in the nucleus accumbens, ACC, and insula. Furthermore, greater post-treatment 
BOLD activation in the insula, VTA, putamen, and fusiform gyrus predicted less successful 
weight maintenance at 9 months follow up (Murdaugh et al., 2012). 
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3.4.4. Limitations of my study 
 
In addition to the brain reward regions discussed thus far, the hypothalamus and certain 
brainstem nuclei are also known to be important in the homeostatic control of food intake. 
Direct information on hypothalamic and brainstem responses was not available in my study.  
In a separate voxel-wise analysis, I did not observe significant responses in these regions 
using the picture processing BOLD fMRI task. Previous similar studies failed to observe 
changes in hypothalamic activation (Malik et al., 2008) or provided no comment on it 
(Farooqi et al., 2007), although other BOLD fMRI investigations have quantified 
hypothalamic signal (Batterham et al., 2007, Fletcher et al., 2010). Approaches that control 
for effects of motion of the hypothalamus and brainstem during the cardiorespiratory cycle 
could enable the study of activation responses in future work (Pattinson et al., 2009). The 
small size of the hypothalamus (approximately 5 mm in diameter) limits its resolution using 
fMRI acquisition parameters applied in my study. Additionally, magnetic susceptibility signal 
loss due to the air-tissue interface of the adjacent sinuses limits assessment of any 
hypothalamic signal changes. Thus, the ascending pathways mediating actions of circulating 
modulators of appetite remain incompletely understood.  
 
In my BOLD fMRI analysis, although there was consistent modulation of % BOLD signal 
change by feeding, PYY3-36 and GLP-17-36 amide infusion across all ROIs studied, statistical 
significance of results was largely limited to the insula. This is most likely explained by the 
large inter-individual variation in BOLD fMRI signal across subjects, thus creating a large 
standard error at the group level, which is a limiting factor where statistical power is 
concerned. The study was powered based on the outcome of reduction in food intake during 
the ad libitum lunch following feeding or gut hormone infusion; a sample size of 16 was 
required in order to have 90% power to detect a difference in mean food intake of 950 kJ, 
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assuming a standard deviation of differences of 1140 kJ, using a paired t test with a 0.05 two 
sided significance level. A much larger subject group may well have allowed further 
statistically significant imaging results to emerge at the group level, notwithstanding 
constraints on scanner time and cost.  
 
A further limitation of my work stems from the concept of a priori choosing ROIs to assess 
the action of feeding or gut hormone infusion. Although I chose ROIs based on the results of 
existing data in the field and also my hypotheses as to their role in food reward, it should be 
noted that an ROI-based analysis, although statistically providing more sound results, 
possesses the inherent problem of potentially missing other regions of the brain which are 
modulated by gut hormones. Notably however, my initial analysis of the effect of the picture 
processing task, examining the brain regions where BOLD signal contrast between viewing 
images of food and non-food was greatest, used data from the fasted saline infusion scans 
and ‘fed saline’ infusion scans. This verified that my choice of ROIs was appropriate and that 
other brain regions significantly responsive to the picture processing task were not being 
missed. Furthermore, the similarity in brain response to feeding as when PYY3-36 and GLP-
17-36 amide were infused provides reassurance regarding my choice of ROIs for assessing the 
action of PYY3-36 and GLP-17-36 amide.  
 
Here, I have presented all BOLD fMRI data as the contrast in BOLD signal during the picture 
processing task when subjects viewed images of food versus non-food, and the effect that 
feeding or gut hormone infusion had on modulating this signal contrast. Presenting data as a 
contrast of BOLD signal is standard practice in the fMRI literature; I chose to compare the 
signal contrast between viewing images of food and non-food, as the image processing task 
that I used was already set up in this way (Beaver et al., 2006). Contrasting the BOLD signal 
in response to viewing images of appetizing food versus bland food, or alternatively 
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appetizing food versus non-food would have been alternative approaches that I could have 
used that are also widely reported in the literature. Regardless of the type of contrast used to 
present the data, an inherent limitation of fMRI analysis stems from this; namely that results 
are not presented directly as ‘BOLD signal’, but instead as ‘BOLD signal change’.  
 
Furthermore, it is important to appreciate that BOLD fMRI signal is not a direct marker of 
neuronal activity; increased neuronal activity in given brain region elicits a local 
haemodynamic response, which causes an increase in blood flow above and beyond that 
necessary for tissue demands. Provided that tissue oxygen extraction remains the same, 
this results in a locally reduced ratio of deoxyhaemoglobin to oxyhaemoglobin concentration. 
The ensuing differences in local magnetic field inhomogeneities can be translated into 
imaging outcomes, whereby the locally reduced ratio of deoxyhaemoglobin to 
oxyhaemoglobin leads to a longer T2*, producing an increased image intensity. If tissue 
oxygen extraction increased as well, then the ratio of deoxyhaemoglobin to oxyhaemoglobin 
concentration would be higher, thus in fact paradoxically leading to reduced signal in more 
active tissue. It is therefore important to note that although BOLD fMRI focuses on the initial 
haemodynamic response observed in metabolically active tissue, the BOLD response is also 
influenced by local changes in oxygen extraction, which may confound results.  
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CHAPTER 4 
 
General Discussion 
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4.1. Summary 
 
I have characterized the effects of single and combined administration of PYY3-36 and GLP-
17-36 amide on brain BOLD fMRI activations in humans. My data shows for the first time that 
combined infusion of PYY3-36 and GLP-17-36 amide leads to an anorectic effect which is similar 
to that observed following a meal. In keeping with this, combined administration modulates 
brain activations implicated in appetite control to an extent similar to that observed 
physiologically after a meal. By administering PYY3-36 and GLP-17-36 amide to fasted 
individuals, it is therefore possible to ‘trick’ the brain into feeling ‘satiated’ in ways that 
appear indistinguishable from the effects of a meal. These findings provide direct evidence 
that the combined action of gut hormones including PYY3-36 and GLP-17-36 amide in the brain 
could explain post-prandial satiety.  
 
There is additional exciting data to suggest that following gastric bypass, where it is known 
that appetite is reduced and that levels of PYY and GLP-1 are elevated, patterns of brain 
activation are similar to those seen in my study after administration of PYY3-36 and GLP-17-36 
amide in healthy volunteers (Ochner et al., 2011, Ochner et al., 2012). I have speculated on 
the significance of some of the brain areas engaged in appetitive processing and suggest 
that a continued and deeper understanding of the neurobiology of appetite will pave the way 
to the development of gut hormones as effective anti-obesity therapies. Given the 
consistency of the imaging data so far, it seems plausible that the administration of 
combined anorectic gut hormones may provide an effective future medical alternative to a 
surgical gastric bypass procedure to treat obesity. 
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4.2. Further work: imaging the hypothalamus 
 
The use of arterial spin labelling (ASL) MRI promises to be a novel technique for the 
investigation of appetitive pathways, potentially allowing for better functional assessment of 
the hypothalamus. By magnetically tagging a column of blood outside the brain, when this 
tagged blood enters a brain region of interest, distortions of the local magnetic field in the 
given region of interest can be assessed. ASL more directly reflects the changes in local 
brain perfusion and has favourable noise properties over BOLD for intersession comparisons 
(Wang et al., 2011) 
 
It is also possible to envisage that using a combination of BOLD and ASL analysis for reward 
regions of interest would allow a better dissection of changes in local blood flow versus 
changes in tissue oxygen extraction; theoretically, as the BOLD signal is based on the 
overall outcome of blood flow and oxygen extraction, whereas the ASL signal focuses on 
blood flow alone, subtraction of ASL from BOLD may provide a marker of local oxygen 
extraction in metabolically active tissues.  
 
Other approaches to provide better BOLD fMRI signal in the hypothalamus could also be 
considered in future work; early studies that have concentrated on hypothalamic signal 
change have involved conventional T2*-weighted sequences to functionally scan a sagittal 
plane through the hypothalamus continuously, acquiring images pre- and post- a given 
stimulus. By concentrating all image processing ability on this thin, central slice, greater 
attention can be devoted to a ROI corresponding to the hypothalamus, although clearly at 
the expense of imaging the rest of the brain. In this manner, Matsuda et al. demonstrated 
that oral glucose ingestion produced a profound transient reduction in hypothalamic BOLD 
fMRI signal in lean subjects (Matsuda et al., 1999). Interestingly, from a clinical perspective, 
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this observation has been extended and it has been subsequently demonstrated that the 
reduction in hypothalamic BOLD signal following glucose ingestion was absent in patients 
with Type 2 diabetes, theorising that inappropriate hypothalamic processing of nutrient 
availability may be involved in the aetiology of the disease (Vidarsdottir et al., 2007). This 
group has also alluded to the effects of gut hormones on hypothalamic activity following 
glucose ingestion. In healthy men, despite causing a threefold lower rise in blood glucose 
concentration than intravenous glucose administration, oral glucose ingestion led to a much 
more robust reduction hypothalamic BOLD signal (Smeets et al., 2007). As well as the effect 
of taste, it was postulated that hormones such as GLP-1, released in response to nutrients 
entering the gut, accounted for this greater hypothalamic response to oral rather than 
intravenous glucose.  
 
In 2000, Liu et al. described a new technique called time clustering analysis (TCA), whereby 
the number of voxels reaching maximum signal intensity as a function of time was examined 
(Liu et al., 2000).  In this way, TCA records the time windows in which maximal brain 
responses occur and from which ROI analysis can be appropriately extracted.  By scanning 
a 1cm midsagittal slice, they were able to further concentrate resolution on the 
hypothalamus and found that significant hypothalamic deactivation occurred 10 minutes 
following glucose ingestion. They also showed that the degree to which the hypothalamic 
signal reduced post-glucose ingestion negatively correlated with fasting plasma insulin 
levels.  
 
However, in contrast to the above findings, a recent study by Purnell et al. in 2011 did not 
detect any signal change in the hypothalamus in response to either glucose or fructose 
infusion in 9 healthy, normal-weight subjects (Purnell et al., 2011). The authors postulated 
that differential activation of excitatory and inhibitory nuclei within the hypothalamus may 
have cancelled out any overall signal change. This illustrates the ongoing limitations when 
attempting to visualise the human hypothalamus in fMRI studies. Clearly, in order to 
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maximally capture hypothalamic signal, dedicated imaging paradigms are required, which 
may limit the ability to simultaneously image brain reward regions.  
 
4.3. Further work: fMRI responses in obesity 
 
My work in this thesis has focused on the effect of normal feeding and the anorectic gut 
hormones PYY3-36 and GLP-17-36 amide on the BOLD fMRI response in individuals of normal 
weight. Translation of these findings into obese individuals are supported by the recent fMRI 
studies of patients pre- and post- bariatric surgery; the similar activation patterns in brain 
reward regions in my work to those observed post- bariatric surgery, where levels of PYY 
and GLP-1 would presumably be elevated, are supportive (Ochner et al., 2011, Ochner et 
al., 2012). However, a limitation of this body of work lies in the fact that fMRI studies of 
bariatric surgery have not directly reported levels of measured anorectic gut hormone levels.  
 
Studies investigating the differential reward system activation patterns when looking at high 
calorie foods between obese and normal weight subjects have shown significantly greater 
activation in the obese group in several brain regions implicated in food reward. In one such 
study, increasing BMI positively predicted BOLD activation (in relation to viewing high calorie 
food images versus non-food images) in the dorsal striatum, anterior insula and lateral OFC 
(Rothemund et al., 2007). A further study of obese women demonstrated that pictures of 
high calorie foods (versus non-food) produced greater activation in an obese group 
compared with controls in several brain regions, including the ventral and dorsal striatum, 
insula, ACC, amygdala and OFC (Stoeckel et al., 2008). Functional connectivity analysis 
indicated that obese women displayed a relative deficiency in the amygdala’s modulation of 
the OFC and ventral striatum, along with excessive modulation of the ventral striatum by the 
OFC (Stoeckel et al., 2009). Collectively, results from the above studies suggest that a 
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hyper-reactive reward system to high calorie food cues is involved in the pathophysiology of 
obesity. 
 
Several studies have shown that obese individuals also respond differently to satiation 
compared with normal weight individuals, hypothesizing that in obesity, there is a degree of 
dysregulation in CNS appetite regions, which may contribute to overeating and hence weight 
gain. One such study measured BOLD fMRI activation pre-and post prandially (following a 
500 kCal meal) in response to pictures of food (a combination of high calorie and low calorie 
images) and non-food in 10 obese and 10 healthy weight adults. During the pre-meal 
condition, obese subjects showed increased activation in the anterior cingulate and medial 
prefrontal cortex, compared to healthy weight controls (Martin et al., 2010), thus concurring 
with the previous observations (Stoeckel et al., 2008). During the post-meal condition, obese 
participants also showed greater BOLD activation in the medial prefrontal cortex compared 
with healthy weight controls. A further recent study by Dimitropoulos et al. of 22 overweight / 
obese males and 16 normal weight males showed that before eating, obese subjects 
showed greater response to food images (versus non-food images) compared with normal 
weight subjects in the anterior prefrontal regions (Dimitropoulos et al., 2012). Post-prandially, 
the obese group demonstrated increased response to all food images (versus non-food) 
compared with normal weight individuals in frontal, temporal and limbic regions. Specific 
greater activation to high calorie foods was seen in the obese group compared with normal 
weight individuals in the lateral OFC, caudate and ACC (Dimitropoulos et al., 2012).  
 
The CNS response to the hormones discussed in this thesis may also be different in 
overweight or obese individuals. As discussed above, in 1999, Matsuda et al. studied the 
hypothalamic response before and after oral glucose ingestion. Although they showed that 
oral glucose ingestion produced a profound transient reduction in hypothalamic signal in 10 
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lean subjects, this response was both significantly delayed and attenuated in 10 obese 
individuals. More tellingly, it was shown that following glucose ingestion, the time taken to 
reach the maximum hypothalamic inhibitory response was closely correlated to fasting 
plasma glucose and insulin levels (which, as expected, were significantly higher in the obese 
group) rather than BMI per se, suggesting hypothalamic dysfunction as either the cause or 
consequence of insulin resistance (Matsuda et al., 1999). 
 
To extend the above findings to the study of reward regions, a later study incorporating 
visual food and non-food cue methodology revealed that BOLD fMRI activation in the right 
hippocampus (with respect to high calorie food images versus other images) correlated 
positively with fasting insulin levels and waist circumference (but not BMI) in 12 normal 
weight and 12 obese adolescents who had all been fed a standard breakfast a few hours 
prior to scanning (Wallner-Liebmann et al., 2010). On the other hand, in that study, there 
was significant negative correlation between activation of the medial right superior frontal 
gyrus and the left thalamus (again, with respect to the contrast between high calorie food 
images versus other images) with fasting insulin levels. The authors postulated that their 
results reflected a permissive role of insulin in the control of eating behaviour by the 
hippocampus. I further speculate that in those with a larger waist circumference and high 
circulating levels of insulin (i.e. peripherally insulin resistant individuals), a degree of central 
insulin resistance in the hippocampus may explain the greater activation in this region, 
despite higher insulin levels. Indeed, a magnetoencephalography study showed that food-
image related brain activity in the fusiform gyrus was increased by local intranasal 
administration of insulin, but that this was reduced in overweight subjects, implying a degree 
of cerebral insulin resistance (Guthoff et al., 2011).  
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Some studies have reported that obese individuals have lower basal fasting levels of PYY 
and have a smaller rise in postprandial levels (Batterham et al., 2003). Obesity does not 
appear to be associated with resistance to PYY3-36, as in obese subjects, there was a 30% in 
a reduction in ad libitum food intake at a buffet meal served 2 hours after completion of a 90 
minute infusion of PYY3-36 (Batterham et al., 2003). This compared with a 31% reduction in 
food intake in a group of lean subjects who also received a peripheral infusion of PYY3-36. 
Additionally, there was also a comparable reduction in 24 hour energy intake in both lean 
and obese subjects following PYY3-36 infusion. Furthermore, in the case of GLP-17-36 amide, the 
reduction in ad libitum energy intake for overweight / obese subjects (10.5%) was 
comparable with that of lean subjects (13.2%) (Verdich et al., 2001). Further fMRI studies of 
BOLD signal in response to infusion of PYY3-36 and GLP-17-36 amide in overweight / obese 
subjects, would nevertheless be interesting to validate the findings from early infusion 
studies.  
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4.4. Conclusion 
 
The use of fMRI to study appetite control in humans is a rapidly evolving field. There 
appears to be a degree of consistency between studies, suggesting that in the fasted state, 
greater BOLD activation is seen in several brain regions implicated in reward processing 
when food cues (and in particular high calorie food cues) are presented to subjects. Obese 
subjects seem to show heightened response to such food cues, which may fundamentally 
contribute to increased wanting of food (and thus increased subsequent food intake) in 
obese individuals. The fMRI data also seems to be in agreement that the consumption of a 
meal (or other surrogate markers of feeding, such as a rise in glucose) tends to deactivate 
key appetite regions in normal weight individuals, and furthermore, that this satiety response 
may also be abnormal in those with obesity. Further studies should lead to consolidation of 
existing concepts on the role of individual brain regions and their interconnections in 
physiological and pathological satiety responses.  
 
Building on this fundamental understanding of the change in BOLD signal between the 
fasted and fed states, recent studies have suggested that in general, orexigenic signals, 
which are in abundance in the fasted state, increase the BOLD response in brain reward 
regions, whereas anorectic signals, which predominate in the fed state, correspondingly 
deactivate the same regions. Subtle differences in brain responses between these studies 
may reflect the slightly different roles of the different hormonal signals in short term versus 
longer tem energy homeostasis, and also may reflect differential action on various appetite 
pathways. Nevertheless, studies in obese patients, assessing the effect of gastric bypass 
surgery on the BOLD fMRI response, have further concurred with the results of studies 
investigating the BOLD response following the exogenous administration of orexigenic and 
anorectic hormones, thus consolidating the overall body of work in the area.  
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Although fMRI is at present used only as a research tool to study appetite, the overall goal in 
the future will be to translate this research into the clinical arena. An obvious role would be to 
help develop pharmacological treatments for obesity, by means of assessing the fMRI 
response to administration of novel agents in obese individuals. Alternatively, we may 
envisage the use of fMRI as a tool to help predict response to gastric bypass surgery; it 
would be interesting to investigate whether particular patterns of fMRI brain activation pre-
operatively predict response to surgery. To aid effective comparison of results, it would be 
enormously useful to strive towards greater consistency between studies, particularly with 
regard to experimental design, image acquisition and image analysis. My research and that 
of others have established key concepts, and it is expected that the coming decade should 
see consolidation of these findings. We are fortunate that fMRI studies have allowed 
scientists to investigate for the first time in humans, the intricacies of appetitive processing.  
As this technology continues to evolve, it will remain an important tool for investigating basic 
physiology as well as evaluating new therapies.   
 
 
 
 
 
 
 
 
 
 
181 
 
APPENDIX 1 
 
Principles of Radioimmunoassay (RIA) 
 
Radioimmunoassay (RIA) is a technique used to measure the concentration of an unknown 
quantity of peptide sample (in this case, the total PYY, PYY3-36 or total GLP-1) in plasma. 
Unlabelled antigen on the peptide in the plasma sample and radiolabelled (using I-125) 
antigen compete for an antibody binding site. The specificity of the antibody is dependent 
upon its ability to recognise structural features of the antigen on the peptide. Antibodies for 
total PYY and total GLP-1 in my assays are produced by immunising rabbits with PYY and 
GLP-1 respectively. The antibody for PYY3-36 used in my assay is produced commercially by 
immunising Guinea Pigs with PYY3-36. 
 
In the RIA, both the radiolabelled peptide and antibody are at specific, constant 
concentrations, with the concentration of antibody being limiting. The known amount of 
radiolabelled antigen will compete with unlabelled antigen (in the plasma sample of peptide) 
for antibody binding, with the amount of radiolabelled antigen bound to the antibody being 
inversely proportional to the amount of unlabelled antigen in the plasma peptide sample 
being assayed. A ‘standard curve’ is also set up, adding known concentrations of pure 
antigen to fixed amounts of antibody and radiolabelled antigen.  
 
Tubes containing unknown concentrations of unlabelled sample antigen, radiolabelled 
antigen and antibody are incubated for 72 hours at 4ºC, following which separation of the 
unbound radiolabelled antigen from the radiolabelled antigen-antibody complex is 
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performed. For GLP-1, separation by adsorption with charcoal is used (free radiolabelled 
antigen is bound by the charcoal pellet following centrifugation, with the supernatant then 
separated from the pellet using a Pasteur pipette). For PYY, separation of the free 
radiolabelled antigen from the radiolabelled antigen-antibody complex using a primary 
antibody / secondary antibody complex is used (free radiolabelled antigen is contained in the 
supernatant following centrifugation, which can then be separated from the radiolabelled 
antigen-antibody complex pellet using a Pasteur pipette). In my assay for total PYY, the 
secondary antibody was raised in sheep against the primary antibodies derived from rabbits. 
In the commercial assay that I used to measure PYY3-36, the secondary antibody was raised 
in goats against the primary antibodies derived from Guinea Pigs.  
 
Following separation of the free radiolabelled antigen from the antibody-bound radiolabelled 
antigen, radioactivity in both fractions is counted using a gamma counter. Using the standard 
curve tubes, the percentage binding of radiolabelled antigen to the antibody is plotted for 
different concentrations of pure ‘standard’ antigen. From this, the concentration of unlabelled 
antigen (and hence peptide) in the unknown plasma samples can be interpolated. 
 
Principles of Enzyme- Linked Immunosorbent Assay (ELISA) 
 
Enzyme-linked immunosorbent assay (ELISA) as used in my work is based on the capture of 
active GLP-1 (GLP-17-36 amide and GLP-17-37) in the plasma sample by a monoclonal antibody, 
already immobilized in the wells of a microwell plate. The antibody binds specifically to the 
N-terminal region of active GLP-1 molecule.  Plasma containing the unknown concentrations 
of active GLP-1 are added to the microwell plate containing the antibody and incubated for 
24 hours at 4ºC. Following washing to remove unbound materials, an anti GLP-1-alkaline 
phosphatase detection conjugate is added, which binds to the immobilized active GLP-1 that 
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is itself bound to the antibody. Following a further washing step to remove unbound 
conjugate, quantification of bound detection conjugate (and hence active GLP-1 that is 
bound to the antibody) is possible by adding MUP (methyl umbelliferyl phosphate), which in 
the presence of alkaline phosphatase, forms the fluorescent product umbelliferone. The 
amount of fluorescence generated is directly proportional to the concentration of active GLP-
1 in the unknown plasma sample. Thus, using a fluorescence plate reader, the concentration 
of active GLP-1 in the plasma sample can be derived. As with the RIA technique, 
interpolation from a reference standard curve (generated in the same assay using reference 
standards of known concentrations of active GLP-1) is required in order to derive the 
concentration of active GLP-1 in each unknown plasma sample.  
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APPENDIX 2 
 
Results of mouse toxicology study 
 
PYY3-36 and GLP-17-36 amide, each at a dose greater than 10 times the maximum intended for 
humans (in pmol/kg body weight), were administered by intra-peritoneal injection to 20 mice, 
and saline was administered to a control group of 10 mice. The mice were coded as detailed 
below. Half the animals in each group were sacrificed by CO2 asphyxiation after 48 hours, 
and the other half after 14 days. The heart, lungs, kidneys, liver, spleen, pancreas, brain and 
gut were dissected, fixed and sent for examination by an independent histopathologist. 
Histology results are detailed below. 
 
CODE:   
1 - 5 = saline injection, sacrificed at 48 hours 
6 - 10 = saline injection, sacrificed at 14 days 
11 - 15 = PYY3-36 injection, sacrificed at 48 hours 
16 - 20 = PYY3-36 injection, sacrificed at 14 days 
21 - 25 = GLP-17-36 amide injection, sacrificed at 48 hours 
26 - 30 = GLP-17-36 amide injection, sacrificed at 14 days 
 
1. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
2. Normal lungs, normal oesophagus, normal heart, normal brain, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunner’s 
glands, normal pancreas with normal islets, normal colon. 
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3. Normal lungs, normal oesophagus, normal heart, normal brain, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunner’s 
glands, normal pancreas with normal islets, normal colon. 
 
4. Normal lungs, fragment of normal thymus gland, normal trachea, normal 
oesophagus, normal heart, normal brain, normal spleen, normal liver, normal kidney, 
normal stomach, normal duodenum with Brunner’s glands, normal pancreas with 
normal islets, normal colon. 
 
5. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
6. Normal lungs, normal trachea, normal oesophagus, normal heart, the brain has 
prominence of both lateral ventricles although the third ventricle is not dilated. This 
may be an incidental finding. There is no cellular reaction. The choroid plexus 
appears normal. Normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
7. Normal lungs, normal trachea, normal heart, normal spleen, normal liver, normal 
kidney, normal stomach, normal duodenum with Brunner’s glands, normal pancreas 
with normal islets, normal colon. There may be subtle ventricular dilatation in the 
brain although preparation is suboptimal. 
 
8. Normal lungs, normal heart, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunner’s glands, normal pancreas with normal 
islets, normal colon. There is possible mild bilateral ventricular dilatation. 
 
9. Normal lungs, normal trachea, normal oesophagus, normal heart, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunner’s 
glands, normal pancreas with normal islets, normal colon. There is possible 
ventricular dilatation although orientation is not optimal and the lateral ventricles were 
not well visualised. 
 
10. Normal lungs, normal heart, normal brain, normal spleen, normal liver, normal 
kidney, normal stomach, normal duodenum with Brunner’s glands, normal pancreas 
with normal islets, normal colon. 
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11. Normal lungs, normal trachea with normal thyroid gland, normal oesophagus, normal 
heart, normal brain, normal spleen, normal liver, normal kidney, normal stomach, 
normal duodenum with Brunner’s glands, normal pancreas with normal islets, normal 
colon. 
 
12. Normal lungs, normal thymus gland, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
13. Normal lungs with normal hilar lymph node, normal trachea, normal oesophagus, 
normal heart, normal brain, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunner’s glands, normal pancreas with normal 
islets, normal colon. 
 
14. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
15. Normal lungs and normal hilar lymph node, normal trachea, normal oesophagus, 
normal heart, normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunner’s glands, normal pancreas with normal islets, normal colon. 
The brain may have slight asymmetric ventricular dilatation although the fourth 
ventricle appears relatively normal. 
 
16. Normal lungs and normal hilar lymph node, normal trachea, normal heart, normal 
brain, normal spleen, normal liver, normal kidney, normal stomach, normal 
duodenum with Brunners glands, normal pancreas with normal islets, normal colon. 
 
17. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
18. Normal lungs, normal heart, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunner’s glands, normal pancreas with normal 
islets, normal colon. There appears to be mild bilateral ventricular dilatation. 
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19. Normal lungs with normal hilar lymph node, normal trachea, normal heart, normal 
brain (although preparation is suboptimal and it's impossible to exclude a minor 
degree of ventricular dilatation), normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunner’s glands, normal pancreas with normal 
islets, normal colon. 
 
20. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
21. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
22. Normal lungs, normal thymus gland, normal trachea, normal oesophagus, normal 
heart, normal brain, normal spleen, normal liver, normal kidney, normal stomach, 
normal duodenum with Brunner’s glands, normal pancreas with normal islets, normal 
colon. 
 
23. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
24. Normal lungs with normal hilar lymph node, normal trachea, normal oesophagus, 
normal heart, normal brain, normal spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunner’s glands, normal pancreas with normal 
islets, normal colon. 
 
25. Normal lungs, normal bronchi, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
 
26. Normal lungs with normal hilar lymph node, normal trachea with normal thyroid and 
parathyroid glands, normal oesophagus, normal heart, normal brain, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunner’s 
glands, normal pancreas with normal islets, normal colon. 
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27. Normal lungs, normal trachea, normal oesophagus, normal heart, the brain appears 
to have an asymmetric dilatation of lateral ventricle although this may be a 
consequence of orientation. Normal will spleen, normal liver, normal kidney, normal 
stomach, normal duodenum with Brunner’s glands, normal pancreas with normal 
islets, normal colon. 
 
28. Normal lungs, normal trachea, normal oesophagus, normal heart, normal spleen, 
normal liver, normal kidney, normal stomach, normal duodenum with Brunner’s 
glands, normal pancreas with normal islets, normal colon. There appears to be mild 
dilatation of the lateral and third ventricle although there is no cellular reaction. brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. is possibly 
subtle dilatation of the lateral ventricles although the third ventricle appears relatively 
normal. 
 
29. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. There is 
possibly subtle dilatation of the lateral ventricles although the third ventricle appears 
relatively normal. 
 
30. Normal lungs, normal trachea, normal oesophagus, normal heart, normal brain, 
normal spleen, normal liver, normal kidney, normal stomach, normal duodenum with 
Brunner’s glands, normal pancreas with normal islets, normal colon. 
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APPENDIX 3 
 
Publications arising from thesis 
The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain 
activity in appetite centers in humans. De Silva A, Salem V, Long CJ, Makwana A, 
Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD, Dhillo WS.Cell 
Metab. 2011 Nov 2;14(5):700-6.  
The use of functional MRI to study appetite control in the CNS. De Silva A, Salem V, 
Matthews PM, Dhillo WS. Experimental Diabetes Research 2012 (2012:764017.Epub 2012 
May 8). 
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in 
Obesity. De Silva A & Bloom SR. Gut and Liver 2012 Jan; 6(01): 10-20. 
Imaging the neuroendocrinology of appetite. Salem V, De Silva A, Matthews PM, Dhillo WS. 
Adipocyte 2012 Jan; 1(1): 68-72. 
Translational studies on PYY as a novel target in obesity. Zac-Varghese S, De Silva A, 
Bloom SR. Curr Opin Pharmacol. 2011 Dec;11(6):582-5. 
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